



The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeartRFA trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002377
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2012
Complete List of Authors:	Risom, Signe; Rigshospitalet, The Heart Centre Zwisler, Ann-Dorthe; National institute of Public Health, University of Copenhagen; Rigshospitalet, The Heart Centre Rasmussen, Trine; Rigshospitalet, The Heart Centre; Gentofte Hospital , Department of cardiology Sibilitz, Kirstine; Rigshospitalet, Cardiology Svendsen, Jesper; Rigshospitalet, The Heart Centre Gluud, Christian; Copenhagen University Hospital, Centre for Clinical Intervention Research Hansen, Jane; Copenhagen Trial Unit, Centre for Clinical Intervention Research Winkel, Per; Copenhagen Trial Unit, Centre for Clinical Intervention Research Thygesen, Lau; University of Southern Denmark, National Institute of Public Health Perhonen, Merja; Corusfit, Hansen, Jim; Gentofte Hospital , Department of cardiology Dunbar, Sandra; Nell Hodgson Woodruff School of Nursing, Emory University Berg, Selina; Rigshospitalet, Cardiology; Gentofte Hospital , Department of cardiology
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Cardiovascular medicine, Nursing, Rehabilitation medicine
Keywords:	Adult cardiology < CARDIOLOGY, Atrial Fibrillation , QUALITATIVE RESEARCH, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32




Figure 1. The CopenHeart_{RFA} trial. Mixed methods research design. Embedded Experimental Model. QUAN= quantitative data, QUAL= qualitative data

33
34
35
36
37
38
39
40
41
42
43

Screening for eligibility (n=?)

Predefined inclusion and exclusion criteria

Exclusion (n=?)
Do not meet inclusion criteria

Eligible patients (n=?)

Refused consent (n=?)

Informed written consent
Collection of baseline data →
Randomized allocation (1:1)
n= expected 210

Intervention Group

Control Group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

002377 on 20 February 2013. Downloaded from <http://bmjopen.bmj.com/> on April 09, 2024 by guest. Protected by copyright.

4 nurse consultations every 4-6 week starting within the first month
Physical exercise training 3 times a week for 12 weeks starting 1 month after ablation

No intervention - Usual care

1 month after ablation
physical tests, questionnaires, echocardiography, biochemistry
4 months after ablation
physical tests, questionnaires, echocardiography, biochemistry
6 months after ablation
questionnaires, last nurse consultation
12 months after ablation
physical tests, questionnaires, biochemistry
24 months after ablation



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5-7
	2b	Specific objectives or hypotheses	7 +9
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7-9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	10
	4b	Settings and locations where the data were collected	10
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	11-17
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	17-21
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	20-21
	7b	When applicable, explanation of any interim analyses and stopping guidelines	23-24
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	10-11
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	10-11
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	N/A
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	10
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	11 + 21

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	21-23
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	24-25
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	N/A
	13b	For each group, losses and exclusions after randomisation, together with reasons	N/A
Recruitment	14a	Dates defining the periods of recruitment and follow-up	N/A
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	N/A
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	N/A
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	N/A
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	27-28
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	28
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	N/A
Other information			
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	29

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeart_{RFA} trial protocol

Signe S. Risom, RN, MSc^{1,§}, Ann-Dorthe Zwisler, MD, Ph.D.^{1,2}, Trine B. Rasmussen RN, MScN^{1,4}, Kirstine Lærum Sibilitz, MD¹, Jesper Hastrup Svendsen, MD, DMSc, FESC^{1,3}, Christian Gluud, MD, DMSc⁵, Jane Lindschou Hansen, MSc⁵, Per Winkel, MD, DMSc⁵, Lau Caspar Thygesen, MSc, Ph.D.², Merja Perhonen MD, Ph.D.⁶, Jim Hansen, MD⁴, Sandra B. Dunbar, RN, DSN, FAAN, FAHA⁷, Selina Kikkenborg Berg, RN, MScN, Ph.D. FESC^{1,4}.

¹ Rigshospitalet, The Heart Centre, Copenhagen University Hospital, Denmark

² National Institute of Public Health, University of Southern Denmark

³ Gentofte Hospital, Department of Cardiology, Denmark

⁴ The Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC)

⁵ Copenhagen Trial Unit, Centre for Clinical Intervention Research. Copenhagen University Hospital, Denmark

⁶ CorusFit, Heikinkatu 3 B, 40100 Jyväskylä, Finland

⁷ Nell Hodgson Woodruff School of Nursing, Emory University
Atlanta, Georgia, United States

§Corresponding author:

Signe Stelling Risom, RN, MSc,
The Heart Centre, Department of Cardiology,
Copenhagen University Hospital,
Blegdamsvej 9, DK-2100 Copenhagen.

Signe.stelling.risom@rh.regionh.dk

Word count:

Abstract: 300, Body: 6.833

Keywords: atrial fibrillation, cardiac rehabilitation, physical exercise, psycho-education

Article summary

Article focus

- The CopenHeart_{RFA} trial is a randomised clinical trial investigating the effects of comprehensive cardiac rehabilitation versus usual care for patients treated for atrial fibrillation (AF) with ablation.
- The hypothesis is that comprehensive cardiac rehabilitation improves physical capacity and mental health.
- Using a mixed methods approach, a broad range of outcome measures are collected to evaluate the intervention.

Key messages

- AF affects 1-2% of the population. Patients with AF experience diminished quality of life and are afraid to do physical exercise after treatment with ablation.
- No studies exploring the effects of rehabilitation of patients treated for AF with ablation have been published.
- This trial is the first to examine physical functioning and to test a comprehensive rehabilitation programme on a large population of patients treated for AF with ablation.

CopenHeart_{RFA} will provide much needed evidence and insight on the post-discharge status and rehabilitation needs of patients treated for AF with ablation.

Strengths and limitations of this study

- The study has been designed to meet the criteria for high quality in non-pharmacological randomised clinical trials with central randomisation, multi-centre participation, blinded assessment and analysis.
- We are aware of the day to day variation that can appear when carrying out ergospirometry, in testing and that the performance can depend on the individual tester. Accordingly, we will interpret the findings conservatively.

Abstract

Introduction

Atrial fibrillation affects almost 2% of the population in the Western world. To preserve sinus rhythm, ablation is undertaken in symptomatic patients. Observational studies show that patients with atrial fibrillation often report low quality of life and are less prone to be physically active due to fear of triggering fibrillation. Small trials indicates that exercise training has a positive effect on exercise capacity and mental health, and both patients with recurrent atrial fibrillation and in sinus rhythm may benefit from rehabilitation in managing life after ablation. No randomised trials have been published on cardiac rehabilitation for atrial fibrillation patients treated with ablation that includes exercise and psycho-educational components.

Aim

To test the effects of an integrated cardiac rehabilitation programme versus treatment as usual for patients with atrial fibrillation treated with ablation.

Methods and analysis design

The trial is a multicentre parallel arm design with 1:1 randomisation to the intervention and control group with blinded outcome assessment. 210 patients treated for atrial fibrillation with radiofrequency ablation will be included. The intervention consists of a rehabilitation programme including four psycho-educative consultations with a specially trained nurse and 12 weeks of individualised exercise training, plus the standard medical follow-up. Patients in the control group will receive the standard medical follow-up. The primary outcome measure is exercise capacity measured by VO₂ peak. The secondary outcome measure is self-rated mental health measured by the Short Form 36 questionnaire. Post intervention, qualitative interviews will be conducted in 10% of the intervention group.

Ethics and dissemination

The protocol is approved by the regional research ethics committee (number. H-1-2011-135), the Danish Data Protection Agency (reg. nr. 2007-58-0015) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may possibly impact on rehabilitation guidelines.

Registration: Clinicaltrials.gov identifier: NCT01523145

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia and affects 2% of the population in the Western world.¹⁻³ Typical symptoms are palpitations, dyspnoea, fatigue, dizziness, and syncope. Patients' symptoms and the length of periods in AF are highly variable both for the individual and between patients.⁴⁻⁶ AF is associated with increased risk of stroke, other thromboembolic events, and heart failure.⁶⁻⁸ Hospitalisations due to AF account for one third of all admissions for cardiac arrhythmias.⁸ As the prevalence of AF increases with age, the incidence of AF is increasing due to an ageing population.^{2, 9, 10} After 40 years of age, the lifetime risk of developing AF is 25%.¹¹ The annual cost of AF is high in comparison with other diseases.¹² Therefore, AF has become an economic burden and this will continue to increase over the coming decades.¹³ Thus, AF has now become a health, social and economic challenge in the Western world.

14

Primary treatment goals for individuals with AF are re-establishing and maintaining sinus rhythm, decreasing AF symptoms, and prevention of complications. In accordance with current national and international guidelines, radiofrequency ablation (RFA) is often undertaken in symptomatic patients. RFA is an invasive treatment, intended to cure AF and has a success rate of 77% versus 52% for antiarrhythmic medication.¹⁵ In Denmark, around 600 RFAs are conducted annually at two heart centres.

A cohort study of 655 patients from a randomised trial found that AF symptoms are a negative predictor for patients' physical capacity,¹⁶ and in the presence of AF, patients do fewer physical activities.¹⁷ Smaller observational studies and a randomised trial investigating the effect of exercise

1
2
3
4 training on AF patients found increased exercise capacity and a decreased resting heart rate after
5
6 training.¹⁸⁻²⁰
7
8

9
10
11 Previous studies show significantly impaired quality of life in patients with AF compared to healthy
12
13 controls measured by the questionnaire Short Form 36 (SF-36). The general health component (\pm
14
15 standard deviation) was 54 ± 21 in AF patients compared to 78 ± 17 in healthy controls.²¹ A
16
17 qualitative study demonstrated that educational help after AF treatment is lacking, even though
18
19 symptoms of distress and lack of self-management regarding symptoms like palpitations, dyspnoea,
20
21 and fatigue are common.²² Furthermore, small observational studies indicate a positive effect of
22
23 exercise training on patients with AF in terms of mental health and physical activity (15% increase
24
25 of VO_2).^{18, 19} However, these findings need confirmation in larger randomised clinical trials.
26
27
28

29
30
31 Secondary prevention initiatives including cardiac rehabilitation are recommended by the European
32
33 Society of Cardiology (ESC).²³ Although evidence of its efficacy is strong, general cardiac
34
35 rehabilitation is still poorly implemented and often only on selected populations thus the
36
37 development of full comprehensive preventive programmes, according to the ESC
38
39 recommendations is warranted.²⁴ Studies exploring the effects of rehabilitation of patients treated
40
41 for AF are lacking. As there is no evidence of its efficacy, the rehabilitation provided is presumably
42
43 often suboptimal or totally lacking. Lessons, however, might be learned from rehabilitation studies
44
45 in patients with related cardiac conditions. The positive effects of cardiac rehabilitation have been
46
47 well documented, particularly in patients with coronary heart disease and heart failure, where
48
49 rehabilitation has been proven to reduce hospital re-admissions and mortality in a cost-effective
50
51 way,^{25, 26} as well as improve quality of life.²⁷ More specifically, studies on the effect of exercise
52
53 training have demonstrated an increase in exercise capacity of up to 38% in patients after valve
54
55
56
57
58
59
60

1
2
3
4 replacement surgery²⁸ and an increase in peak VO₂ of 2.3±2.2 (SD) ml/kg per minute in the
5
6 intervention group compared with -0.3±2.1 (SD) ml/kg per minute in the control group, as well as a
7
8 significant change in quality of life in older patients with heart failure.²⁹ Traditional cardiac
9
10 rehabilitation has focused on physical training and standardized programmes, but studies indicate
11
12 that individualized content and supervised exercise components are key design characteristics for
13
14 improving outcomes.³⁰ In addition to exercise training, there is evidence to support interventions
15
16 that include patient education, which in patients with coronary heart disease has been shown to
17
18 improve health related quality of life and decrease healthcare costs,³¹ and psychological support,
19
20 which has been shown to improve psychological symptoms in patients with coronary heart disease,
21
22 such as depression and anxiety.³² Evidence on the efficacy of comprehensive interventions for
23
24 patients treated for AF, however, is needed.
25
26
27

28 Interventions designed to cover both physical and psychological problems may provide the best
29
30 method for optimising functioning and enhancing quality of life.³³ We have not been able to
31
32 identify randomised trials or observational studies in patients who have undergone RFA for AF that
33
34 offer both psycho-educational intervention and physical training. Therefore, the CopenHeart_{RFA} trial
35
36 was undertaken with the aim of testing a rehabilitation programme consisting of physical exercise
37
38 and a psycho-educational intervention versus treatment as usual for RFA treated AF patients.
39
40
41
42
43
44

45 **Methods**

46 **Design**

47
48 Major parts of the method section and trial design in this paper are similar to two other randomised
49
50 clinical trials, CopenHeart_{VR} and CopenHeart_{IE}, and therefore sections from this paper will be
51
52 copied in these trial protocols (Sibilitz KL et al. *Effect of integrated cardiac rehabilitation versus*
53
54 *treatment as usual for patients with isolated heart valve surgery: The randomised CopenHeart*
55
56
57
58
59
60

1
2
3
4 *valvular trial protocol*. drafted October 2012; and Rasmussen TB et al. *A randomised clinical trial*
5 *of comprehensive cardiac rehabilitation versus usual care for patients treated for infective*
6 *endocarditis – the CopenHeart_{IE}*. Accepted for publication, BMJ Open, October 2012).
7
8
9

10
11
12
13
14 The CopenHeart_{RFA} trial is a multi-centre, multidisciplinary randomised clinical superiority trial.
15
16 Secondary, qualitative data are also collected and the two methods are integrated by applying a
17
18 mixed method embedded experimental design (Figure 1).^{34,35} Quantitative methods are applied,
19
20 with specified quantitative pre- and post-measures to evaluate the effect of the experimental
21
22 intervention. Alongside quantitative measurements, qualitative data will be collected. The premise
23
24 of mixed methods research is that the use of qualitative and quantitative approaches in combination
25
26 provides a better understanding of the research problems than either approach alone, because
27
28 different types of questions require different types of data and that mixed methods research provides
29
30 strengths that offset the weaknesses of both qualitative and quantitative research.³⁴ The methods are
31
32 integrated by applying a mixed method embedded experimental design and include qualitative data
33
34 to develop the intervention and to examine the process of the intervention and the results of the trial
35
36 (see Figure 1).^{34,35} The rationale for this approach is that the quantitative findings provide a general
37
38 understanding of the research problem through statistical results while qualitative findings refine
39
40 and explain the results by exploring participants' views in greater detail. Evaluation using
41
42 qualitative research methods is increasingly promoted in evidence-based rehabilitation.³⁶⁻³⁹
43
44 Qualitative research alongside randomised controlled trials can contribute in several ways to the
45
46 development and evaluation of complex healthcare interventions and may be particularly useful in
47
48 evaluating interventions that involve social and behavioural processes that are difficult to explore or
49
50 capture using quantitative methods alone.⁴⁰ As patient participation is paramount for the efficacy of
51
52 the rehabilitation,⁴¹ we find it highly valuable to include the patients' perspective in the
53
54
55
56
57
58
59
60

1
2
3
4 development and evaluation of the intervention. This paper presents the study protocol for the
5
6 CopenHeart_{RFA} randomised clinical trial. The complementary studies are briefly described in a
7
8 separate section.
9

10 The trial is described in accordance with the current SPIRIT guidelines (Standard Protocol Items:
11
12 Recommendations for Interventional Trials).⁴² Results will be reported following the CONSORT
13
14 (CONsolidated Standards Of Reporting Trials) guidelines for non-pharmacological interventions.⁴³
15
16
17
18
19

20 **Trial hypotheses**

21 The primary hypothesis is that the rehabilitation program increases physical capacity among AF
22
23 patients treated with RFA after 4 months measured by VO₂ peak, which is expected to be 20%
24
25 more than in the control group receiving standard treatment alone. The estimate of 20% is based on
26
27 findings from pilot studies including patients with permanent AF which found an increase of 15%
28
29 in VO₂ peak. We therefore expect a VO₂ peak in the intervention group of 18 ml/kg/min and of 15
30
31 ml/kg/min in the control group, corresponding to a difference of 20% (3 ml/kg/min).⁴⁴
32
33
34
35
36

37 The secondary hypothesis is that the rehabilitation programme increases quality of life and self-
38
39 rated mental health among AF patients treated with RFA after 6 months by 3 points on the Medical
40
41 Outcome Study Short Form 36 (SF-36) questionnaire mental component scale, compared with
42
43 control participants receiving standard treatment.¹⁹
44
45
46
47
48

49 Exploratory hypotheses are that the experimental intervention decreases AF recurrence; improves
50
51 self-rated health and sleep-quality; reduces early retirement from work, use of health care services
52
53 and mortality, and is cost efficient.
54
55
56
57
58
59
60

Trial participants

Consecutive patients hospitalised for AF and treated with RFA at two heart centres in Denmark (Gentofte Hospital and Rigshospitalet, Copenhagen University Hospital) will be screened for inclusion and approached for trial participation (Figure 2). Regardless of RFA outcome, both patients with recurrent AF and patients in sinus rhythm after the ablation will be included in the trial. Patients 18 years of age or older, Danish speaking, and providing verbal and written informed consent will be eligible for participation. Patients unable to understand trial instructions, pregnant or breastfeeding, with reduced ability to follow the planned programme due to other physical illness, who prior to RFA have been doing intense physical exercise or sports at competitive level several times a week, or do not wish to participate, and patients already enrolled in clinical trials that prohibit participation in additional trials are excluded.

Trial procedure, randomisation, and follow-up

Patients will be approached for participation during their hospitalisation for RFA. Information will be given by a nurse or physician from the research team, who will obtain informed written consent after the RFA procedure. A brief oral introduction is initially given together with written information describing the trial and implications for the patient in detail. The patient is given ample time to read the information and if necessary involve a relative in the decision making. The enrolling nurse or physician will return after the RFA or call the patient to answer any questions the patient or their relative might have. The patient should subsequently be able to provide informed consent or reject participation. After the informed consent form is signed, baseline data will be collected including the baseline questionnaire package, demographic variables, and clinical characteristics (Table 2). Then the Copenhagen Trial Unit (<http://www.ctu.dk/>) is contacted for central randomisation of the participant. Randomisation is conducted according to a computer-

1
2
3
4 generated allocation sequence with a varying block size kept unknown to the investigators.
5
6 Participants are randomised 1:1 to the experimental intervention group or the control group and
7
8 stratified according to sex and type of AF (persistent or paroxysmal). Thus, neither investigators nor
9
10 patients or relatives can influence to which group the patients are allocated. For both groups, the
11
12 follow-up assessment will take place at 1 month, 4 months, 6 months, and 12 months post-
13
14 discharge, and a register-based follow-up assessment will be conducted at 24 months (Table 2). In
15
16 case of complications to the RFA after enrolment in the trial, the patients will be handled
17
18 individually (e.g., arrhythmia or inguinal haematoma).
19
20
21

22
23 The patients answer questionnaires independently of the researchers, and before randomisation. All
24
25 questionnaires are distributed electronically, thus data management is handled independently from
26
27 the researchers that interpret data. All data are stored electronically in a coded database, and in an
28
29 independent spread sheet, only accessible for the CopenHeart group.
30
31

32
33 Personal information about potential and enrolled patients will be collected electronically and
34
35 shared in a database only accessible to those within the project group responsible for patient
36
37 recruitment, in order to protect confidentiality before, during and after the trial.
38
39

40
41 Due to the nature of rehabilitation, the intervention group is not blinded for the patients or the
42
43 investigators, but the outcome assessment of the primary outcome, the statistical analyses, and
44
45 drawing of conclusions will be conducted blinded for the allocated intervention group.
46
47

48 **The experimental intervention group**

49
50 Patients in the experimental intervention group will follow the integrated cardiac rehabilitation
51
52 programme consisting of a psycho-educational component and an exercise training component
53
54
55
56
57
58
59
60

1
2
3
4 alongside standard treatment (described below). The patients will be contacted at 1, 4, 6 and 12
5
6 months for outcome assessment including clinical data collection.
7
8

9 10 *The physical exercise training component*

11 The intervention has been developed and partly tested in a clinical rehabilitation trial, the COPE-
12 ICD trial⁴⁵, which included patients with an implantable cardioverter defibrillator. We here
13
14 observed a significant impact of the intervention on peak VO₂, physical capacity and self-assessed
15
16 mental health. The intervention has been modified for patients treated for atrial fibrillation with
17
18 ablation as described below. The CopenHeart physical exercise intervention meets European²⁴ and
19
20 Danish guidelines⁴⁶ for physical exercise in patients with heart disease, and complies with The
21
22 National Danish Board of Health recommendations for physical exercise in daily living for heart
23
24 patients.⁴⁷
25
26
27
28

29 The physical exercise starts one month after the ablation and after the first ergospirometry test and
30
31 comprises the following three elements:
32
33
34
35

36 Individually planned physical exercise by specially trained physiotherapists. Integrating detailed
37
38 information concerning AF symptoms and RFA, co-morbidity, hospitalisation, activities of daily
39
40 living, and level of physical activity prior to RFA, a specially trained physiotherapist conducts a
41
42 patient telephone consultation up to 30 minutes. The consultation is based on initial testing of the
43
44 patient including a cardiopulmonary exercise test, a 6 minutes walking test and a 'sit and stand' test,
45
46 described in the outcome section. For all patients, a rehabilitation plan is prepared as an individual
47
48 training diary, and all patients are instructed in the use of a heart rate monitor (Polar Watch
49
50 provided by Rigshospitalet). The heart rate monitor and diary is essential to ensure CopenHeart
51
52 training protocol compliance and they are returned for data collection at the end of the exercise
53
54 training intervention.
55
56
57
58
59
60

1
2
3
4 Intensive exercise training programme. Physical exercise is initiated at Rigshospitalet four weeks
5
6 after RFA to ensure optimal rest and healing. Using wireless electrodes integrated into t-shirts
7
8 (Corus-Fit, CardioCardio and Corus Exercise Assistant, CEA, version 2.0.16, Finland) potential
9
10 cardiac arrhythmias, electrocardiographic abnormalities such as ST-depression, ST-elevation, Q- or
11
12 T-wave altering, atrial fibrillation, and ventricular arrhythmias and training intensity level are
13
14 monitored.
15

16
17
18 After 1-3 exercise training sessions at Rigshospitalet, the patient continues the programme at a local
19
20 CopenHeart certified training facility supervised by physiotherapists or as supervised home-based
21
22 training. Supervised home-based exercise training has shown similar results to hospital-based
23
24 exercise training³¹ and has been confirmed in a Danish setting.⁴⁸
25
26

27 The physical exercise training continues for 12 weeks, comprising three sessions weekly of 60
28
29 minutes, in total, 36 sessions. The training protocol consists of cardiovascular training and strength
30
31 exercises to improve endurance and muscular strength.
32
33

34
35
36
37 An exercise session consists of 10 minutes warm up, 20 minutes bicycling, 20 minutes strength, and
38
39 a 10 minutes stretching and cool-down period. . Using the results from the cardiopulmonary
40
41 exercise test performed prior to the initial training session, in combination with the Borg scale
42
43 measuring subjective exhaustion, the aerobic exercise is performed with gradually increasing
44
45 intensity throughout the exercise intervention period, corresponding to 13 to 17 on the Borg Scale
46
47 and 50% to 80% of the maximum heart rate. The anaerobic resistance training is initiated at 30% to
48
49 40 % of 1 repetition maximum (RM) for the upper body, and 40% to 50 % of 1 RM for the lower
50
51 body, with an increasing work load during the training sessions. To achieve cardiovascular
52
53 adjustment and reduce the risk of malignant cardiac arrhythmias and ischemia, the training session
54
55
56
57
58
59
60

1
2
3
4 is initiated and terminated with a warm up and a cool down period to gradually increase and
5
6 decrease training intensity and heart rate. This cardiovascular adjustment has been proven to reduce
7
8 the risk of ischemia and arrhythmia in relation to exercise training.^{49, 50} Training is predominantly
9
10 performed in the upright position to reduce left ventricle preload (diastolic volume) and the risk of
11
12 ischemia and arrhythmias due to heart failure.⁵⁰

13 Sustained moderate physical exercise daily. Participants are instructed to perform moderate physical
14
15 exercise at least 30 minutes a day during the intervention period, e.g., bicycling, walking,
16
17 gardening, jogging or recreational sports. Participants are encouraged to continue with moderate
18
19 physical exercise throughout life.
20
21
22
23

24 ***The psycho-educational component***

25
26 The aim of the psycho-educational intervention is to provide emotional support and improve coping
27
28 skills and illness appraisal in order for the patient to respond appropriately to physical and
29
30 psychological symptoms. Education and information about the disease prepare the patient for
31
32 expected symptoms and sensations. Dialogue and shared reflection facilitate strategies for coping
33
34 with symptoms and experiences associated with the condition, e.g., anxiety and fear. Cardiac care
35
36 nurses with specific training will perform the psycho-educational intervention. Some of the most
37
38 commonly reported concerns of patients treated for AF with RFA, such as recurrent AF, and
39
40 concerns about being able to manage a working life are outlined in a guide which nurses use to
41
42 address when and if relevant (see Table 1). Information given will also be based on national
43
44 guidelines and standard treatment of patients treated for AF. The consultations focus on managing
45
46 life after AF treated with RFA by establishing a joint approach to disease management and coping
47
48 strategies, taking a holistic view. The psycho-educational intervention is inspired by R.R. Parse's
49
50 Human Becoming Practice Methodologies' three dimensions.⁵¹ These are interpreted as: 1) discuss
51
52 and give meaning to the past, present and future, 2) explore and discuss events and possibilities and
53
54
55
56
57
58
59
60

3) move along with envisioned possibilities. According to this theory, there are three ways of changing health: creative imaging, that is to see, hear and feel what a situation might be like if lived in a different way, affirming personal patterns and value priorities, and shedding light on paradoxes, that is, looking at the incongruence in a situation and changing the view held of something. The nurse is present in the process through discussions, silent immersion and reflection. The human becoming practice methodology was chosen to apply a holistic patient approach, focusing on the coping and transformation process of the individual person. Furthermore, the method is already extensively used in the outpatient heart clinics at the heart centre at Rigshospitalet, such as for patients with inherited heart diseases and adults with congenital heart disease and is documented in the COPE-ICD trial.^{45, 52} The consultations take place in a quiet setting at the out-patient clinic and will last for approximately one hour. The nurse is able to facilitate contact with or seek advice from a physician if needed. The first consultation will be approximately one month after discharge, and then once every four to six weeks, with a total of four consultations. Consultations can be done by telephone, in accordance with the patient's wishes. The primary investigator will attend the consultations regularly to ensure protocol compliance.

Table1. Guide to the psycho-educative consultation.

Number visit	1	2	3	4
Ask the patient how he/she has been since the ablation.				
What has happened since last time he/she was here?	X	X	X	X
Invite the patient to talk about his/her thoughts and questions.	X	X	X	X
Ask about the time leading up to RFA and his/her AF history. Experiences before, under and	X			

1
2
3
4 after the hospitalization and RFA.

5
6 Talk about how it is to have had/ have AF and X

7
8 been through RFA, how that have affected the patient's

9
10 life. Is there something he/she avoids or feel like

11
12 he/she cannot do anymore? This in relation to family

13
14 relations, friends and free time/ leisure activities.

15
16 Make sure that the patient has started the physical X X X

17
18 training and talk about how it is going. Are training

19
20 appointments booked?

21
22 Talk about if the patient has changed his/her X

23
24 feelings or thoughts of the body and its functions.

25
26 Talk about recognition of symptoms, how the patient X X (X) (X)

27
28 is feeling about recurrence of AF and opinions about

29
30 future AF treatment. Worries about recurrence of AF,

31
32 strategies of prevention.

33
34 Information/recommendations in relation to the X X X X

35
36 subjects/problems discussed.

37
38
39
40
41
42
43
44 ***Intervention deviations***

45
46 Both components of the intervention will be supervised regularly by the primary investigator to

47
48 ensure protocol compliance. Modification of the allocated intervention due to surgery

49
50 complications, rehospitalisation or emerging co-morbidities (e.g. recurrent AF, musculoskeletal

51
52 problems) will be individually assessed, and the time of the primary outcome assessment at four

1
2
3
4 months (described in section below) will be corrected in accordance with changes in the
5
6 intervention.
7
8

9 10 **Control group: treatment as usual**

11 Patients in the control group will follow standard treatment for patients treated for AF with RFA
12 including 3-6 months follow-up with a physician and a 12 months follow-up with a nurse.
13

14 Furthermore, patients will be contacted at 1, 4, 6 and 12 months for outcome assessment including
15
16 clinical data collection.
17
18
19

20 21 22 **Outcomes and data collection**

23
24 Data will be collected to evaluate the effect and meaning of the intervention. The primary and
25
26 secondary outcomes reflect the primary modifiable factors of the intervention. Since almost no
27
28 evidence exists for rehabilitation programmes for patients treated for AF with RFA, data on a
29
30 number of outcomes will be collected for exploratory analyses.
31
32
33
34
35

36 *Primary outcome*

37
38 **Physical capacity measured by peak VO₂ according to a standardised protocol developed in**
39
40 **accordance with guidelines^{53,54} 1, 4 and 12 months after randomisation (Table 1).**
41
42
43
44

45 Physical capacity is measured by peak VO₂ using cardiopulmonary exercise testing (Ergo-Spiro CS-
46
47 200, Schiller, Schweiz). The test is performed according to current guidelines for ergospirometry
48
49 testing, and by ergometer bicycle, simultaneously monitoring heart-rhythm, blood pressure,
50
51 electrocardiogram (ECG), and measuring gas-exchange during workload and in the following
52
53 recovery period. The average test duration is 10-15 minutes including pre- and post- test phase
54
55 without work load. Before each session calibration is performed to address changes in room
56
57
58
59
60

1
2
3
4 temperature, humidity and air oxygen content. A standardised ramp-protocol is used with initial
5
6 work load of 25 or 50 watts, increasing gradually by 12.5 watts every minute until peak exhaustion.
7

8 Peak exhaustion is evaluated by a respiratory exchange ratio (RER) \geq T 1.10 or subjective
9
10 exhaustion of the patient. In order to equally encourage the patients, independent of the tester, a
11
12 standardised guide has been developed. During the test period, clinical manifestations, ECG
13
14 abnormalities (ST depression, ST elevation, Q- and T-wave changes, supraventricular or ventricular
15
16 arrhythmias), blood pressure response, and several physiological variables are observed and
17
18 documented. The test will be performed by either a cardiac care nurse or a physician. For safety
19
20 reasons preset criteria for initiation and/or termination of the test have been defined.
21
22
23

24 25 26 *Secondary outcome*

27
28 Self-rated mental health is measured by the SF-36 questionnaire,⁵⁵⁻⁵⁷ mental component score, after
29
30 1 month, 4 months, 6 months and 12 months (Table 2).
31
32

33 34 35 *Exploratory outcomes*

36
37 Long-term follow-up: Register data regarding mortality, causes of death, hospitalisation/re-
38
39 hospitalisation, emergency room visits, outpatient visits, health care costs, visits to the general
40
41 practitioner, medication use, employment status and payment of welfare benefits (sick leave
42
43 payment and early retirement pension) will be collected at 24 months to assess long term effects of
44
45 the intervention (Table 2). Danish recording keeping for the data mentioned above functions well,
46
47 with only a small percentage of lost data.⁵⁸ Consequently the method is well suited as an outcome
48
49 measure in small patient populations. Data will be extracted from the Danish National Patient
50
51 Register, the Danish National Health Service Register, the Danish National Prescription Registry,
52
53
54
55
56
57
58
59
60

the Danish National Causes of Death Register and records of transfer payments and labour market affiliation.⁵⁹⁻⁶²

6 minutes walking test: The maximum walking distance (in meters) within 6 minutes is measured, using standardized instructions,⁶³ while subjective exhaustion with regard to fatigue and dyspnoea using the Borg scale⁶⁴ is registered.

Sit and stand test: The maximum amount of times a patient can sit and rise from a normal chair within 30 seconds is recorded. Subjective exhaustion is measured using the Borg exhaustion scale.⁶⁴

Biochemical screening: Potassium, sodium, haemoglobin and creatinine. 1 EDTA plasma heparin tube will be frozen (80°) for further analyses (pro-BNP, BNP, copeptin).

Other exploratory outcomes: AF recurrence, self-rated health and sleep-quality, retirement from work, use of health care services, mortality and cost efficiency (Table 2).

Table 2. Exploratory quantities subjected to post-hoc analysis

Quantity	Time of measure (months)	Type of quantity
Demographic		
Sex	BL	Binary (M/F)
Age, height, weight,	BL, 1,4,12	Continuous
Marital, occupational, educational status	BL	Categorical
Clinical		
NYHA- classification	BL, 1, 4, 12	Continuous
Previous heart disease, diabetes mellitus, kidney disease, pulmonary disease (COPD), co-morbidities, hypertension, dyslipidaemia, smoking	BL	Binary (Y/N)
Medication	BL, 1, 4, 12	Binary (Y/N)
AF specific data:		
Type of atrial fibrillation	BL	Categorical
Number of ablations	BL, 1,4,12	Binary (Y/N)
Atrial fibrillation symptoms	BL, 1,4,12	Continuous
CHA ₂ DS ₂ VASc score	BL, 1,4, 12	Continuous
The European Heart Rhythm Association symptom score	BL, 1,4, 12	Continuous

Paraclinical and imaging		
Blood work (Haemoglobin, infection-, kidney- liver and selected nutritional parameters, electrolytes, cholesterol- and thyroid status, ProBNP)	BL, 1, 4, 12	Continuous
Electrocardiogram	BL, 4, 12	Continuous
Physical function		
6 minute walking test ⁶³	BL, 1, 4, 12	Continuous
Sit to stand test ⁶⁵	1, 4, 12	Continuous
EVO recording	1,4,12	Categorical
Questionnaires		
Physical activity level ⁶⁶	BL, 1, 4, 6, 12, 24	Binary (Y/N)
SF-36 ⁶⁷ HADS ⁶⁸ , QoL-CV ⁶⁹	BL, 1, 4, 6, 12, 24	Continuous
Emotions and Health ⁷⁰	BL	Continuous
Rehabilitation ⁷¹	12	Continuous
HeartQoL R ⁷² , EQ-5D ⁷³	BL, 6, 12, 24	Continuous
IPAQ ⁷⁴	1, 4, 12, 24	Continuous
MFI-20 ⁷⁵	BL, 1, 4, 12	Continuous
PSQI ⁷⁶	1, 6	Continuous
AFEQT ⁷⁷	BL, 1,4,12,24	Continuous

AFEQT, Atrial Fibrillation Effect on Quality-of-life; BL, baseline; CHA₂DS₂VASc, score for Atrial Fibrillation Stroke Risk; EQ-5D, EuroQoL; HADS, Hospital Anxiety and Depression Scale; HeartQoL R, Heart-Related Quality of Life; IPAQ, International Physical Activity Questionnaire; PSQI, Pittsburgh Sleep Quality Index; QoL-CV, Quality of Life - Cardiac Version; SF-36, Short Form 36.

Sample size calculation for the primary outcome

We are performing a randomised trial where the continuous variable VO₂ peak is the primary outcome. The control and the intervention group are independent and the ratio of patients in the intervention group to the patients in the control group is 1:1. A previous trial of patients with permanent AF found that VO₂ peak was normally distributed with a standard deviation of 3.8 ml/kg/min.⁴⁴ As the CopenHeart_{RFA} trial has a more varied patient population who have all been treated for AF with RFA, which means that the majority of the patients will have sinus rhythm and

1
2
3
4 the rest will have AF, the patients are not directly comparable with the patients in the previous trial,
5
6 and we assume a standard deviation of 6 ml/kg/min to be more relevant. We consider a 0.5 standard
7
8 deviation to be the minimal relevant difference, equivalent to 3 ml/kg/min. Therefore, if the true
9
10 difference between the intervention group and control group is 3 ml/kg/min and the standard
11
12 deviation is 6 ml/kg/min in the control group, 105 patients in the intervention group and 105 in the
13
14 control group (a total of 210 patients) are needed to reject the null hypothesis, stating that the mean
15
16 in the intervention group and the control group is the same, with a power of 95%. The type I error
17
18 probability associated with this test of this null hypothesis is 5%.
19
20
21
22
23

24 **Power calculation for the secondary outcome**

25
26 The secondary outcome measure is the continuous variable mental component, SF 36. If the true
27
28 difference between the intervention and control group is 7 points, and the standard deviation in the
29
30 control group is 18 points.²¹ We will be able to reject the null hypothesis that the population means
31
32 of the experimental and control groups are equal with a probability of (power) 0.80. The type I error
33
34 probability associated with this test of this null hypothesis is 5%.
35
36
37
38
39

40 **Statistical analyses**

41
42 Data will be pseudo-anonymised and analysed blinded by a trial-independent statistician using
43
44 intention-to-treat analyses and a mixed model with repeated measures (MMRM) for continuous
45
46 outcome measures.⁷⁸ Using MMRM ensures that missing data values (in case of the primary and
47
48 secondary outcome) will not create bias as long as the values are missing at random. Two-sided
49
50 tests are performed. The level of significance is set at 5%. With regard to multiplicity, gate keeping
51
52 will be used to adjust the observed P values for primary and secondary outcomes.⁷⁹ Both unadjusted
53
54 and adjusted P values will be reported.
55
56
57
58
59
60

1
2
3
4 For the primary and secondary outcomes, sensitivity analysis will be conducted to assess the
5
6 potential impact of values missing not at random. For each intervention group (A and B) some
7
8 quantities (imputing quantities) are computed to be used to impute missing values in a group (A or
9
10 B) as follows. A comparison between group A and group B where missing values in group A are
11
12 imputed using imputing quantities obtained from group A and missing values from group B are
13
14 imputed using imputing quantities obtained from group B is referred to as a best case analysis. If
15
16 missing values in group A are imputed using imputing quantities obtained from group B and vice
17
18 versa the comparison is called a worst case analysis. The imputing quantities for the primary
19
20 outcome are the group mean at T1 (\bar{X}_1), the group mean at T4 (\bar{X}_4), the group mean at T6
21
22 (\bar{X}_6), the mean difference between the value measured at T4 and that measured at T1 (Δ_1),
23
24 and the mean difference between the value measured at T6 and that measured at T4 (Δ_2). Table
25
26 3 explains how the quantities are used to impute missing values in a group (either the same group or
27
28 the other intervention group). If the standard error (SE) of a parameter estimate calculated using
29
30 imputed data is smaller than that of the corresponding parameter calculated using complete case
31
32 data it is replaced by the latter SE when the P value is calculated (Table 3).
33
34
35
36
37
38
39

40 Long-term register-based outcomes will be analysed by two different models: non-negative count
41
42 outcomes (e.g., number of contacts with hospital or number of visits to general practitioners) will be
43
44 analysed by a Poisson model or a zero-inflated Poisson model if the number of zeros are large, and
45
46 time-to-event data (e.g., cause-specific mortality and leaving the labor market) will be analysed
47
48 with survival methods (Kaplan-Meier estimator and Cox regression model). Especially for socio-
49
50 economic outcomes, competing risks due to mortality will be considered if a large proportion of
51
52 patients die during follow-up.
53
54
55
56
57
58
59
60

Exploratory data will be analysed using appropriate statistical methods according to the type of data (see Table 2). SPSS version 17.0 and SAS version 9.3 will be used.

Table 3. Statistical analysis

Observed pattern in group B at 1, 4, and 6 months	Imputed value in group B at 1 month	Imputed value in group B at 4 month	Imputed value in group B at 6 months
mis ^A , mis, mis	X1-bar ^B	X4-bar ^C	X6-bar ^D
mis, mis, Y3 ^E	$Y3 - (\delta1^F + \delta2^G)^H$	Y3 - delta2	
mis, Y2, mis	Y2 - delta1		Y2 + delta2
Y1, mis, mis		Y1 + delta1	Y1 + delta1 + delta2
Y1, Y2, mis			Y2 + delta2
Y1, mis, Y3		$(Y1 + \delta1 + Y3 - \delta2)/2$	
mis, Y2, Y3	Y2 - delta1		

Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group B). mis=missing value, X1=value at month 1, X4=value at month 4, X6=value at month 6.

^AThe value at 4 months is missing in group B, ^BMean of values observed in group A at time 1 month. ^CMean of values observed in group A at time 4 months. ^DMean of values observed in group A at time 6 months. ^EObserved value in group B at time 6 months. ^FThe mean of difference between values observed at time 4 months and value observed at time 1 month in group A, ^GThe mean of difference between value observed at time 6 months and value observed at time 4 months in group A, ^HIf an imputed value is 0 it is set equal to 0.

Interim analysis and Data Monitoring Safety Committee (DMSC)

The DMSC works independently from the funder and has no competing interests, and consists of two clinicians and a statistician. The committee is responsible for safeguarding the interests of trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the clinical trial. In line with the terms of the Data Monitoring

1
2
3
4 and Safety Committee charter, one formal interim analysis meeting will be held to review data
5
6 relating to treatment efficacy, participant safety, and quality of trial conduct. The three members of
7
8 the Data Monitoring and Safety Committee will meet when the 12 week follow-up data of about
9
10 50% of the trial participants have been obtained. Any serious adverse events will be registered as
11
12 part of the data collection and the overall number of adverse events will be reported at the meeting.
13
14

15 16 **Complementary studies**

17
18 **The Surveysbased study.** The post-discharge status of the patients treated with RFA will be
19
20 explored through a national survey. The standardised questionnaires SF-36,⁶⁷ Hospital Anxiety and
21
22 Depression Scale (HADS),⁶⁸ EuroQoL-EQ-5D,^{69, 70} Heart Related Quality of Life (HeartQoL R),⁷¹
23
24 International Physical Activity Questionnaire (IPAQ),^{72, 73} and a questionnaire developed by the
25
26 Danish Heart Foundation on the extent and quality of rehabilitation offered will be sent to patients
27
28 having undergone treatment for RFA, 6-12 months post-discharge. The instruments are all validated
29
30 and have good reliability and responsiveness.^{68, 72, 74, 75, 80, 81} The data will provide knowledge on
31
32 patients' self-rated health, quality of life, anxiety and depression, economic situation and the extent
33
34 and quality of the rehabilitation currently received. Patients were identified through the National
35
36 Patient Register⁵⁹ and questionnaires were sent out to 608 patients. We anticipate 25% will decline
37
38 participation, leaving an estimated 456 questionnaire respondents. Data will be anonymised and
39
40 analysed by relevant descriptive statistical methods.
41
42
43
44
45
46

47 **Qualitative post intervention study**

48
49 After the intervention, 10% of the participants from the intervention group will be strategically
50
51 chosen for an interview in order to explore the experiences and processes behind the potential
52
53 effects of the intervention. The qualitative study will explore patient experiences of participating in
54
55 the CopenHeart_{RFA} programme and investigate which components were meaningful.
56
57
58
59
60

1
2
3
4 To achieve maximum variation, qualified interviewees are chosen on the basis of sex, AF type, and
5
6 current heart rhythm.⁸² The analysis will be inspired by Ricoeur's theory of interpretation consisting
7
8 of three levels: naive reading, structured analysis and critical interpretation and discussion.⁸³
9

10 **Economic evaluation**

11
12 An economic evaluation will be conducted alongside the trial to assess the cost-utility of cardiac
13
14 rehabilitation compared with treatment as usual in the study population. The economic evaluation
15
16 will compare the costs to quality adjusted life years (QALY) and take a societal perspective, as
17
18 recommended nationally. QALYs and costs will be assessed at the end of the intervention, 6 months
19
20 from randomisation, and later after 24 months from randomisation using register-based follow up.
21
22

23
24 QALYs will be estimated using the self-completed EQ-5D instrument, which is a standardised
25
26 instrument assessing 5 dimensions of self-reported health status (mobility, self-care, usual activities,
27
28 pain/discomfort and anxiety/depression).^{84, 85} The estimated calculations will be valued using
29
30 Danish preference weights.⁸⁶ Information on costs will only include costs that are expected to differ
31
32 between the intervention and usual care group.⁷³ Costs included in the evaluation are health costs
33
34 associated with the rehabilitation programme, other health care costs (health care utilization besides
35
36 rehabilitation), patient costs and costs of productivity losses. Information on costs will be collected
37
38 by a mixture of activity-based costing, surveys, patient diary and by the use of public records.
39
40 Results from the analysis will be reported as an incremental cost-effectiveness analysis (ICER).
41
42 Sensitivity analysis will be conducted to express uncertainty in the estimates.⁸⁷ The reporting of the
43
44 ICER is presented using Bayesian methods, including bootstrapping and presented as cost-
45
46 effectiveness acceptability curves.⁸⁸
47
48
49
50

51 **Ethics**

52
53 The inclusion started December 2011 and is approved by the Regional Ethics Committee (number
54
55 H-1-2011-135) and the Danish Data Protection Agency (no. 2007-58-0015). All eligible patients
56
57

1
2
3
4 will be informed about the trial verbally and in writing, and the patients are included after informed
5 consent has been obtained. All data will be handled confidentially and patients ensured anonymity.
6
7

8 The trial complies with the latest Declaration of Helsinki and is registered at ClinicalTrials.gov
9
10 (NCT01523145). An independent international safety committee monitors the trial. All serious and
11
12 adverse events will be registered and reported in accordance with the safety charter.
13
14

15
16 Not providing rehabilitation to the control group can be ethically justified as current national and
17
18 international guidelines give no specific recommendations on cardiac rehabilitation for patients
19
20 treated for AF with RFA. The scope and quality of rehabilitation offered to this population is
21
22 unknown, but suspicions are that generally no rehabilitation is offered in Denmark. The only way
23
24 patients can get supervised exercise training is if they voluntarily enrol in a programme e.g. through
25
26 non-profit organisations. The survey based complementary study, described previously in this
27
28 paper, will hopefully provide more insight into this. In screening patients for participation, the
29
30 enrolling nurse or physician will exclude those with a compelling rehabilitation need. Furthermore,
31
32 patients are informed of the study design before giving their consent, and are free to decline
33
34 participation.
35
36
37
38

39 **Discussion**

40
41 Due to the difference in the three patient groups that are included in the overall CopenHeart trial,
42
43 patients treated for infective endocarditis, heart valve surgery and patients treated for AF with RFA,
44
45 the intervention and outcome measures differ slightly, most importantly in the case of the psycho-
46
47 educational intervention, which is longer for patients treated for infective endocarditis and heart
48
49 valve surgery, because of the complexity of the diseases and the longer hospitalisation. Biochemical
50
51 markers are similarly chosen differently to address the various co-morbidities of the three diseases
52
53 and some disease specific questionnaires are chosen to capture the specific disease relevant issues.
54
55
56
57
58
59
60

1
2
3
4
5
6 To our knowledge no previous randomised clinical trials or observational studies have been
7
8 conducted focusing on integrated cardiac rehabilitation for AF patients treated with RFA, so
9
10 therefore it is not known what effect, if any, rehabilitation has on these patients. However, in the
11
12 light of evidence from other groups of patients with heart disease a positive effect can be
13
14 expected.^{23, 89, 90}

15
16
17 This trial is different from previous trials because we apply a comprehensive coronary rehabilitation
18
19 intervention which consists of both a physical training component and a psycho-educational
20
21 component. This combination is hypothesised to strengthen the patient both physically and mentally
22
23 even if the patient has AF. Also we use mixed methods, which has its strengths in both using
24
25 qualitative and quantitative research design.³⁴

26
27
28
29
30
31 The major strengths of this randomised clinical trial are that it includes consecutive patients with a
32
33 reasonable number of inclusion and exclusion criteria securing external validity for the results. The
34
35 trial employs central, stratified randomisation which secures against selection bias.⁹¹⁻⁹³ The primary
36
37 outcome is assessed blinded to intervention and so are all statistical analyses, which should reduce
38
39 detection and interpretation bias.⁹¹⁻⁹³ The long-term outcomes are based on data taken from public
40
41 registry data, which are also likely not to include biased reporting of outcomes.

42
43
44
45
46 The secondary outcomes of self-rated mental health are by nature subjective and are likely to be
47
48 biased.⁹¹⁻⁹³ The patients answer questionnaires independently of the researchers. Data management
49
50 is handled independently from the researchers that interpret data. All questionnaires are distributed
51
52 electronically. All data entry is stored electronically in a coded database, and in an independent
53
54 spread sheet, only accessible for the CopenHeart Group.

1
2
3
4
5
6 Trial limitations include the fact that it is known from previous rehabilitation trials³³ that patients in
7
8 the control group have a tendency to do physical training due to the focus on the subject in the
9
10 recruitment process. We will be aware of that when we recruit and not focus on giving extensive
11
12 information about the exercise programme, or encourage patients to do physical training before
13
14 knowing what group they are randomised to. Any difference between patients completing the
15
16 intervention and those not completing (drop-outs) will be carefully discussed when evaluating the
17
18 intervention, results and the suitability for implementation. The trial is designed with multiple
19
20 statistical comparisons so results will be interpreted with caution. Further limitations of the trial and
21
22 methods used are similar to those of other trials including physical exercise and physical testing,
23
24 namely time-of-day, and day-to-day variation using exercise testing.⁹⁴ To ensure standard testing of
25
26 all physical exercise tests in the trial, standardised instructions for patients have been developed as
27
28 described in the methods section. Conversely, the trial population will be representative for the true
29
30 RFA population, meaning that some patients will have AF and some sinus rhythm while exercising
31
32 and testing, and this will facilitate implementation of The CopenHeart_{RFA} trial rehabilitation
33
34 programme in daily clinical practice.
35
36
37
38
39
40
41

42 The challenge with the set-up is that patients come from considerable distances and therefore some
43
44 will decline participation. Also, due to the nature of rehabilitation trials, the patients have to meet at
45
46 the hospital frequently, especially when randomised to the experimental intervention group.
47
48

49 The trial will, to our knowledge, be the largest trial conducted dealing with rehabilitation AF
50
51 ablation recipients. If a positive effect of integrated rehabilitation is found, it may have an impact on
52
53 the rehabilitation offered to patients treated for AF with RFA at international level. The trial is
54
55 expected to identify an intervention which can improve health and quality of life for the patients,
56
57
58
59
60

1
2
3
4 and subsequently reduce healthcare utilization and costs, as well as mortality.
5
6
7
8

9 10 **Publication policy**

11 The results of the trial will be published in appropriate peer-reviewed journals regardless of the
12 outcome. Authorship will be determined according to the guidelines of the International Committee
13 of Medical Journal Editors.
14
15
16
17
18
19

20 The outcome data will be analysed and published in the short term of 4 and 6 months and the long
21 term of 24 months. Due to the comprehensiveness of the outcome measures further post hoc
22 analysis will be published in separate papers. Economic and long term follow up will be reported as
23 data becomes accessible.
24
25
26
27
28
29
30

31 **Timetable**

32 Recruitment started in December 2011 in one heart centre and in July 2012 in the other participating
33 heart centre and is planned to finish in December 2013. To achieve adequate participant enrolment,
34 patients in doubt are contacted after hospital discharge by phone. The inclusion rate is closely
35 monitored every week.
36
37
38
39
40
41
42
43
44

45 **Acknowledgements and Funding**

46 The rehabilitation team responsible for the intervention programme and trial administration is:
47 Rikke Brandt Jakobsen, Lone Siersbæk-Hansen, Lars Tang, Helena Tjalk Sørensen, Signe Gills,
48 Helle Tauby, Katrine Haase and Line Ellemann-Jensen.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The trial is partly funded by The Danish Council for Strategic Research, The Lundbeck Foundation,
5
6 and The Heart Centre at Rigshospitalet. The funders have no influence on the trial design, the
7
8 execution of the trial or the interpretation of data.
9
10

11 12 **Authors' contributions**

13
14 SKB and ADZ in collaboration with SSR, JLH, MP, LCT, PW and CG designed the trial. SSR in
15
16 collaboration with SKB, ADZ, TBR, KLS, JHS, CG, LCT, SD, JLH and SD drafted the manuscript.
17
18 All revised the manuscript critically. All authors have given their final approval of the version to be
19
20 published.
21
22

23 24 **Competing interests**

25
26 None.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 1. Stewart S, Hart CL, Hole DJ, McMurray JJV. Population prevalence, incidence, and
8
9
10 predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart* 2001; November
11
12
13 01;86(5):516-21.
14
- 15
16
17 2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of
18
19
20 diagnosed atrial fibrillation in adults: national implications for rhythm management and
21
22
23 stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA)
24
25
26 Study. *JAMA* 2001; May 9;285(18):2370-5.
27
28
29
- 30
31
32 3. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Predictors and
33
34
35 prognosis of paroxysmal atrial fibrillation in general practice in the UK. *BMC Cardiovasc*
36
37
38 *Disord* 2005; Jul 11;5:20.
39
40
41
- 42
43
44 4. European Heart Rhythm Association, European Association for Cardio-Thoracic
45
46
47 Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management
48
49
50 of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the
51
52
53 European Society of Cardiology (ESC). *Europace* 2010; Oct;12(10):1360-420.
54
55
56
57
58
59
60

1
2
3
4 5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergman. Antiarrhythmics for
5
6
7
8 maintaining sinus rhythm after cardioversion of atral fibrillation (Review) 2009;The
9
10
11 Cochrane Libraly(1).

12
13
14
15 6. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome
16
17
18 parameters for trials in atrial fibrillation: recommendations from a consensus conference
19
20
21
22 organized by the German Atrial Fibrillation Competence NETwork and the European Heart
23
24
25 Rhythm Association. *Europace* 2007; Nov;9(11):1006-23.
26
27

28
29
30 7. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term
31
32
33 risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am*
34
35
36
37 *J Med* 2002; Oct 1;113(5):359-64.
38

39
40
41 8. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits.
42
43
44
45
46
47
48
49 *Int J Cardiol* 2011; Jun 25;.

50
51
52 9. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al.
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J* 2006; Apr;27(8):949-53.

- 1
2
3
4 10. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation
5
6
7
8 and flutter in the United States. *Am J Cardiol* 2009; Dec 1;104(11):1534-9.
9
10
11
12 11. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk
13
14 for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004; Aug
15
16 31;110(9):1042-6.
17
18
19
20
21
22
23 12. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. *Eur J*
24
25
26
27 *Health Econ* 2011; Oct;12(5):479-87.
28
29
30
31
32 13. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost
33
34 of illness of atrial fibrillation: a systematic review of the recent literature. *Europace* 2011;
35
36 Oct;13(10):1375-85.
37
38
39
40
41
42 14. Brenyo AJ, Aktas MK. Non-pharmacologic management of atrial fibrillation. *Am J*
43
44
45
46 *Cardiol* 2011; Jul 15;108(2):317-25.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 15. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. *Circ Arrhythm Electrophysiol* 2009; Aug;2(4):349-61.

16. Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN. Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). *Am Heart J* 2007; Apr;153(4):566-72.

17. Hansson A, Madsen-Hardig B, Olsson SB. Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance. *BMC Cardiovasc Disord* 2004; Aug 3;4:13.

18. Hegbom F, Sire S, Heldal M, Orning OM, Stavem K, Gjesdal K. Short-term exercise training in patients with chronic atrial fibrillation: effects on exercise capacity, AV conduction, and quality of life. *J Cardiopulm Rehabil* 2006; Jan-Feb;26(1):24-9.

19. Hegbom F, Stavem K, Sire S, Heldal M, Orning OM, Gjesdal K. Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation. *Int J Cardiol* 2007; Mar 2;116(1):86-92.

1
2
3
4 20. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized
5
6
7 study of the effects of exercise training on patients with atrial fibrillation. *Am Heart J* 2011;
8
9
10
11 Dec;162(6):1080-7.

12
13
14
15 21. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment
16
17
18 of health-related quality of life in patients with intermittent atrial fibrillation: implications for
19
20
21 the assessment of investigational therapy. *J Am Coll Cardiol* 2000; Oct;36(4):1303-9.

22
23
24
25 22. McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative
26
27
28 study. *J Cardiovasc Nurs* 2011; Jul-Aug;26(4):336-44.

29
30
31
32 23. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al.
33
34
35 Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A
36
37
38 position paper from the Cardiac Rehabilitation Section of the European Association of
39
40
41
42 Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2010;
43
44
45
46
47
48 Feb;17(1):1-17.

49
50
51
52 24. Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et
53
54
55
56 al. Secondary prevention in the clinical management of patients with cardiovascular

diseases. Core components, standards and outcome measures for referral and delivery.

Eur J Prev Cardiol 2012; Jun 20;

25. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev* 2011; Jul 6;(7)(7):CD001800.

26. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, et al. Exercise based rehabilitation for heart failure. *Cochrane Database Syst Rev* 2010; Apr 14;(4)(4):CD003331.

27. Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review. *Int J Nurs Stud* 2012; Jun;49(6):755-71.

28. Sire S. Physical training and occupational rehabilitation after aortic valve replacement. *Eur Heart J* 1987; Nov;8(11):1215-20.

1
2
3
4 29. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in
5
6
7
8 older patients with heart failure and preserved ejection fraction: a randomized, controlled,
9
10
11 single-blind trial. *Circ Heart Fail* 2010; Nov 1;3(6):659-67.
12

13
14
15 30. Clark AM, Catto S, Bowman G, Macintyre PD. Design matters in secondary
16
17
18 prevention: individualization and supervised exercise improves the effectiveness of cardiac
19
20
21 rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2011; Oct;18(5):761-9.
22
23

24
25
26 31. Clark AM, Haykowsky M, Kryworuchko J, MacClure T, Scott J, DesMeules M, et al. A
27
28
29 meta-analysis of randomized control trials of home-based secondary prevention programs
30
31
32 for coronary artery disease. *Eur J Cardiovasc Prev Rehabil* 2010; Jun;17(3):261-70.
33
34

35
36
37 32. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. Psychological
38
39
40 interventions for coronary heart disease. *Cochrane Database Syst Rev* 2011; Aug
41
42
43 10;(8)(8):CD002902.
44
45

46
47
48 33. Berg SK. *Comprehensive rehabilitation for patients with ICD: PhD dissertation.*

49
50
51 [Aarhus]: Faculty of Health Sciences, Aarhus University; 2011.
52
53
54

1
2
3
4 34. Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research*.
5
6
7

8 Thousand Oaks, Calif.: SAGE Publications; 2007.
9
10

11
12 35. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed
methods studies. *BMJ* 2010; Sep 17;341:c4587.

36. Carter RE, Lubinsky J, Domholdt E. *Rehabilitation research: principles and
applications*. 4. ed. ed. St. Louis, Mo.: Elsevier Saunders; 2011.

37. Law MC, MacDermid J. *Evidence-based rehabilitation: A guide to practice*. 2. edition
ed. Thorofare, NJ: Slack; 2008.

38. Clark N, Boyd NR, Goodman RM, Windsor RA. *Evaluation of health promotion, health
education, and disease prevention programs*. 3. ed. ed. Boston: McGraw-Hill; 2004.

39. Hammell KW, Carpenter C. *Qualitative research in evidence-based rehabilitation*.
Edinburgh: Churchill Livingstone; 2004.

1
2
3
4 40. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised
5
6
7 controlled trials of complex healthcare interventions: methodological study. *BMJ* 2009; Sep
8
9
10
11 10;339:b3496.

12
13
14
15 41. Neubeck L, Freedman SB, Clark AM, Briffa T, Bauman A, Redfern J. Participating in
16
17
18 cardiac rehabilitation: a systematic review and meta-synthesis of qualitative data. *Eur J*
19
20
21
22 *Prev Cardiol* 2012; Jun;19(3):494-503.

23
24
25
26
27 42. Chan A, Tetzlaff J, Altman D, Gotzsche P, Hrobjartsson A, et al. The SPIRIT initiative:
28
29
30 Defining Standard Protocol Items for Randomized Trials [conference abstract]. *German J*
31
32
33 *Evid Quality Health Care (Suppl)* 2008;(102:S27).

34
35
36
37
38 43. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group. Extending
39
40
41 the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation
42
43
44 and elaboration. *Ann Intern Med* 2008; Feb 19;148(4):295-309.

45
46
47
48
49 44. Mertens DJ, Kavanagh T. Exercise training for patients with chronic atrial fibrillation. *J*
50
51
52
53 *Cardiopulm Rehabil* 1996; May-Jun;16(3):193-6.

1
2
3
4 45. Berg SK, Svendsen JH, Zwisler AD, Pedersen BD, Preisler P, Siersbaek-Hansen L, et
5
6
7
8 al. COPE-ICD: a randomised clinical trial studying the effects and meaning of a
9
10
11 comprehensive rehabilitation programme for ICD recipients -design, intervention and
12
13
14 population. *BMC Cardiovasc Disord* 2011; Jun 17;11:33.

15
16
17
18
19 46. Zwisler A, Madsen M, Konstantin Nissen N. *Hjerterehabilitering: en medicinsk*
20
21
22 *teknologivurdering: evidens fra litteraturen og DANREHAB-forsøget.* [http://www.si-](http://www.sifolkesundhed.dk/upload/hjerterehabilitering_001.pdf)
23
24
25 [folkesundhed.dk/upload/hjerterehabilitering_001.pdf](http://www.sifolkesundhed.dk/upload/hjerterehabilitering_001.pdf). Version: 1,0 ed. Kbh.:
26
27
28 Sundhedsstyrelsen; 2006.

29
30
31
32
33 47. Anbefalinger for fysisk aktivitet. Available at:
34
35
36
37 [http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til](http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til%20voksne.aspx)
38
39
40 [%20voksne.aspx](http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til%20voksne.aspx). Accessed 09/13, 2011.

41
42
43
44 48. Oerkild B, Frederiksen M, Hansen JF, Simonsen L, Skovgaard LT, Prescott E. Home-
45
46
47
48 based cardiac rehabilitation is as effective as centre-based cardiac rehabilitation among
49
50
51 elderly with coronary heart disease: results from a randomised clinical trial. *Age Ageing*
52
53
54 2011; Jan;40(1):78-85.

1
2
3
4 49. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ. Comprehensive
5
6
7 cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a
8
9
10
11 randomised controlled trial. *Heart* 2003; Feb;89(2):155-60.
12

13
14
15 50. Lampman RM, Knight BP. Prescribing exercise training for patients with defibrillators.
16
17
18
19 *Am J Phys Med Rehabil* 2000; May-Jun;79(3):292-7.
20

21
22
23 51. Parse RR. *The human becoming school of thought: a perspective for nurses and other*
24
25
26
27 *health professionals*. Thousand Oaks, Calif.: Sage; 1998.
28

29
30
31 52. Berg SK, Pedersen BD, Svendsen JH, Zwisler AD, Kristensen L, Pedersen PU.
32
33
34 COPE-ICD: Patient experience of participation in an ICD specific rehabilitation
35
36
37 programme. *Eur J Cardiovasc Nurs* 2011; Apr 22;.
38

39
40
41 53. Mezzani A, Agostoni P, Cohen-Solal A, Corra U, Jegier A, Kouidi E, et al. Standards
42
43
44 for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac
45
46
47 patients: a report from the Exercise Physiology Section of the European Association for
48
49
50 Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2009;
51
52
53 Jun;16(3):249-67.
54
55
56
57
58
59
60

1
2
3
4 54. Gibbons L, Blair SN, Kohl HW, Cooper K. The safety of maximal exercise testing.
5
6
7

8 *Circulation* 1989; Oct;80(4):846-52.
9

10
11 55. Bjørner JB, Trab Damsgaard M, Watt T, Bech P, Rasmussen NK, Søndergaard
12

13 Kristensen T, et al. *Dansk manual til SF-36: et spørgeskema om helbredsstatus*. [S.I.]: Lif;
14

15
16
17 1997.
18
19

20
21 56. Ware JE,Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
22

23
24
25
26
27 Conceptual framework and item selection. *Med Care* 1992; Jun;30(6):473-83.
28

29
30 57. McHorney CA, Ware JE,Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey
31

32
33
34 (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental
35

36
37
38 health constructs. *Med Care* 1993; Mar;31(3):247-63.
39

40
41 58. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National
42

43
44
45
46 Hospital Register. A valuable source of data for modern health sciences. *Dan Med Bull*
47

48
49 1999; Jun;46(3):263-8.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 59. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J*
5
6
7
8 *Public Health* 2011; Jul;39(7 Suppl):30-3.

9
10
11
12 60. Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service
13
14
15
16 Register. *Scand J Public Health* 2011; Jul;39(7 Suppl):34-7.

17
18
19
20 61. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry.
21
22
23
24 *Scand J Public Health* 2011; Jul;39(7 Suppl):38-41.

25
26
27
28 62. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health*
29
30
31
32 2011; Jul;39(7 Suppl):26-9.

33
34
35
36 63. ATS Committee on Proficiency Standards for Clinical Pulmonary Function
37
38
39 Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit*
40
41
42
43 *Care Med* 2002; Jul 1;166(1):111-7.

44
45
46
47 64. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*
48
49
50
51 1982;14(5):377-81.

52
53
54
55 65. Rikli RE, Jones CJ. *Senior fitness test manual*. Champaign, Ill.: Human Kinetics; 2001.

1
2
3
4 66. Ekholm O, Hesse U, Davidsen M, Kjoller M. The study design and characteristics of
5
6
7 the Danish national health interview surveys. *Scand J Public Health* 2009; Sep;37(7):758-

8
9
10
11 65.

12
13
14
15 67. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey.: Manual and Interpretation
16
17
18 guide 2005;The Health Institute, New England Medical Center, Boston, Massachussetts.

19
20
21
22
23 68. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
24
25
26
27 *Scand* 1983; Jun;67(6):361-70.

28
29
30
31 69. Ferrans CE, Powers MJ. Quality of life index: development and psychometric
32
33
34 properties. *ANS Adv Nurs Sci* 1985; Oct;8(1):15-24.

35
36
37
38 70. Bowman G, Watson R, Trotman-Beasty A. Primary emotions in patients after
39
40
41 myocardial infarction. *J Adv Nurs* 2006; Mar;53(6):636-45.

42
43
44
45 71. Bøgelund M, Mønsted C. *Hjertepatienters brug og oplevelse af rehabilitering 2010.*

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Kbh.: Hjerteforeningen; 2010.

- 1
2
3
4 72. Oldridge N, Saner H, McGee HM, HeartQoL Study Investigators. The Euro Cardio-QoL
5
6
7
8 Project. An international study to develop a core heart disease health-related quality of life
9
10
11 questionnaire, the HeartQoL. *Eur J Cardiovasc Prev Rehabil* 2005; Apr;12(2):87-94.
12
13
14
15 73. Drummond MF. *Methods for the economic evaluation of health care programmes*. 3rd
16
17
18 edition ed. Oxford: Oxford University Press; 2005.
19
20
21
22
23 74. Hallal PC, Victora CG. Reliability and validity of the International Physical Activity
24
25
26 Questionnaire (IPAQ). *Med Sci Sports Exerc* 2004; Mar;36(3):556.
27
28
29
30
31 75. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. *J*
32
33
34
35 *Psychosom Res* 1993; Oct;37(7):753-62.
36
37
38
39 76. Buysse DJ, Reynolds CF,3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
40
41
42 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*
43
44
45 1989; May;28(2):193-213.
46
47
48
49 77. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, et al.
50
51
52
53
54 Development and validation of the Atrial Fibrillation Effect on QualiTY-of-Life (AFEQT)
55
56
57
58
59
60

1
2
3
4 Questionnaire in patients with atrial fibrillation. *Circ Arrhythm Electrophysiol* 2011;
5
6
7
8 Feb;4(1):15-25.
9

10
11
12 78. DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for
13
14 handling missing data in clinical trials. *J Biopharm Stat* 2009; Nov;19(6):1055-73.
15
16
17

18
19
20 79. Dmitrienko A, Wiens BL, Tamhane AC, Wang X. Tree-structured gatekeeping tests in
21
22 clinical trials with hierarchically ordered multiple objectives. *Stat Med* 2007; May
23
24
25
26
27 30;26(12):2465-78.
28

29
30
31 80. McHorney CA, Ware JE, Rogers W, Raczek A, Lu JFR. The validity and relative
32
33 precision of MOS short- and long-form health status scales and Dartmouth COOP charts:
34
35 results from the Medical Outcomes Study.
36
37
38

39
40
41 81. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac
42
43 rehabilitation. *Heart* 2006; Jan;92(1):62-7.
44
45
46
47

48
49
50 82. Polit DF, Beck CT. *Essentials of nursing research: methods, appraisal, and utilization*.
51
52
53
54 6. edition ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.
55
56

1
2
3
4 83. Ricoeur P. *Interpretation theory: discourse and the surplus of meaning*. 5. print. ed.

5
6
7
8 Fort Worth, Tex.: Texas Christian University Press; 1976.

9
10
11
12 84. EuroQol--a new facility for the measurement of health-related quality of life. The

13
14
15 EuroQol Group. *Health Policy* 1990; Dec;16(3):199-208.

16
17
18
19
20 85. Brooks R. EuroQol: the current state of play. *Health Policy* 1996; Jul;37(1):53-72.

21
22
23
24 86. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO

25
26
27
28 value set for EQ-5D health states. *Scand J Public Health* 2009; Jul;37(5):459-66.

29
30
31
32 87. Fox-Rushby JA, Cairns J. *Economic evaluation*. Maidenhead: Open University Press;

33
34
35
36 2005.

37
38
39
40 88. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-

41
42
43
44 effectiveness acceptability curves. *Health Econ* 2001; Dec;10(8):779-87.

45
46
47
48 89. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based

49
50
51
52 rehabilitation for patients with coronary heart disease: systematic review and meta-

53
54
55
56 analysis of randomized controlled trials. *Am J Med* 2004; May 15;116(10):682-92.

1
2
3
4 90. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation for
5
6
7
8 heart failure. *Cochrane Database Syst Rev* 2004;(3)(3):CD003331.
9

10
11
12 91. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence
13
14 of bias in treatment effect estimates in controlled trials with different interventions and
15
16 outcomes: meta-epidemiological study. *BMJ* 2008; Mar 15;336(7644):601-5.
17
18
19

20
21
22 92. Gluud L. Bias in clinical intervention research. *Am J Epidemiol* 2006;163(6):493-501.
23
24
25

26
27
28 93. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported
29
30 study design characteristics on intervention effect estimates from randomised controlled
31
32 trials: combined analysis of meta-epidemiological studies. *Health Technol Assess* 2012;
33
34
35 Sep;16(35):1-82.
36
37
38

39
40
41 94. Rowland T, Unnithan V, Barker P, Lindley M, Roche D, Garrard M. Time-of-day effect
42
43 on cardiac responses to progressive exercise. *Chronobiol Int* 2011; Aug;28(7):611-6.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeartRFA trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002377.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2013
Complete List of Authors:	Risom, Signe; Rigshospitalet, The Heart Centre Zwisler, Ann-Dorthe; National institute of Public Health, University of Copenhagen; Rigshospitalet, The Heart Centre Rasmussen, Trine; Rigshospitalet, The Heart Centre; Gentofte Hospital , Department of cardiology Sibilitz, Kirstine; Rigshospitalet, Cardiology Svendsen, Jesper; Rigshospitalet, The Heart Centre Gluud, Christian; Copenhagen University Hospital, Centre for Clinical Intervention Research Hansen, Jane; Copenhagen Trial Unit, Centre for Clinical Intervention Research Winkel, Per; Copenhagen Trial Unit, Centre for Clinical Intervention Research Thygesen, Lau; University of Southern Denmark, National Institute of Public Health Perhonen, Merja; Corusfit, Hansen, Jim; Gentofte Hospital , Department of cardiology Dunbar, Sandra; Nell Hodgson Woodruff School of Nursing, Emory University Berg, Selina; Rigshospitalet, Cardiology; Gentofte Hospital , Department of cardiology
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Cardiovascular medicine, Nursing, Rehabilitation medicine
Keywords:	Adult cardiology < CARDIOLOGY, Atrial Fibrillation , QUALITATIVE RESEARCH, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeart_{RFA} trial protocol

Signe S. Risom, RN, MSc^{1,§}, Ann-Dorthe Zwisler, MD, Ph.D.^{1,2}, Trine B. Rasmussen RN, MScN^{1,4}, Kirstine Lærum Sibilitz, MD¹, Jesper Hastrup Svendsen, MD, DMSc, FESC^{1,3}, Christian Gluud, MD, DMSc⁵, Jane Lindschou Hansen, MSc⁵, Per Winkel, MD, DMSc⁵, Lau Caspar Thygesen, MSc, Ph.D.², Merja Perhonen MD, Ph.D.⁶, Jim Hansen, MD⁴, Sandra B. Dunbar, RN, DSN, FAAN, FAHA⁷, Selina Kikkenborg Berg, RN, MScN, Ph.D. FESC^{1,4}.

¹ Rigshospitalet, The Heart Centre, Copenhagen University Hospital, Denmark

² National Institute of Public Health, University of Southern Denmark

³ Gentofte Hospital, Department of Cardiology, Denmark

⁴ The Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC)

⁵ Copenhagen Trial Unit, Centre for Clinical Intervention Research. Copenhagen University Hospital, Denmark

⁶ CorusFit, Heikinkatu 3 B, 40100 Jyväskylä, Finland

⁷ Nell Hodgson Woodruff School of Nursing, Emory University
Atlanta, Georgia, United States

§Corresponding author:

Signe Stelling Risom, RN, MSc,
The Heart Centre, Department of Cardiology,
Copenhagen University Hospital,
Blegdamsvej 9, DK-2100 Copenhagen.

Signe.stelling.risom@rh.regionh.dk

Word count:

Abstract: 300, Body: 7.035

Keywords: atrial fibrillation, cardiac rehabilitation, physical exercise, psycho-education

Article summary

Article focus

- The CopenHeart_{RFA} trial is a randomised clinical trial investigating the effects of comprehensive cardiac rehabilitation versus usual care for patients treated for atrial fibrillation (AF) with ablation.
- The hypothesis is that comprehensive cardiac rehabilitation improves physical capacity and mental health.
- Using a mixed methods approach, a broad range of outcome measures are collected to evaluate the intervention.

Key messages

- AF affects 1-2% of the population. Patients with AF experience diminished quality of life and are afraid to do physical exercise after treatment with ablation.
- No studies exploring the effects of rehabilitation of patients treated for AF with ablation have been published.
- This trial is the first to examine physical functioning and to test a comprehensive rehabilitation programme on a large population of patients treated for AF with ablation.

CopenHeart_{RFA} will provide much needed evidence and insight on the post-discharge status and rehabilitation needs of patients treated for AF with ablation.

Strengths and limitations of this study

- The study has been designed to meet the criteria for high quality in non-pharmacological randomised clinical trials with central randomisation, multi-centre participation, blinded assessment and analysis.
- We are aware of the day to day variation that can appear when carrying out ergospirometry, in testing and that the performance can depend on the individual tester. Accordingly, we will interpret the findings conservatively.

Abstract

Introduction

Atrial fibrillation affects almost 2% of the population in the Western world. To preserve sinus rhythm, ablation is undertaken in symptomatic patients. Observational studies show that patients with atrial fibrillation often report low quality of life and are less prone to be physically active due to fear of triggering fibrillation. Small trials indicates that exercise training has a positive effect on exercise capacity and mental health, and both patients with recurrent atrial fibrillation and in sinus rhythm may benefit from rehabilitation in managing life after ablation. No randomised trials have been published on cardiac rehabilitation for atrial fibrillation patients treated with ablation that includes exercise and psycho-educational components.

Aim

To test the effects of an integrated cardiac rehabilitation programme versus treatment as usual for patients with atrial fibrillation treated with ablation.

Methods and analysis design

The trial is a multicentre parallel arm design with 1:1 randomisation to the intervention and control group with blinded outcome assessment. 210 patients treated for atrial fibrillation with radiofrequency ablation will be included. The intervention consists of a rehabilitation programme including four psycho-educative consultations with a specially trained nurse and 12 weeks of individualised exercise training, plus the standard medical follow-up. Patients in the control group will receive the standard medical follow-up. The primary outcome measure is exercise capacity measured by VO₂ peak. The secondary outcome measure is self-rated mental health measured by the Short Form 36 questionnaire. Post intervention, qualitative interviews will be conducted in 10% of the intervention group.

Ethics and dissemination

The protocol is approved by the regional research ethics committee (number. H-1-2011-135), the Danish Data Protection Agency (reg. nr. 2007-58-0015) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may possibly impact on rehabilitation guidelines.

Registration: Clinicaltrials.gov identifier: NCT01523145

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia and affects 2% of the population in the Western world.¹⁻³ Typical symptoms are palpitations, dyspnoea, fatigue, dizziness, and syncope. Patients' symptoms and the length of periods in AF are highly variable both for the individual and between patients.⁴⁻⁶ AF is associated with increased risk of stroke, other thromboembolic events, and heart failure.⁶⁻⁸ Hospitalisations due to AF account for one third of all admissions for cardiac arrhythmias.⁸ As the prevalence of AF increases with age, the incidence of AF is increasing due to an ageing population.^{2,9,10} After 40 years of age, the lifetime risk of developing AF is 25%.¹¹ The annual cost of AF is high in comparison with other diseases.¹² Therefore, AF has become an economic burden and this will continue to increase over the coming decades.¹³ Thus, AF has now become a health, social and economic challenge in the Western world.

14

Primary treatment goals for individuals with AF are re-establishing and maintaining sinus rhythm, decreasing AF symptoms, and prevention of complications. In accordance with current national and international guidelines, radiofrequency ablation (RFA) is often undertaken in symptomatic patients. RFA is an invasive treatment, intended to cure AF and has a success rate of 77% versus 52% for antiarrhythmic medication.¹⁵ In Denmark, around 600 RFAs are conducted annually at two heart centres.

A cohort study of 655 patients from a randomised trial found that AF symptoms are a negative predictor for patients' physical capacity,¹⁶ and in the presence of AF, patients do fewer physical activities.¹⁷ Smaller observational studies and a randomised trial investigating the effect of exercise

1
2
3
4 training on AF patients found increased exercise capacity and a decreased resting heart rate after
5
6 training.¹⁸⁻²⁰
7
8
9

10
11 Previous studies show significantly impaired quality of life in patients with AF compared to healthy
12
13 controls measured by the questionnaire Short Form 36 (SF-36). The general health component (\pm
14
15 standard deviation) was 54 ± 21 in AF patients compared to 78 ± 17 in healthy controls.²¹ A
16
17 qualitative study demonstrated that educational help after AF treatment is lacking, even though
18
19 symptoms of distress and lack of self-management regarding symptoms like palpitations, dyspnoea,
20
21 and fatigue are common.²² Furthermore, small observational studies indicate a positive effect of
22
23 exercise training on patients with AF in terms of mental health and physical activity (15% increase
24
25 of VO_2).^{18, 19} However, these findings need confirmation in larger randomised clinical trials.
26
27
28
29

30
31 Secondary prevention initiatives including cardiac rehabilitation are recommended by the European
32
33 Society of Cardiology (ESC).²³ Studies exploring the effects of rehabilitation for patients treated for
34
35 AF are lacking. As there is no evidence of its efficacy, rehabilitation is not systematically provided
36
37 in Denmark and most often patients treated for AF with RFA are not offered any rehabilitation at
38
39 all. The evidence for general cardiac rehabilitation is strong, but it is found that it is poorly
40
41 implemented and only selected patient groups are offered full comprehensive cardiac rehabilitation
42
43 programmes, even though ESC recommends such programmes.²⁴ Research has mainly been
44
45 conducted within patients with coronary heart disease and heart failure, where rehabilitation has
46
47 been proven to reduce hospital re-admissions and mortality in a cost-effective way,^{25, 26} as well as
48
49 improve quality of life.²⁷ More specifically, studies on the effect of exercise training have
50
51 demonstrated an increase in exercise capacity of up to 38% in patients after valve replacement
52
53 surgery²⁸ and an increase in peak VO_2 of 2.3 ± 2.2 (SD) ml/kg per minute in the intervention group
54
55
56
57
58
59
60

1
2
3
4 compared with -0.3 ± 2.1 (SD) ml/kg per minute in the control group, as well as a significant change
5
6 in quality of life in older patients with heart failure.²⁹
7

8 .. Traditional cardiac rehabilitation has focused on physical training and standardized programmes,
9
10 but studies now indicate that individualized content and supervised exercise components can
11
12 improving outcomes.³⁰ In addition to exercise training, there is evidence to support interventions
13
14 that include patient education, which in patients with coronary heart disease has shown to improve
15
16 health related quality of life and decrease healthcare costs,³¹ and psychological support, which has
17
18 been shown to improve psychological symptoms, such as depression and anxiety.³² Interventions
19
20 designed to cover both physical and psychological problems may provide the best method for
21
22 optimising functioning and enhancing quality of life.³³ We have not been able to identify
23
24 randomised trials or observational studies in patients who have undergone RFA for AF that offer
25
26 both psycho-educational intervention and physical training. Therefore, the CopenHeart_{RFA} trial was
27
28 undertaken with the aim of testing a rehabilitation programme consisting of physical exercise and a
29
30 psycho-educational intervention versus treatment as usual for RFA treated AF patients.
31
32
33
34
35
36
37

38 **Methods**

39 **Design**

40 Major parts of the method section and trial design in this paper are similar to two other randomised
41
42 clinical trials, CopenHeart_{VR} and CopenHeart_{IE}, and therefore sections from this paper will be
43
44 copied in these trial protocols (Sibilitz KL et al. *Effect of integrated cardiac rehabilitation versus*
45
46 *treatment as usual for patients with isolated heart valve surgery: The randomised CopenHeart*
47
48 *valvular trial protocol*. drafted October 2012; and Rasmussen TB et al. *A randomised clinical trial*
49
50 *of comprehensive cardiac rehabilitation versus usual care for patients treated for infective*
51
52 *endocarditis – the CopenHeart_{IE}*. Accepted for publication, BMJ Open, October 2012).
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 The CopenHeart_{RFA} trial is a multi-centre, multidisciplinary randomised clinical superiority trial.
8
9
10 Secondary, qualitative data are also collected and the two methods are integrated by applying a
11
12 mixed method embedded experimental design (Figure 1).^{34, 35} Quantitative methods are applied,
13
14 with specified quantitative pre- and post-measures to evaluate the effect of the experimental
15
16 intervention. Alongside quantitative measurements, qualitative data will be collected. The premise
17
18 of mixed methods research is that the use of qualitative and quantitative approaches in combination
19
20 provides a better understanding of the research problems than either approach alone, because
21
22 different types of questions require different types of data and that mixed methods research provides
23
24 strengths that offset the weaknesses of both qualitative and quantitative research.³⁴ The methods are
25
26 integrated by applying a mixed method embedded experimental design and include qualitative data
27
28 to develop the intervention and to examine the process of the intervention and the results of the trial
29
30 (see Figure 1).^{34, 35} The rationale for this approach is that the quantitative findings provide a general
31
32 understanding of the research problem through statistical results while qualitative findings refine
33
34 and explain the results by exploring participants' views in greater detail and will be presented by
35
36 themes of patient thoughts or concerns about the intervention. Evaluation using qualitative research
37
38 methods is increasingly promoted in evidence-based rehabilitation.³⁶⁻³⁹ Qualitative research
39
40 alongside randomised controlled trials can contribute in several ways to the development and
41
42 evaluation of complex healthcare interventions and may be particularly useful in evaluating
43
44 interventions that involve social and behavioural processes that are difficult to explore or capture
45
46 using quantitative methods alone.⁴⁰ As patient participation is paramount for the efficacy of the
47
48 rehabilitation,⁴¹ we find it highly valuable to include the patients' perspective in the development
49
50 and evaluation of the intervention. This paper presents the study protocol for the CopenHeart_{RFA}
51
52
53
54
55
56
57
58
59
60

1
2
3
4 randomised clinical trial. The complementary studies, including the qualitative part of the trial are
5
6 briefly described in a separate section.
7

8
9 The trial is described in accordance with the current SPIRIT guidelines (Standard Protocol Items:
10
11 Recommendations for Interventional Trials).⁴² Results will be reported following the CONSORT
12
13 (CONsolidated Standards Of Reporting Trials) guidelines for non-pharmacological interventions.⁴³
14
15

21 22 **Trial hypotheses**

23
24 The primary hypothesis is that the rehabilitation program increases physical capacity among AF
25
26 patients treated with RFA after 4 months measured by VO₂ peak, which is expected to be 20%
27
28 more than in the control group receiving standard treatment alone. The estimate of 20% is based on
29
30 findings from pilot studies including patients with permanent AF which found an increase of 15%
31
32 in VO₂ peak. We therefore expect a VO₂ peak in the intervention group of 18 ml/kg/min and of 15
33
34 ml/kg/min in the control group, corresponding to a difference of 20% (3 ml/kg/min).⁴⁴
35
36

37
38
39 The secondary hypothesis is that the rehabilitation programme increases quality of life and self-
40
41 rated mental health among AF patients treated with RFA after 6 months by 3 points on the Medical
42
43 Outcome Study Short Form 36 (SF-36) questionnaire mental component scale, compared with
44
45 control participants receiving standard treatment.¹⁹
46
47

48
49
50 Exploratory hypotheses are that the experimental intervention decreases AF recurrence; improves
51
52 self-rated health and sleep-quality; reduces early retirement from work, use of health care services
53
54 and mortality, and is cost efficient.
55
56

Trial participants

Consecutive patients hospitalised for AF and treated with RFA at two heart centres in Denmark (Gentofte Hospital and Rigshospitalet, Copenhagen University Hospital) will be screened for inclusion and approached for trial participation (Figure 2). Regardless of RFA outcome, both patients with recurrent AF and patients in sinus rhythm after the ablation will be included in the trial. Patients 18 years of age or older, Danish speaking, and providing verbal and written informed consent will be eligible for participation. Patients unable to understand trial instructions, pregnant or breastfeeding, with reduced ability to follow the planned programme due to other physical illness, who prior to RFA have been doing intense physical exercise or sports at competitive level several times a week, or do not wish to participate, and patients already enrolled in clinical trials that prohibit participation in additional trials are excluded.

Trial procedure, randomisation, and follow-up

Patients will be approached for participation during their hospitalisation for RFA. Information will be given by a nurse or physician from the research team, who will obtain informed written consent after the RFA procedure. A brief oral introduction is initially given together with written information describing the trial and implications for the patient in detail. The patient is given ample time to read the information and if necessary involve a relative in the decision making. The enrolling nurse or physician will return after the RFA or call the patient to answer any questions the patient or their relative might have. The patient should subsequently be able to provide informed consent or reject participation. After the informed consent form is signed, baseline data will be collected including the baseline questionnaire package, demographic variables, and clinical characteristics (Table 2). Then the Copenhagen Trial Unit (<http://www.ctu.dk/>) is contacted for

1
2
3
4 central randomisation of the participant. Randomisation is conducted according to a computer-
5 generated allocation sequence with a varying block size kept unknown to the investigators.
6
7

8 Participants are randomised 1:1 to the experimental intervention group or the control group and
9 stratified according to sex and type of AF (persistent or paroxysmal). Thus, neither investigators nor
10 patients or relatives can influence to which group the patients are allocated. For both groups, the
11 follow-up assessment will take place at 1 month, 4 months, 6 months, and 12 months post-
12 discharge, and a register-based follow-up assessment will be conducted at 24 months (Table 2). In
13 case of complications to the RFA after enrolment in the trial, the patients will be handled
14 individually (e.g., arrhythmia or inguinal haematoma).
15
16
17
18
19
20
21
22
23

24
25 The patients answer questionnaires independently of the researchers, and before randomisation. All
26 questionnaires are distributed electronically, thus data management is handled independently from
27 the researchers that interpret data. All data are stored electronically in a coded database, and in an
28 independent spread sheet, only accessible for the CopenHeart group.
29
30
31
32
33

34
35 Personal information about potential and enrolled patients will be collected electronically and
36 shared in a database only accessible to those within the project group responsible for patient
37 recruitment, in order to protect confidentiality before, during and after the trial.
38
39
40
41

42 Due to the nature of rehabilitation, the intervention group is not blinded for the patients or the
43 investigators, but the outcome assessment of the primary outcome, the statistical analyses, and
44 drawing of conclusions will be conducted blinded for the allocated intervention group.
45
46
47
48

49 **The experimental intervention group**

50 Patients in the experimental intervention group will follow the integrated cardiac rehabilitation
51 programme consisting of a psycho-educational component and an exercise training component
52
53
54
55
56
57
58
59
60

1
2
3
4 alongside standard treatment (described below). The patients will be contacted at 1, 4, 6 and 12
5
6 months for outcome assessment including clinical data collection.
7
8

9 10 *The physical exercise training component*

11 The intervention has been developed and partly tested in a clinical rehabilitation trial, the COPE-
12 ICD trial⁴⁵, which included patients with an implantable cardioverter defibrillator. We here
13
14 observed a significant impact of the intervention on peak VO₂, physical capacity and self-assessed
15
16 mental health. The intervention has been modified for patients treated for atrial fibrillation with
17
18 ablation as described below. The CopenHeart physical exercise intervention meets European²⁴ and
19
20 Danish guidelines⁴⁶ for physical exercise in patients with heart disease, and complies with The
21
22 National Danish Board of Health recommendations for physical exercise in daily living for heart
23
24 patients.⁴⁷
25
26
27

28 The physical exercise starts one month after the ablation and after the first ergospirometry test and
29
30 comprises the following three elements:
31
32
33

34
35
36 Individually planned physical exercise by specially trained physiotherapists. Integrating detailed
37
38 information concerning AF symptoms and RFA, co-morbidity, hospitalisation, activities of daily
39
40 living, and level of physical activity prior to RFA, a specially trained physiotherapist conducts a
41
42 patient telephone consultation up to 30 minutes. The consultation is based on initial testing of the
43
44 patient including a cardiopulmonary exercise test, a 6 minutes walking test and a 'sit and stand' test,
45
46 described in the outcome section. For all patients, a rehabilitation plan is prepared as an individual
47
48 training diary, and all patients are instructed in the use of a heart rate monitor (Polar Watch
49
50 provided by Rigshospitalet). The heart rate monitor and diary is essential to ensure CopenHeart
51
52 training protocol compliance and they are returned for data collection at the end of the exercise
53
54 training intervention.
55
56
57
58
59
60

1
2
3
4 Intensive exercise training programme. Physical exercise is initiated at Rigshospitalet four weeks
5
6 after RFA to ensure optimal rest and healing. Using wireless electrodes integrated into t-shirts
7
8 (Corus-Fit, CardioCardio and Corus Exercise Assistant, CEA, version 2.0.16, Finland) potential
9
10 cardiac arrhythmias, electrocardiographic abnormalities such as ST-depression, ST-elevation, Q- or
11
12 T-wave altering, atrial fibrillation, and ventricular arrhythmias and training intensity level are
13
14 monitored.
15

16
17
18 After 1-3 exercise training sessions at Rigshospitalet, the patient continues the programme at a local
19
20 CopenHeart certified training facility supervised by physiotherapists or as supervised home-based
21
22 training. Supervised home-based exercise training has shown similar results to hospital-based
23
24 exercise training³¹ and has been confirmed in a Danish setting.⁴⁸
25
26

27 The physical exercise training continues for 12 weeks, comprising three sessions weekly of 60
28
29 minutes, in total, 36 sessions. The training protocol consists of cardiovascular training and strength
30
31 exercises to improve endurance and muscular strength.
32
33

34
35
36
37 An exercise session consists of 10 minutes warm up, 20 minutes bicycling, 20 minutes strength, and
38
39 a 10 minutes stretching and cool-down period. . Using the results from the cardiopulmonary
40
41 exercise test performed prior to the initial training session, in combination with the Borg scale
42
43 measuring subjective exhaustion, the aerobic exercise is performed with gradually increasing
44
45 intensity throughout the exercise intervention period, corresponding to 13 to 17 on the Borg Scale
46
47 and 50% to 80% of the maximum heart rate. The anaerobic resistance training is initiated at 30% to
48
49 40 % of 1 repetition maximum (RM) for the upper body, and 40% to 50 % of 1 RM for the lower
50
51 body, with an increasing work load during the training sessions. To achieve cardiovascular
52
53 adjustment and reduce the risk of malignant cardiac arrhythmias and ischemia, the training session
54
55
56
57
58
59
60

1
2
3
4 is initiated and terminated with a warm up and a cool down period to gradually increase and
5
6 decrease training intensity and heart rate. This cardiovascular adjustment has been proven to reduce
7
8 the risk of ischemia and arrhythmia in relation to exercise training.^{49, 50} Training is predominantly
9
10 performed in the upright position to reduce left ventricle preload (diastolic volume) and the risk of
11
12 ischemia and arrhythmias due to heart failure.⁵⁰

13 Sustained moderate physical exercise daily. Participants are instructed to perform moderate physical
14
15 exercise at least 30 minutes a day during the intervention period, e.g., bicycling, walking,
16
17 gardening, jogging or recreational sports. Participants are encouraged to continue with moderate
18
19 physical exercise throughout life.
20
21
22
23

24 ***The psycho-educational component***

25
26 The aim of the psycho-educational intervention is to provide emotional support and improve coping
27
28 skills and illness appraisal in order for the patient to respond appropriately to physical and
29
30 psychological symptoms. Education and information about the disease prepare the patient for
31
32 expected symptoms and sensations. Dialogue and shared reflection facilitate strategies for coping
33
34 with symptoms and experiences associated with the condition, e.g., anxiety and fear. Cardiac care
35
36 nurses with specific training will perform the psycho-educational intervention. Some of the most
37
38 commonly reported concerns of patients treated for AF with RFA, such as recurrent AF, and
39
40 concerns about being able to manage a working life are outlined in a guide which nurses use to
41
42 address when and if relevant (see Table 1). Information given will also be based on national
43
44 guidelines and standard treatment of patients treated for AF. The consultations focus on managing
45
46 life after AF treated with RFA by establishing a joint approach to disease management and coping
47
48 strategies, taking a holistic view. The psycho-educational intervention is inspired by R.R. Parse's
49
50 Human Becoming Practice Methodologies' three dimensions.⁵¹ These are interpreted as: 1) discuss
51
52 and give meaning to the past, present and future, 2) explore and discuss events and possibilities and
53
54
55
56
57
58
59
60

3) move along with envisioned possibilities. According to this theory, there are three ways of changing health: creative imaging, that is to see, hear and feel what a situation might be like if lived in a different way, affirming personal patterns and value priorities, and shedding light on paradoxes, that is, looking at the incongruence in a situation and changing the view held of something. The nurse is present in the process through discussions, silent immersion and reflection. The human becoming practice methodology was chosen to apply a holistic patient approach, focusing on the coping and transformation process of the individual person. Furthermore, the method is already extensively used in the outpatient heart clinics at the heart centre at Rigshospitalet, such as for patients with inherited heart diseases and adults with congenital heart disease and is documented in the COPE-ICD trial.^{45, 52} The consultations take place in a quiet setting at the out-patient clinic and will last for approximately one hour. The nurse is able to facilitate contact with or seek advice from a physician if needed. The first consultation will be approximately one month after discharge, and then once every four to six weeks, with a total of four consultations. Consultations can be done by telephone, in accordance with the patient's wishes. The primary investigator will attend the consultations regularly to ensure protocol compliance.

Table 1. Guide to the psycho-educative consultation.

Number visit	1	2	3	4
Ask the patient how he/she has been since the ablation.				
What has happened since last time he/she was here?	X	X	X	X
Invite the patient to talk about his/her thoughts and questions.	X	X	X	X
Ask about the time leading up to RFA and his/her AF history. Experiences before, under and	X			

1
2
3
4 after the hospitalization and RFA.
5

6 Talk about how it is to have had/ have AF and X
7
8 been through RFA, how that have affected the patient's
9
10 life. Is there something he/she avoids or feel like
11
12 he/she cannot do anymore? This in relation to family
13
14 relations, friends and free time/ leisure activities.
15
16

17
18 Make sure that the patient has started the physical X X X
19
20 training and talk about how it is going. Are training
21
22 appointments booked?
23

24 Talk about if the patient has changed his/her X
25
26 feelings or thoughts of the body and its functions.
27

28
29 Talk about recognition of symptoms, how the patient X X (X) (X)
30
31 is feeling about recurrence of AF and opinions about
32
33 future AF treatment. Worries about recurrence of AF,
34
35 strategies of prevention.
36

37
38 Information/recommendations in relation to the X X X X
39
40 subjects/problems discussed.
41
42
43

44 ***Intervention deviations***

45
46 Both components of the intervention will be supervised regularly by the primary investigator to
47
48 ensure protocol compliance. Modification of the allocated intervention due to surgery
49
50 complications, rehospitalisation or emerging co-morbidities (e.g. recurrent AF, musculoskeletal
51
52 problems) will be individually assessed, and the time of the primary outcome assessment at four
53
54
55
56
57
58
59
60

1
2
3
4 months (described in section below) will be corrected in accordance with changes in the
5
6 intervention.
7
8

9 10 **Control group: treatment as usual**

11 Patients in the control group will follow standard treatment for patients treated for AF with RFA
12 including 3-6 months follow-up with a physician and a 12 months follow-up with a nurse.
13

14 Furthermore, patients will be contacted at 1, 4, 6 and 12 months for outcome assessment including
15
16 clinical data collection.
17
18
19

20 21 22 **Outcomes and data collection**

23 Data will be collected to evaluate the effect and meaning of the intervention. The primary and
24
25 secondary outcomes reflect the primary modifiable factors of the intervention. Since this is a
26
27 complex intervention with two main components, an exercise component and a psycho-educational
28
29 component, this is reflected in the primary and secondary outcome. The intervention has been tested
30
31 in ICD patients (unpublished data in the COPE-ICD trail, available on request) and the intervention
32
33 reflects well in the chosen measures that have found to be sensitive to changes based on the
34
35 intervention. Since almost no evidence exists for rehabilitation programmes for patients treated for
36
37 AF with RFA, data on a number of outcomes will be collected for exploratory analyses.
38
39
40
41
42
43
44

45 ***Primary outcome***

46
47 **Physical capacity measured by peak VO₂ according to a standardised protocol developed in**
48
49 **accordance with guidelines^{53,54} 1, 4 and 12 months after randomisation (Table 1).**
50
51

52
53
54 Physical capacity is measured by peak VO₂ using cardiopulmonary exercise testing (Ergo-Spiro CS-
55
56 200, Schiller, Schweiz). This is chosen as a primary outcome since this is standard in exercise based
57
58
59
60

17

1
2
3
4 rehabilitation trails. The test is performed according to current guidelines for ergospirometry
5 testing, and by ergometer bicycle, simultaneously monitoring heart-rhythm, blood pressure,
6 electrocardiogram (ECG), and measuring gas-exchange during workload and in the following
7 recovery period. The average test duration is 10-15 minutes including pre- and post- test phase
8 without work load. Before each session calibration is performed to address changes in room
9 temperature, humidity and air oxygen content. A standardised ramp-protocol is used with initial
10 work load of 25 or 50 watts, increasing gradually by 12.5 watts every minute until peak exhaustion.
11 Peak exhaustion is evaluated by a respiratory exchange ratio (RER) \geq 1.10 or subjective
12 exhaustion of the patient. In order to equally encourage the patients, independent of the tester, a
13 standardised guide has been developed. During the test period, clinical manifestations, ECG
14 abnormalities (ST depression, ST elevation, Q- and T-wave changes, supraventricular or ventricular
15 arrhythmias), blood pressure response, and several physiological variables are observed and
16 documented. The test will be performed by either a cardiac care nurse or a physician. For safety
17 reasons preset criteria for initiation and/or termination of the test have been defined.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 *Secondary outcome*

38 Self-rated mental health is measured by the SF-36 questionnaire,⁵⁵⁻⁵⁷ mental component score, after
39 1 month, 4 months, 6 months and 12 months (Table 2).
40
41
42
43
44
45

46 *Exploratory outcomes*

47 Long-term follow-up: Register data regarding mortality, causes of death, hospitalisation/re-
48 hospitalisation, emergency room visits, outpatient visits, health care costs, visits to the general
49 practitioner, medication use, employment status and payment of welfare benefits (sick leave
50 payment and early retirement pension) will be collected at 24 months to assess long term effects of
51
52
53
54
55
56
57
58
59
60

the intervention (Table 2). Danish recording keeping for the data mentioned above functions well, with only a small percentage of lost data.⁵⁸ Consequently the method is well suited as an outcome measure in small patient populations. Data will be extracted from the Danish National Patient Register, the Danish National Health Service Register, the Danish National Prescription Registry, the Danish National Causes of Death Register and records of transfer payments and labour market affiliation.⁵⁹⁻⁶²

6 minutes walking test: The maximum walking distance (in meters) within 6 minutes is measured, using standardized instructions,⁶³ while subjective exhaustion with regard to fatigue and dyspnoea using the Borg scale⁶⁴ is registered.

Sit and stand test: The maximum amount of times a patient can sit and rise from a normal chair within 30 seconds is recorded. Subjective exhaustion is measured using the Borg exhaustion scale.⁶⁴

Biochemical screening: Potassium, sodium, haemoglobin and creatinine. 1 EDTA plasma heparin tube will be frozen (80°) for further analyses (pro-BNP, BNP, copeptin).

Other exploratory outcomes: AF recurrence, self-rated health and sleep-quality, retirement from work, use of health care services, mortality and cost efficiency (Table 2).

Table 2. Exploratory quantities subjected to post-hoc analysis

Quantity	Time of measure (months)	Type of quantity
Demographic		
Sex	BL	Binary (M/F)
Age, height, weight,	BL, 1,4,12	Continuous
Marital, occupational, educational status	BL	Categorical
Clinical		
NYHA- classification	BL, 1, 4, 12	Continuous
Previous heart disease, diabetes mellitus, kidney disease, pulmonary disease (COPD), co-morbidities, hypertension, dyslipidaemia, smoking	BL	Binary (Y/N)
Medication	BL, 1, 4, 12	Binary (Y/N)

AF specific data:		
Type of atrial fibrillation	BL	Categorical
Number of ablations	BL, 1,4,12	Binary (Y/N)
Atrial fibrillation symptoms	BL, 1,4,12	Continuous
CHA ₂ DS ₂ VASc score	BL, 1,4, 12	Continuous
The European Heart Rhythm Association symptom score	BL, 1,4, 12	Continuous
Paraclinical and imaging		
Blood work (Haemoglobin, infection-, kidney- liver and selected nutritional parameters, electrolytes, cholesterol- and thyroid status, ProBNP)	BL, 1, 4, 12	Continuous
Electrocardiogram	BL, 4, 12	Continuous
Physical function		
6 minute walking test ⁶³	BL, 1, 4, 12	Continuous
Sit to stand test ⁶⁵	1, 4, 12	Continuous
EVO recording	1,4,12	Categorical
Questionnaires		
Physical activity level ⁶⁶	BL, 1, 4, 6, 12, 24	Binary (Y/N)
SF-36 ⁶⁷ HADS ⁶⁸ , QoL-CV ⁶⁹	BL, 1, 4, 6, 12, 24	Continuous
Emotions and Health ⁷⁰	BL	Continuous
Rehabilitation ⁷¹	12	Continuous
HeartQoL R ⁷² , EQ-5D ⁷³	BL, 6, 12, 24	Continuous
IPAQ ⁷⁴	1, 4, 12, 24	Continuous
MFI-20 ⁷⁵	BL, 1, 4, 12	Continuous
PSQI ⁷⁶	1, 6	Continuous
AFEQT ⁷⁷	BL, 1,4,12,24	Continuous

AFEQT, Atrial Fibrillation Effect on Quality-of-life; BL, baseline; CHA₂DS₂VASc, score for Atrial Fibrillation Stroke Risk; EQ-5D, EuroQoL; HADS, Hospital Anxiety and Depression Scale; HeartQoL R, Heart-Related Quality of Life; IPAQ, International Physical Activity Questionnaire; PSQI, Pittsburgh Sleep Quality Index; QoL-CV, Quality of Life - Cardiac Version; SF-36, Short Form 36.

Sample size calculation for the primary outcome

We are performing a randomised trial where the continuous variable VO₂ peak is the primary outcome. The control and the intervention group are independent and the ratio of patients in the

1
2
3
4 intervention group to the patients in the control group is 1:1. A previous trial of patients with
5
6 permanent AF found that VO_2 peak was normally distributed with a standard deviation of 3.8
7
8 ml/kg/min.⁴⁴ As the CopenHeart_{RFA} trial has a more varied patient population who have all been
9
10 treated for AF with RFA, which means that the majority of the patients will have sinus rhythm and
11
12 the rest will have AF, the patients are not directly comparable with the patients in the previous trial,
13
14 and we assume a standard deviation of 6 ml/kg/min to be more relevant. We consider a 0.5 standard
15
16 deviation to be the minimal relevant difference, equivalent to 3 ml/kg/min. Therefore, if the true
17
18 difference between the intervention group and control group is 3 ml/kg/min and the standard
19
20 deviation is 6 ml/kg/min in the control group, 105 patients in the intervention group and 105 in the
21
22 control group (a total of 210 patients) are needed to reject the null hypothesis, stating that the mean
23
24 in the intervention group and the control group is the same, with a power of 95%. The type I error
25
26 probability associated with this test of this null hypothesis is 5%.
27
28
29
30
31
32

33 **Power calculation for the secondary outcome**

34
35 The secondary outcome measure is the continuous variable mental component, SF 36. If the true
36
37 difference between the intervention and control group is 7 points, and the standard deviation in the
38
39 control group is 18 points,²¹ we will be able to reject the null hypothesis that the population means
40
41 of the experimental and control groups are equal with a probability of (power) 0.80. The type I error
42
43 probability associated with this test of this null hypothesis is 5%.
44
45
46
47
48

49 **Statistical analyses**

50
51 Data will be pseudo-anonymised and analysed blinded by a trial-independent statistician using
52
53 intention-to-treat analyses and a mixed model with repeated measures (MMRM) for continuous
54
55 outcome measures.⁷⁸ Using MMRM ensures that missing data values (in case of the primary and
56
57
58
59
60

1
2
3
4 secondary outcome) will not create bias as long as the values are missing at random. Two-sided
5
6 tests are performed. The level of significance is set at 5%. With regard to multiplicity, gate keeping
7
8 will be used to adjust the observed P values for primary and secondary outcomes.⁷⁹ Both unadjusted
9
10 and adjusted P values will be reported.

11
12 For the primary and secondary outcomes, sensitivity analysis will be conducted to assess the
13
14 potential impact of values missing not at random. For each intervention group (A and B) some
15
16 quantities (imputing quantities) are computed to be used to impute missing values in a group (A or
17
18 B) as follows. A comparison between group A and group B where missing values in group A are
19
20 imputed using imputing quantities obtained from group A and missing values from group B are
21
22 imputed using imputing quantities obtained from group B is referred to as a best case analysis. If
23
24 missing values in group A are imputed using imputing quantities obtained from group B and vice
25
26 versa the comparison is called a worst case analysis. The imputing quantities for the primary
27
28 outcome are the group mean at T1 (\bar{X}_1), the group mean at T4 (\bar{X}_4), the group mean at T6
29
30 (\bar{X}_6), the mean difference between the value measured at T4 and that measured at T1 (Δ_1),
31
32 and the mean difference between the value measured at T6 and that measured at T4 (Δ_2). Table
33
34 3 explains how the quantities are used to impute missing values in a group (either the same group or
35
36 the other intervention group). If the standard error (SE) of a parameter estimate calculated using
37
38 imputed data is smaller than that of the corresponding parameter calculated using complete case
39
40 data it is replaced by the latter SE when the P value is calculated (Table 3).
41
42
43
44
45
46
47

48 Long-term register-based outcomes will be analysed by two different models: non-negative count
49
50 outcomes (e.g., number of contacts with hospital or number of visits to general practitioners) will be
51
52 analysed by a Poisson model or a zero-inflated Poisson model if the number of zeros are large, and
53
54 time-to-event data (e.g., cause-specific mortality and leaving the labor market) will be analysed
55
56
57
58
59
60

with survival methods (Kaplan-Meier estimator and Cox regression model). Especially for socio-economic outcomes, competing risks due to mortality will be considered if a large proportion of patients die during follow-up.

Exploratory data will be analysed using appropriate statistical methods according to the type of data (see Table 2). SPSS version 17.0 and SAS version 9.3 will be used.

Table 3. Statistical analysis

Observed pattern in group B at 1, 4, and 6 months	Imputed value in group B at 1 month	Imputed value in group B at 4 month	Imputed value in group B at 6 months
mis ^A , mis, mis	$X1\text{-bar}^B$	$X4\text{-bar}^C$	$X6\text{-bar}^D$
mis, mis, Y3 ^E	$Y3 - (\text{delta}1^F + \text{delta}2^G)^H$	$Y3 - \text{delta}2$	
mis, Y2, mis	$Y2 - \text{delta}1$		$Y2 + \text{delta}2$
Y1, mis, mis		$Y1 + \text{delta}1$	$Y1 + \text{delta}1 + \text{delta}2$
Y1, Y2, mis			$Y2 + \text{delta}2$
Y1, mis, Y3		$(Y1 + \text{delta}1 + Y3 - \text{delta}2)/2$	
mis, Y2, Y3	$Y2 - \text{delta}1$		

Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group B). mis=missing value, X1=value at month 1, X4=value at month 4, X6=value at month 6.

^AThe value at 4 months is missing in group B, ^BMean of values observed in group A at time 1 month. ^CMean of values observed in group A at time 4 months. ^DMean of values observed in group A at time 6 months. ^EObserved value in group B at time 6 months. ^FThe mean of difference between values observed at time 4 months and value observed at time 1 month in group A, ^GThe mean of difference between value observed at time 6 months and value observed at time 4 months in group A, ^HIf an imputed value is 0 it is set equal to 0.

Interim analysis and Data Monitoring Safety Committee (DMSC)

The DMSC works independently from the funder and has no competing interests, and consists of two clinicians and a statistician. The committee is responsible for safeguarding the interests of trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the clinical trial. In line with the terms of the Data Monitoring and Safety Committee charter, one formal interim analysis meeting will be held to review data relating to treatment efficacy, participant safety, and quality of trial conduct. The three members of the Data Monitoring and Safety Committee will meet when the 12 week follow-up data of about 50% of the trial participants have been obtained. Any serious adverse events will be registered as part of the data collection and the overall number of adverse events will be reported at the meeting.

Complementary studies

The Surveysbased study. The post-discharge status of the patients treated with RFA will be explored through a national survey. The standardised questionnaires SF-36,⁶⁷ Hospital Anxiety and Depression Scale (HADS),⁶⁸ EuroQoL-EQ-5D,^{69, 70} Heart Related Quality of Life (HeartQoL R),⁷¹ International Physical Activity Questionnaire (IPAQ),^{72, 73} and a questionnaire developed by the Danish Heart Foundation on the extent and quality of rehabilitation offered will be sent to patients having undergone treatment for RFA, 6-12 months post-discharge. The instruments are all validated and have good reliability and responsiveness.^{68, 72, 74, 75, 80, 81} The data will provide knowledge on patients' self-rated health, quality of life, anxiety and depression, economic situation and the extent and quality of the rehabilitation currently received. Patients were identified through the National Patient Register⁵⁹ and questionnaires were sent out to 608 patients. We anticipate 25% will decline participation, leaving an estimated 456 questionnaire respondents. Data will be anonymised and analysed by relevant descriptive statistical methods.

Qualitative post intervention study

After the intervention, 10% of the participants from the intervention group will be strategically chosen for an interview in order to explore the experiences and processes behind the potential effects of the intervention. The qualitative study will explore patient experiences of participating in the CopenHeart_{RFA} programme and investigate which components were meaningful.

To achieve maximum variation, qualified interviewees are chosen on the basis of sex, AF type, and current heart rhythm.⁸² The analysis will be inspired by Ricoeur's theory of interpretation consisting of three levels: naive reading, structured analysis and critical interpretation and discussion.⁸³

The results will be presented in themes based on patient experience and evaluation of the intervention. As an example we will look for explanations for the results in physical capacity and mental health as described by the patients. We are using mixed method to explore all aspects of the intervention, but the qualitative findings are seen as a complementary study to the primary randomised clinical trial.

Economic evaluation

An economic evaluation will be conducted alongside the trial to assess the cost-utility of cardiac rehabilitation compared with treatment as usual in the study population. The economic evaluation will compare the costs to quality adjusted life years (QALY) and take a societal perspective, as recommended nationally. QALYs and costs will be assessed at the end of the intervention, 6 months from randomisation, and later after 24 months from randomisation using register-based follow up.

QALYs will be estimated using the self-completed EQ-5D instrument, which is a standardised instrument assessing 5 dimensions of self-reported health status (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).^{84, 85} The estimated calculations will be valued using Danish preference weights.⁸⁶ Information on costs will only include costs that are expected to differ

1
2
3
4 between the intervention and usual care group.⁷³ Costs included in the evaluation are health costs
5 associated with the rehabilitation programme, other health care costs (health care utilization besides
6 rehabilitation), patient costs and costs of productivity losses. Information on costs will be collected
7 by a mixture of activity-based costing, surveys, patient diary and by the use of public records.
8 Results from the analysis will be reported as an incremental cost-effectiveness analysis (ICER).
9 Sensitivity analysis will be conducted to express uncertainty in the estimates.⁸⁷ The reporting of the
10 ICER is presented using Bayesian methods, including bootstrapping and presented as cost-
11 effectiveness acceptability curves.⁸⁸

22 23 24 **Ethics**

25 The inclusion started December 2011 and is approved by the Regional Ethics Committee (number
26 H-1-2011-135) and the Danish Data Protection Agency (no. 2007-58-0015). All eligible patients
27 will be informed about the trial verbally and in writing, and the patients are included after informed
28 consent has been obtained. All data will be handled confidentially and patients ensured anonymity.
29 The trial complies with the latest Declaration of Helsinki and is registered at ClinicalTrials.gov
30 (NCT01523145). An independent international safety committee monitors the trial. All serious and
31 adverse events will be registered and reported in accordance with the safety charter.

32 Not providing rehabilitation to the control group can be ethically justified as current national and
33 international guidelines give no specific recommendations on cardiac rehabilitation for patients
34 treated for AF with RFA. The scope and quality of rehabilitation offered to this population is
35 unknown, but suspicions are that generally no rehabilitation is offered in Denmark. The only way
36 patients can get supervised exercise training is if they voluntarily enrol in a programme e.g. through
37 non-profit organisations. The survey based complementary study, described previously in this
38 paper, will hopefully provide more insight into this. In screening patients for participation, the

1
2
3
4 enrolling nurse or physician will exclude those with a compelling rehabilitation need. Furthermore,
5
6 patients are informed of the study design before giving their consent, and are free to decline
7
8 participation.
9

10 11 12 13 14 **Discussion**

15
16 Due to the difference in the three patient groups that are included in the overall CopenHeart trial,
17
18 patients treated for infective endocarditis, heart valve surgery and patients treated for AF with RFA,
19
20 the intervention and outcome measures differ slightly, most importantly in the case of the psycho-
21
22 educational intervention, which is longer for patients treated for infective endocarditis and heart
23
24 valve surgery, because of the complexity of the diseases and the longer hospitalisation. Biochemical
25
26 markers are similarly chosen differently to address the various co-morbidities of the three diseases
27
28 and some disease specific questionnaires are chosen to capture the specific disease relevant issues.
29
30
31

32
33
34 To our knowledge no previous randomised clinical trials or observational studies have been
35
36 conducted focusing on integrated cardiac rehabilitation for AF patients treated with RFA, so
37
38 therefore it is not known what effect, if any, rehabilitation has on these patients. However, in the
39
40 light of evidence from other groups of patients with heart disease a positive effect can be
41
42 expected.^{23, 89, 90}
43
44

45
46 This trial is different from previous trials because we apply a comprehensive rehabilitation
47
48 intervention which consists of both a physical training component and a psycho-educational
49
50 component. This combination is hypothesised to strengthen the patient both physically and mentally
51
52 even if the patient has AF. Also we use mixed methods, which has its strengths in both using
53
54 qualitative and quantitative research design.³⁴
55
56
57
58
59
60

1
2
3
4 The major strengths of this randomised clinical trial are that it includes consecutive patients with a
5 reasonable number of inclusion and exclusion criteria securing external validity for the results. The
6 trial employs central, stratified randomisation which secures against selection bias.⁹¹⁻⁹³ The primary
7 outcome is assessed blinded to intervention and so are all statistical analyses, which should reduce
8 detection and interpretation bias.⁹¹⁻⁹³ The long-term outcomes are based on data taken from public
9 registry data, which are also likely not to include biased reporting of outcomes.
10
11
12
13
14
15
16
17
18
19

20 The secondary outcomes of self-rated mental health are by nature subjective and are likely to be
21 biased.⁹¹⁻⁹³ The patients answer questionnaires independently of the researchers. Data management
22 is handled independently from the researchers that interpret data. All questionnaires are distributed
23 electronically. All data entry is stored electronically in a coded database, and in an independent
24 spread sheet, only accessible for the CopenHeart Group.
25
26
27
28
29
30
31
32

33 Trial limitations include the fact that it is known from previous rehabilitation trials³³ that patients in
34 the control group have a tendency to do physical training due to the focus on the subject in the
35 recruitment process. We will be aware of that when we recruit and not focus on giving extensive
36 information about the exercise programme, or encourage patients to do physical training before
37 knowing what group they are randomised to. Any difference between patients completing the
38 intervention and those not completing (drop-outs) will be carefully discussed when evaluating the
39 intervention, results and the suitability for implementation. The trial is designed with multiple
40 statistical comparisons so results will be interpreted with caution. Further limitations of the trial and
41 methods used are similar to those of other trials including physical exercise and physical testing,
42 namely time-of-day, and day-to-day variation using exercise testing.⁹⁴ To ensure standard testing of
43 all physical exercise tests in the trial, standardised instructions for patients have been developed as
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 described in the methods section. Conversely, the trial population will be representative for the true
5 RFA population, meaning that some patients will have AF and some sinus rhythm while exercising
6 and testing, and this will facilitate implementation of The CopenHeart_{RFA} trial rehabilitation
7 programme in daily clinical practice. We are aware that patients treated with RFA are a highly
8 selected group of patients with paroxysmal or persistent AF, and they are properly more likely to
9 participate and complete a rehabilitation programme, compared to patients with e.g. permanent AF
10 since patients with permanent AF often are older and suffer from co-morbidity⁴. Therefore we do
11 not expect to generalize the results to all AF patients.
12
13
14
15
16
17
18
19
20
21
22
23

24 The challenge with the set-up is that patients come from considerable distances and therefore some
25 will decline participation. Also, due to the nature of rehabilitation trials, the patients have to meet at
26 the hospital frequently, especially when randomised to the experimental intervention group.
27
28
29
30

31 The trial will, to our knowledge, be the largest trial conducted dealing with rehabilitation AF
32 ablation recipients. If a positive effect of integrated rehabilitation is found, it may have an impact on
33 the rehabilitation offered to patients treated for AF with RFA at international level. The trial is
34 expected to identify an intervention which can improve health and quality of life for the patients,
35 and subsequently reduce healthcare utilization and costs, as well as mortality.
36
37
38
39
40
41
42
43
44
45

46 **Publication policy**

47 The results of the trial will be published in appropriate peer-reviewed journals regardless of the
48 outcome. Authorship will be determined according to the guidelines of the International Committee
49 of Medical Journal Editors.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The outcome data will be analysed and published in the short term of 4 and 6 months and the long
5
6 term of 24 months. Due to the comprehensiveness of the outcome measures further post hoc
7
8 analysis will be published in separate papers. Economic and long term follow up will be reported as
9
10 data becomes accessible.
11

12 13 14 15 **Timetable**

16
17 Recruitment started in December 2011 in one heart centre and in July 2012 in the other participating
18
19 heart centre and is planned to finish in December 2013. To achieve adequate participant enrolment,
20
21 patients in doubt are contacted after hospital discharge by phone. The inclusion rate is closely
22
23 monitored every week.
24
25

26 27 28 **Acknowledgements and Funding**

29
30 The rehabilitation team responsible for the intervention programme and trial administration is:

31
32 Rikke Brandt Jakobsen, Lone Siersbæk-Hansen, Lars Tang, Helena Tjalk Sørensen, Signe Gills,
33
34 Helle Tauby, Katrine Haase and Line Ellemann-Jensen.
35
36

37
38 The trial is partly funded by The Danish Council for Strategic Research, The Lundbeck Foundation,
39
40 and The Heart Centre at Rigshospitalet. The funders have no influence on the trial design, the
41
42 execution of the trial or the interpretation of data.
43
44

45 46 **Authors' contributions**

47
48 SKB and ADZ in collaboration with SSR, JLH, MP, LCT, PW and CG designed the trial. SSR in
49
50 collaboration with SKB, ADZ, TBR, KLS, JHS, CG, LCT, SD, JLH and SD drafted the manuscript.
51
52

53 All revised the manuscript critically. All authors have given their final approval of the version to be
54
55 published.
56
57

Competing interests

None.

1. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart* 2001; November 01;86(5):516-21.

2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001; May 9;285(18):2370-5.

3. Ruigomez A, Johansson S, Wallander MA, et al. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. *BMC Cardiovasc Disord* 2005; Jul 11;5:20.

4. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Europace* 2010; Oct;12(10):1360-420.

1
2
3
4 5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmics for maintaining
5
6
7
8 sinus rhythm after cardioversion of atral fibrillation (Review) 2009;The Cochrane Libraly(1).
9

10
11
12 6. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation:
13
14
15 recommendations from a consensus conference organized by the German Atrial
16
17
18 Fibrillation Competence NETwork and the European Heart Rhythm Association. *Europace*
19
20
21 2007; Nov;9(11):1006-23.
22
23

24
25
26 7. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks
27
28
29 associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med*
30
31
32 2002; Oct 1;113(5):359-64.
33
34

35
36
37 8. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits.
38
39
40
41 *Int J Cardiol* 2011; Jun 25;.
42
43

44
45
46 9. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of
47
48
49 atrial fibrillation: the Rotterdam study. *Eur Heart J* 2006; Apr;27(8):949-53.
50
51
52

- 1
2
3
4 10. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and
5
6
7
8 flutter in the United States. *Am J Cardiol* 2009; Dec 1;104(11):1534-9.
9
10
11
12 11. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial
13
14
15 fibrillation: the Framingham Heart Study. *Circulation* 2004; Aug 31;110(9):1042-6.
16
17
18
19
20 12. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. *Eur J*
21
22
23 *Health Econ* 2011; Oct;12(5):479-87.
24
25
26
27
28 13. Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: a
29
30
31 systematic review of the recent literature. *Europace* 2011; Oct;13(10):1375-85.
32
33
34
35
36 14. Brenyo AJ, Aktas MK. Non-pharmacologic management of atrial fibrillation. *Am J*
37
38
39 *Cardiol* 2011; Jul 15;108(2):317-25.
40
41
42
43
44 15. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with
45
46
47 antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and
48
49
50 meta-analyses. *Circ Arrhythm Electrophysiol* 2009; Aug;2(4):349-61.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 16. Atwood JE, Myers JN, Tang XC, et al. Exercise capacity in atrial fibrillation: a substudy
5
6
7
8 of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). *Am Heart J* 2007;
9
10
11 Apr;153(4):566-72.
12
13
14
15 17. Hansson A, Madsen-Hardig B, Olsson SB. Arrhythmia-provoking factors and
16
17
18 symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with
19
20
21
22 100 patients seeking hospital assistance. *BMC Cardiovasc Disord* 2004; Aug 3;4:13.
23
24
25
26 18. Hegbom F, Sire S, Heldal M, et al. Short-term exercise training in patients with chronic
27
28
29 atrial fibrillation: effects on exercise capacity, AV conduction, and quality of life. *J*
30
31
32
33 *Cardiopulm Rehabil* 2006; Jan-Feb;26(1):24-9.
34
35
36
37 19. Hegbom F, Stavem K, Sire S, et al. Effects of short-term exercise training on
38
39
40 symptoms and quality of life in patients with chronic atrial fibrillation. *Int J Cardiol* 2007;
41
42
43
44 Mar 2;116(1):86-92.
45
46
47
48
49 20. Osbak PS, Mourier M, Kjaer A, et al. A randomized study of the effects of exercise
50
51
52 training on patients with atrial fibrillation. *Am Heart J* 2011; Dec;162(6):1080-7.
53
54
55
56
57
58
59
60

1
2
3
4 21. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in
5
6
7
8 patients with intermittent atrial fibrillation: implications for the assessment of investigational
9
10
11 therapy. *J Am Coll Cardiol* 2000; Oct;36(4):1303-9.

12
13
14
15 22. McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative
16
17
18 study. *J Cardiovasc Nurs* 2011; Jul-Aug;26(4):336-44.

19
20
21
22
23 23. Piepoli MF, Corra U, Benzer W, et al. Secondary prevention through cardiac
24
25
26 rehabilitation: from knowledge to implementation. A position paper from the Cardiac
27
28
29 Rehabilitation Section of the European Association of Cardiovascular Prevention and
30
31
32
33 Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2010; Feb;17(1):1-17.

34
35
36
37
38 24. Piepoli MF, Corra U, Adamopoulos S, et al. Secondary prevention in the clinical
39
40
41 management of patients with cardiovascular diseases. Core components, standards and
42
43
44 outcome measures for referral and delivery. *Eur J Prev Cardiol* 2012; Jun 20;.

45
46
47
48
49 25. Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for
50
51
52 coronary heart disease. *Cochrane Database Syst Rev* 2011; Jul 6;(7)(7):CD001800.

1
2
3
4 26. Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart failure.
5
6

7
8 *Cochrane Database Syst Rev* 2010; Apr 14;(4)(4):CD003331.
9

10
11
12 27. Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review.
13

14
15 *Int J Nurs Stud* 2012; Jun;49(6):755-71.
16
17

18
19
20 28. Sire S. Physical training and occupational rehabilitation after aortic valve replacement.
21

22
23 *Eur Heart J* 1987; Nov;8(11):1215-20.
24
25

26
27
28 29. Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with
29
30
31 heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.
32

33
34 *Circ Heart Fail* 2010; Nov 1;3(6):659-67.
35
36

37
38
39 30. Clark AM, Catto S, Bowman G, et al. Design matters in secondary prevention:
40

41
42 individualization and supervised exercise improves the effectiveness of cardiac
43

44
45
46 rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2011; Oct;18(5):761-9.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 31. Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of randomized control
5
6
7
8 trials of home-based secondary prevention programs for coronary artery disease. *Eur J*
9
10
11 *Cardiovasc Prev Rehabil* 2010; Jun;17(3):261-70.

12
13
14
15 32. Whalley B, Rees K, Davies P, et al. Psychological interventions for coronary heart
16
17
18 disease. *Cochrane Database Syst Rev* 2011; Aug 10;(8)(8):CD002902.

19
20
21
22 33. Berg SK. *Comprehensive rehabilitation for patients with ICD: PhD dissertation.*
23
24
25
26 [Aarhus]: Faculty of Health Sciences, Aarhus University; 2011.

27
28
29
30
31 34. Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research.*
32
33
34
35 Thousand Oaks, Calif.: SAGE Publications; 2007.

36
37
38
39 35. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed
40
41
42
43 methods studies. *BMJ* 2010; Sep 17;341:c4587.

44
45
46
47 36. Carter RE, Lubinsky J, Domholdt E. *Rehabilitation research: principles and*
48
49
50
51 *applications*. 4. ed. ed. St. Louis, Mo.: Elsevier Saunders; 2011.

1
2
3
4 37. Law MC, MacDermid J. *Evidence-based rehabilitation: A guide to practice*. 2. edition
5
6
7
8 ed. Thorofare, NJ: Slack; 2008.

9
10
11
12 38. Clark N, Boyd NR, Goodman RM, et al. *Evaluation of health promotion, health*
13
14
15 *education, and disease prevention programs*. 3. ed. ed. Boston: McGraw-Hill; 2004.

16
17
18
19
20 39. Hammell KW, Carpenter C. *Qualitative research in evidence-based rehabilitation*.
21
22
23
24 Edinburg: Churchill Livingstone; 2004.

25
26
27
28 40. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised
29
30
31 controlled trials of complex healthcare interventions: methodological study. *BMJ* 2009; Sep
32
33
34 10;339:b3496.

35
36
37
38
39 41. Neubeck L, Freedman SB, Clark AM, et al. Participating in cardiac rehabilitation: a
40
41
42 systematic review and meta-synthesis of qualitative data. *Eur J Prev Cardiol* 2012;
43
44
45 Jun;19(3):494-503.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 42. Chan A, Tetzlaff J, Altman D, et al. The SPIRIT initiative: Defining Standard Protocol
5
6
7
8 Items for Randomized Trials [conference abstract]. *German J Evid Quality Health Care*
9
10
11 (*Suppl*) 2008;(102:S27).

12
13
14
15 43. Boutron I, Moher D, Altman DG, et al. Extending the CONSORT statement to
16
17
18 randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern*
19
20
21
22 *Med* 2008; Feb 19;148(4):295-309.

23
24
25
26 44. Mertens DJ, Kavanagh T. Exercise training for patients with chronic atrial fibrillation. *J*
27
28
29
30 *Cardiopulm Rehabil* 1996; May-Jun;16(3):193-6.

31
32
33
34 45. Berg SK, Svendsen JH, Zwisler AD, et al. COPE-ICD: a randomised clinical trial
35
36
37
38 studying the effects and meaning of a comprehensive rehabilitation programme for ICD
39
40
41
42 recipients -design, intervention and population. *BMC Cardiovasc Disord* 2011; Jun
43
44
45 17;11:33.

46
47
48
49 46. Zwisler A, Madsen M, Konstantin Nissen N. *Hjerterehabilitering: en medicinsk*
50
51
52 *teknologivurdering: evidens fra litteraturen og DANREHAB-forsøget*. <http://www.si->
53
54

1
2
3
4 folkesundhed.dk/upload/hjerterehabilitering_001.pdf. Version: 1,0 ed. Kbh.:
5
6

7
8 Sundhedsstyrelsen; 2006.
9

10
11
12 47. Anbefalinger for fysisk aktivitet. Available at:
13

14
15 <http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til>
16
17
18 [%20voksne.aspx](http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til). Accessed 09/13, 2011.
19
20

21
22
23 48. Oerkild B, Frederiksen M, Hansen JF, et al. Home-based cardiac rehabilitation is as
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
effective as centre-based cardiac rehabilitation among elderly with coronary heart disease:
results from a randomised clinical trial. *Age Ageing* 2011; Jan;40(1):78-85.

49. Fitchet A, Doherty PJ, Bundy C, et al. Comprehensive cardiac rehabilitation
programme for implantable cardioverter-defibrillator patients: a randomised controlled trial.
Heart 2003; Feb;89(2):155-60.

50. Lampman RM, Knight BP. Prescribing exercise training for patients with defibrillators.
Am J Phys Med Rehabil 2000; May-Jun;79(3):292-7.

1
2
3
4 51. Parse RR. *The human becoming school of thought: a perspective for nurses and other*
5
6
7
8 *health professionals*. Thousand Oaks, Calif.: Sage; 1998.

9
10
11
12 52. Berg SK, Pedersen BD, Svendsen JH, et al. COPE-ICD: Patient experience of
13
14
15 participation in an ICD specific rehabilitation programme. *Eur J Cardiovasc Nurs* 2011; Apr
16
17
18 22;.

19
20
21
22 53. Mezzani A, Agostoni P, Cohen-Solal A, et al. Standards for the use of cardiopulmonary
23
24
25 exercise testing for the functional evaluation of cardiac patients: a report from the Exercise
26
27
28 Physiology Section of the European Association for Cardiovascular Prevention and
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2009; Jun;16(3):249-67.

54. Gibbons L, Blair SN, Kohl HW, et al. The safety of maximal exercise testing.
Circulation 1989; Oct;80(4):846-52.

55. Bjørner JB, Trab Damsgaard M, Watt T, et al. *Dansk manual til SF-36: et*
spørgeskema om helbredsstatus. [S.l.]: Lif; 1997.

1
2
3
4 56. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.

5
6
7
8 Conceptual framework and item selection. *Med Care* 1992; Jun;30(6):473-83.

9
10
11 57. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey

12 (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental

13
14
15
16
17
18
19 health constructs. *Med Care* 1993; Mar;31(3):247-63.

20
21
22 58. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
valuable source of data for modern health sciences. *Dan Med Bull* 1999; Jun;46(3):263-8.

59. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J*

60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Public Health 2011; Jul;39(7 Suppl):30-3.

60. Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service

Register. *Scand J Public Health* 2011; Jul;39(7 Suppl):34-7.

61. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry.

Scand J Public Health 2011; Jul;39(7 Suppl):38-41.

1
2
3
4 62. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health*
5
6
7
8 2011; Jul;39(7 Suppl):26-9.
9

10
11 63. ATS Committee on Proficiency Standards for Clinical Pulmonary Function
12
13 Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit*
14
15
16
17
18
19 *Care Med* 2002; Jul 1;166(1):111-7.
20
21

22
23 64. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*
24
25
26
27 1982;14(5):377-81.
28
29

30
31 65. Rikli RE, Jones CJ. *Senior fitness test manual*. Champaign, Ill.: Human Kinetics; 2001.
32
33

34
35 66. Ekholm O, Hesse U, Davidsen M, et al. The study design and characteristics of the
36
37
38
39 Danish national health interview surveys. *Scand J Public Health* 2009; Sep;37(7):758-65.
40
41

42
43 67. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey.: Manual and Interpretation
44
45
46
47 guide 2005;The Health Institute, New England Medical Center, Boston, Massachussetts.
48
49

50
51 68. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
52
53
54
55 *Scand* 1983; Jun;67(6):361-70.
56
57

- 1
2
3
4 69. Ferrans CE, Powers MJ. Quality of life index: development and psychometric
5
6
7 properties. *ANS Adv Nurs Sci* 1985; Oct;8(1):15-24.
8
9
10
11
12 70. Bowman G, Watson R, Trotman-Beasty A. Primary emotions in patients after
13
14 myocardial infarction. *J Adv Nurs* 2006; Mar;53(6):636-45.
15
16
17
18
19
20 71. Bøgelund M, Mønsted C. *Hjertepatienters brug og oplevelse af rehabilitering 2010*.
21
22
23 Kbh.: Hjertereforeningen; 2010.
24
25
26
27
28 72. Oldridge N, Saner H, McGee HM, et al. The Euro Cardio-QoL Project. An international
29
30 study to develop a core heart disease health-related quality of life questionnaire, the
31
32 HeartQoL. *Eur J Cardiovasc Prev Rehabil* 2005; Apr;12(2):87-94.
33
34
35
36
37
38
39 73. Drummond MF. *Methods for the economic evaluation of health care programmes*. 3rd
40
41 edition ed. Oxford: Oxford University Press; 2005.
42
43
44
45
46
47 74. Hallal PC, Victora CG. Reliability and validity of the International Physical Activity
48
49 Questionnaire (IPAQ). *Med Sci Sports Exerc* 2004; Mar;36(3):556.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 75. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. *J*
5
6
7
8 *Psychosom Res* 1993; Oct;37(7):753-62.
9

10
11
12 76. Buysse DJ, Reynolds CF,3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a
13
14
15 new instrument for psychiatric practice and research. *Psychiatry Res* 1989;
16
17
18 May;28(2):193-213.
19
20

21
22
23 77. Spertus J, Dorian P, Bubien R, et al. Development and validation of the Atrial
24
25
26 Fibrillation Effect on QualiTY-of-Life (AFEQT) Questionnaire in patients with atrial
27
28
29 fibrillation. *Circ Arrhythm Electrophysiol* 2011; Feb;4(1):15-25.
30
31
32

33
34
35 78. DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for
36
37
38 handling missing data in clinical trials. *J Biopharm Stat* 2009; Nov;19(6):1055-73.
39
40

41
42 79. Dmitrienko A, Wiens BL, Tamhane AC, et al. Tree-structured gatekeeping tests in
43
44
45 clinical trials with hierarchically ordered multiple objectives. *Stat Med* 2007; May
46
47
48 30;26(12):2465-78.
49
50

1
2
3
4 80. McHorney CA, Ware JE, Rogers W, et al. The validity and relative precision of MOS
5
6
7 short- and long-form health status scales and Dartmouth COOP charts: results from the
8
9
10
11 Medical Outcomes Study.
12

13
14
15 81. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac
16
17
18 rehabilitation. *Heart* 2006; Jan;92(1):62-7.
19

20
21
22
23 82. Polit DF, Beck CT. *Essentials of nursing research: methods, appraisal, and utilization*.
24
25
26 6. edition ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.
27
28

29
30
31 83. Ricoeur P. *Interpretation theory: discourse and the surplus of meaning*. 5. print. ed.
32
33
34 Fort Worth, Tex.: Texas Christian University Press; 1976.
35
36

37
38
39 84. EuroQol--a new facility for the measurement of health-related quality of life. The
40
41
42 EuroQol Group. *Health Policy* 1990; Dec;16(3):199-208.
43
44

45
46
47 85. Brooks R. EuroQol: the current state of play. *Health Policy* 1996; Jul;37(1):53-72.
48

49
50
51 86. Wittrup-Jensen KU, Lauridsen J, Gudex C, et al. Generation of a Danish TTO value set
52
53
54 for EQ-5D health states. *Scand J Public Health* 2009; Jul;37(5):459-66.
55
56

1
2
3
4 87. Fox-Rushby JA, Cairns J. *Economic evaluation*. Maidenhead: Open University Press;
5
6
7
8 2005.
9

10
11
12 88. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-
13
14
15 effectiveness acceptability curves. *Health Econ* 2001; Dec;10(8):779-87.
16
17

18
19
20 89. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with
21
22
23 coronary heart disease: systematic review and meta-analysis of randomized controlled
24
25
26 trials. *Am J Med* 2004; May 15;116(10):682-92.
27
28

29
30
31 90. Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure.
32
33
34
35 *Cochrane Database Syst Rev* 2004;(3)(3):CD003331.
36
37

38
39 91. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect
40
41
42 estimates in controlled trials with different interventions and outcomes: meta-
43
44
45 epidemiological study. *BMJ* 2008; Mar 15;336(7644):601-5.
46
47

48
49
50 92. Gluud L. Bias in clinical intervention research. *Am J Epidemiol* 2006;163(6):493-501.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 93. Savovic J, Jones H, Altman D, et al. Influence of reported study design characteristics
5
6
7 on intervention effect estimates from randomised controlled trials: combined analysis of
8
9
10
11 meta-epidemiological studies. *Health Technol Assess* 2012; Sep;16(35):1-82.
12
13

14
15 94. Rowland T, Unnithan V, Barker P, et al. Time-of-day effect on cardiac responses to
16
17
18 progressive exercise. *Chronobiol Int* 2011; Aug;28(7):611-6.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 **The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation**
9
10 **patients treated with ablation: the randomised CopenHeart_{RFA} trial protocol**
11

12
13 Signe S. Risom, RN, MSc^{1,§}, Ann-Dorthe Zwisler, MD, Ph.D.^{1,2}, Trine B. Rasmussen RN,
14 MScN^{1,4}, Kirstine Lærum Sibilitz, MD¹, Jesper Hastrup Svendsen, MD, DMSc, FESC^{1,3}, Christian
15 Gluud, MD, DMSc⁵, Jane Lindschou Hansen, MSc⁵, Per Winkel, MD, DMSc⁵, Lau Caspar
16 Thygesen, MSc, Ph.D.², Merja Perhonen MD, Ph.D.⁶, Jim Hansen, MD⁴, Sandra B. Dunbar, RN,
17 DSN, FAAN, FAHA⁷, Selina Kikkenborg Berg, RN, MScN, Ph.D. FESC^{1,4}.
18
19
20
21
22
23
24

25 ¹ Rigshospitalet, The Heart Centre, Copenhagen University Hospital, Denmark

26 ² National Institute of Public Health, University of Southern Denmark

27 ³ Gentofte Hospital, Department of Cardiology, Denmark

28 ⁴ The Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC)

29 ⁵ Copenhagen Trial Unit, Centre for Clinical Intervention Research. Copenhagen University
30 Hospital, Denmark

31 ⁶ CorusFit, Heikinkatu 3 B, 40100 Jyväskylä, Finland

32 ⁷ Nell Hodgson Woodruff School of Nursing, Emory University
33 Atlanta, Georgia, United States
34
35

36 §Corresponding author:

37 Signe Stelling Risom, RN, MSc,
38 The Heart Centre, Department of Cardiology,
39 Copenhagen University Hospital,
40 Blegdamsvej 9, DK-2100 Copenhagen.
41
42
43
44
45
46
47
48
49
50
51
52

1
2
3
4
5
6
7
8 Signe.stelling_risom@rh.regionh.dk
9

10
11 Word count:

12
13 Abstract: 300, Body: ~~6.833~~ 7.035
14
15

16
17 Keywords: atrial fibrillation, cardiac rehabilitation, physical exercise, psycho-education
18
19

20
21
22
23 **Article summary**

24 Article focus

- 25
26
- 27 • The CopenHeart_{RFA} trial is a randomised clinical trial investigating the effects of
28 comprehensive cardiac rehabilitation versus usual care for patients treated for atrial
29 fibrillation (AF) with ablation.
30
31
 - 32 • The hypothesis is that comprehensive cardiac rehabilitation improves physical capacity and
33 mental health.
34
35
 - 36 • Using a mixed methods approach, a broad range of outcome measures are collected to
37 evaluate the intervention.
38
39
- 40

41 Key messages

- 42
- 43 • AF affects 1-2% of the population. Patients with AF experience diminished quality of life
44 and are afraid to do physical exercise after treatment with ablation.
45
 - 46 • No studies exploring the effects of rehabilitation of patients treated for AF with ablation
47 have been published.
48
49
 - 50 • This trial is the first to examine physical functioning and to test a comprehensive
51 rehabilitation programme on a large population of patients treated for AF with ablation.
52
53
- 54

2

55
56
57
58
59
60

CopenHeart_{RFA} will provide much needed evidence and insight on the post-discharge status and rehabilitation needs of patients treated for AF with ablation.

Strengths and limitations of this study

- The study has been designed to meet the criteria for high quality in non-pharmacological randomised clinical trials with central randomisation, multi-centre participation, blinded assessment and analysis.
- We are aware of the day to day variation that can appear when carrying out ergospirometry, in testing and that the performance can depend on the individual tester. Accordingly, we will interpret the findings conservatively.

Abstract

Introduction

Atrial fibrillation affects almost 2% of the population in the Western world. To preserve sinus rhythm, ablation is undertaken in symptomatic patients. Observational studies show that patients with atrial fibrillation often report low quality of life and are less prone to be physically active due to fear of triggering fibrillation. Small trials indicates that exercise training has a positive effect on exercise capacity and mental health, and both patients with recurrent atrial fibrillation and in sinus rhythm may benefit from rehabilitation in managing life after ablation. No randomised trials have been published on cardiac rehabilitation for atrial fibrillation patients treated with ablation that includes exercise and psycho-educational components.

Aim

To test the effects of an integrated cardiac rehabilitation programme versus treatment as usual for patients with atrial fibrillation treated with ablation.

Methods and analysis design

The trial is a multicentre parallel arm design with 1:1 randomisation to the intervention and control group with blinded outcome assessment. 210 patients treated for atrial fibrillation with radiofrequency ablation will be included. The intervention consists of a rehabilitation programme including four psycho-educative consultations with a specially trained nurse and 12 weeks of individualised exercise training, plus the standard medical follow-up. Patients in the control group will receive the standard medical follow-up. The primary outcome measure is exercise capacity measured by VO₂ peak. The secondary outcome measure is self-rated mental health measured by the Short Form 36 questionnaire. Post intervention, qualitative interviews will be conducted in 10% of the intervention group.

Ethics and dissemination

The protocol is approved by the regional research ethics committee (number. H-1-2011-135), the Danish Data Protection Agency (reg. nr. 2007-58-0015) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may possibly impact on rehabilitation guidelines.

Registration: Clinicaltrials.gov identifier: NCT01523145

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia and affects 2% of the population in the Western world.¹⁻³ Typical symptoms are palpitations, dyspnoea, fatigue, dizziness, and syncope. Patients' symptoms and the length of periods in AF are highly variable both for the individual and between patients.⁴⁻⁶ AF is associated with increased risk of stroke, other thromboembolic events, and heart failure.⁶⁻⁸ Hospitalisations due to AF account for one third of all admissions for cardiac arrhythmias.⁸ As the prevalence of AF increases with age, the incidence of AF is increasing due to an ageing population.^{2, 9, 10} After 40 years of age, the lifetime risk of developing AF is 25%.¹¹ The annual cost of AF is high in comparison with other diseases.¹² Therefore, AF has become an economic burden and this will continue to increase over the coming decades.¹³ Thus, AF has now become a health, social and economic challenge in the Western world.

Primary treatment goals for individuals with AF are re-establishing and maintaining sinus rhythm, decreasing AF symptoms, and prevention of complications. In accordance with current national and international guidelines, radiofrequency ablation (RFA) is often undertaken in symptomatic patients. RFA is an invasive treatment, intended to cure AF and has a success rate of 77% versus 52% for antiarrhythmic medication.¹⁵ In Denmark, around 600 RFAs are conducted annually at two heart centres.

A cohort study of 655 patients from a randomised trial found that AF symptoms are a negative predictor for patients' physical capacity,¹⁶ and in the presence of AF, patients do fewer physical activities.¹⁷ Smaller observational studies and a randomised trial investigating the effect of exercise

1
2
3
4
5
6
7
8 training on AF patients found increased exercise capacity and a decreased resting heart rate after
9 training.¹⁸⁻²⁰

11
12
13 Previous studies show significantly impaired quality of life in patients with AF compared to healthy
14 controls measured by the questionnaire Short Form 36 (SF-36). The general health component (\pm
15 standard deviation) was 54 ± 21 in AF patients compared to 78 ± 17 in healthy controls.²¹ A
16 qualitative study demonstrated that educational help after AF treatment is lacking, even though
17 symptoms of distress and lack of self-management regarding symptoms like palpitations, dyspnoea,
18 and fatigue are common.²² Furthermore, small observational studies indicate a positive effect of
19 exercise training on patients with AF in terms of mental health and physical activity (15% increase
20 of VO_2).^{18, 19} However, these findings need confirmation in larger randomised clinical trials.

21
22
23
24
25
26
27
28
29
30
31 Secondary prevention initiatives including cardiac rehabilitation are recommended by the European
32 Society of Cardiology (ESC).²³ Studies exploring the effects of rehabilitation for patients treated for
33 AF are lacking. As there is no evidence of its efficacy, rehabilitation is not systematically provided
34 in Denmark and most often patients treated for AF with RFA are not offered any rehabilitation at
35 all. The evidence for general cardiac rehabilitation is strong, but it is found that it is poorly
36 implemented and only selected patient groups are offered full comprehensive cardiac rehabilitation
37 programmes, even though ESC recommends such programmes.²⁴ Research has mainly been
38 conducted within patients with coronary heart disease and heart failure, where rehabilitation has
39 been proven to reduce hospital re-admissions and mortality in a cost-effective way,^{25, 26} as well as
40 improve quality of life.²⁷ More specifically, studies on the effect of exercise training have
41 demonstrated an increase in exercise capacity of up to 38% in patients after valve replacement
42 surgery²⁸ and an increase in peak VO_2 of 2.3 ± 2.2 (SD) ml/kg per minute in the intervention group

1
2
3
4
5
6
7
8 compared with -0.3 ± 2.1 (SD) ml/kg per minute in the control group, as well as a significant change
9 in quality of life in older patients with heart failure.²⁹
10
11 Although evidence of its efficacy is strong, general cardiac rehabilitation is still poorly implemented
12 and often only on selected populations thus the development of full comprehensive preventive
13 programmes, according to the ESC recommendations is warranted.²⁴ Studies exploring the effects
14 of rehabilitation of patients treated for AF are lacking. As there is no evidence of its efficacy, the
15 rehabilitation provided is presumably often suboptimal or totally lacking. Lessons, however, might
16 be learned from rehabilitation studies in patients with related cardiac conditions. The positive
17 effects of cardiac rehabilitation have been well documented, particularly in patients with coronary
18 heart disease and heart failure, where rehabilitation has been proven to reduce hospital re-
19 admissions and mortality in a cost effective way,^{25, 26} as well as improve quality of life.²⁷ More
20 specifically, studies on the effect of exercise training have demonstrated an increase in exercise
21 capacity of up to 38% in patients after valve replacement surgery²⁸ and an increase in peak VO_2 of
22 2.3 ± 2.2 (SD) ml/kg per minute in the intervention group compared with -0.3 ± 2.1 (SD) ml/kg per
23 minute in the control group, as well as a significant change in quality of life in older patients with
24 heart failure.²⁹ Traditional cardiac rehabilitation has focused on physical training and standardized
25 programmes, but studies now indicate that individualized content and supervised exercise
26 components can are key design characteristics for improving outcomes.³⁰ In addition to exercise
27 training, there is evidence to support interventions that include patient education, which in patients
28 with coronary heart disease has been shown to improve health related quality of life and decrease
29 healthcare costs,³¹ and psychological support, which has been shown to improve psychological
30 symptoms in patients with coronary heart disease, such as depression and anxiety.³² Evidence on the
31 efficacy of comprehensive interventions for patients treated for AF, however, is needed.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interventions designed to cover both physical and psychological problems may provide the best method for optimising functioning and enhancing quality of life.³³ We have not been able to identify randomised trials or observational studies in patients who have undergone RFA for AF that offer both psycho-educational intervention and physical training. Therefore, the CopenHeart_{RFA} trial was undertaken with the aim of testing a rehabilitation programme consisting of physical exercise and a psycho-educational intervention versus treatment as usual for RFA treated AF patients.

Methods

Design

Major parts of the method section and trial design in this paper are similar to two other randomised clinical trials, CopenHeart_{VR} and CopenHeart_{IE}, and therefore sections from this paper will be copied in these trial protocols (Sibilitz KL et al. *Effect of integrated cardiac rehabilitation versus treatment as usual for patients with isolated heart valve surgery: The randomised CopenHeart valvular trial protocol*. drafted October 2012; and Rasmussen TB et al. *A randomised clinical trial of comprehensive cardiac rehabilitation versus usual care for patients treated for infective endocarditis – the CopenHeart_{IE}*. Accepted for publication, BMJ Open, October 2012).

The CopenHeart_{RFA} trial is a multi-centre, multidisciplinary randomised clinical superiority trial.

Secondary, qualitative data are also collected and the two methods are integrated by applying a mixed method embedded experimental design (Figure 1).^{34, 35} Quantitative methods are applied,

with specified quantitative pre- and post-measures to evaluate the effect of the experimental

intervention. **Alongside quantitative measurements, qualitative data will be collected.** The premise

of mixed methods research is that the use of qualitative and quantitative approaches in combination

1
2
3
4
5
6
7
8 provides a better understanding of the research problems than either approach alone, because
9
10 different types of questions require different types of data and that mixed methods research provides
11 strengths that offset the weaknesses of both qualitative and quantitative research.³⁴ The methods are
12 integrated by applying a mixed method embedded experimental design and include qualitative data
13 to develop the intervention and to examine the process of the intervention and the results of the trial
14 (see Figure 1).^{34,35} The rationale for this approach is that the quantitative findings provide a general
15 understanding of the research problem through statistical results, while qualitative findings refine
16 and explain the results by exploring participants' views in greater detail, and will be presented by
17 themes of patient thoughts or concerns about the intervention. Evaluation using qualitative research
18 methods is increasingly promoted in evidence-based rehabilitation.³⁶⁻³⁹ Qualitative research
19 alongside randomised controlled trials can contribute in several ways to the development and
20 evaluation of complex healthcare interventions and may be particularly useful in evaluating
21 interventions that involve social and behavioural processes that are difficult to explore or capture
22 using quantitative methods alone.⁴⁰ As patient participation is paramount for the efficacy of the
23 rehabilitation,⁴¹ we find it highly valuable to include the patients' perspective in the development
24 and evaluation of the intervention. This paper presents the study protocol for the CopenHeart_{RFA}
25 randomised clinical trial. The complementary studies, including the qualitative part of the trial are
26 briefly described in a separate section.
27
28 The trial is described in accordance with the current SPIRIT guidelines (Standard Protocol Items:
29 Recommendations for Interventional Trials).⁴² Results will be reported following the CONSORT
30 (CONsolidated Standards Of Reporting Trials) guidelines for non-pharmacological interventions.⁴³

Formatted: Highlight

Formatted: Not Highlight

Formatted: Font color: Red, Not Highlight

Formatted: Highlight

Trial hypotheses

The primary hypothesis is that the rehabilitation program increases physical capacity among AF patients treated with RFA after 4 months measured by VO₂ peak, which is expected to be 20% more than in the control group receiving standard treatment alone. The estimate of 20% is based on findings from pilot studies including patients with permanent AF which found an increase of 15% in VO₂ peak. We therefore expect a VO₂ peak in the intervention group of 18 ml/kg/min and of 15 ml/kg/min in the control group, corresponding to a difference of 20% (3 ml/kg/min).⁴⁴

The secondary hypothesis is that the rehabilitation programme increases quality of life and self-rated mental health among AF patients treated with RFA after 6 months by 3 points on the Medical Outcome Study Short Form 36 (SF-36) questionnaire mental component scale, compared with control participants receiving standard treatment.¹⁹

Exploratory hypotheses are that the experimental intervention decreases AF recurrence; improves self-rated health and sleep-quality; reduces early retirement from work, use of health care services and mortality, and is cost efficient.

Trial participants

Consecutive patients hospitalised for AF and treated with RFA at two heart centres in Denmark (Gentofte Hospital and Rigshospitalet, Copenhagen University Hospital) will be screened for inclusion and approached for trial participation (Figure 2). Regardless of RFA outcome, both patients with recurrent AF and patients in sinus rhythm after the ablation will be included in the trial. Patients 18 years of age or older, Danish speaking, and providing verbal and written informed consent will be eligible for participation. Patients unable to understand trial instructions, pregnant or

1
2
3
4
5
6
7
8 breastfeeding, with reduced ability to follow the planned programme due to other physical illness,
9
10 who prior to RFA have been doing intense physical exercise or sports at competitive level several
11
12 times a week, or do not wish to participate, and patients already enrolled in clinical trials that
13
14 prohibit participation in additional trials are excluded.

15 16 17 **Trial procedure, randomisation, and follow-up**

18
19 Patients will be approached for participation during their hospitalisation for RFA. Information will
20
21 be given by a nurse or physician from the research team, who will obtain informed written consent
22
23 after the RFA procedure. A brief oral introduction is initially given together with written
24
25 information describing the trial and implications for the patient in detail. The patient is given ample
26
27 time to read the information and if necessary involve a relative in the decision making. The
28
29 enrolling nurse or physician will return after the RFA or call the patient to answer any questions the
30
31 patient or their relative might have. The patient should subsequently be able to provide informed
32
33 consent or reject participation. After the informed consent form is signed, baseline data will be
34
35 collected including the baseline questionnaire package, demographic variables, and clinical
36
37 characteristics (Table 2). Then the Copenhagen Trial Unit (<http://www.ctu.dk/>) is contacted for
38
39 central randomisation of the participant. Randomisation is conducted according to a computer-
40
41 generated allocation sequence with a varying block size kept unknown to the investigators.
42
43 Participants are randomised 1:1 to the experimental intervention group or the control group and
44
45 stratified according to sex and type of AF (persistent or paroxysmal). Thus, neither investigators nor
46
47 patients or relatives can influence to which group the patients are allocated. For both groups, the
48
49 follow-up assessment will take place at 1 month, 4 months, 6 months, and 12 months post-
50
51 discharge, and a register-based follow-up assessment will be conducted at 24 months (Table 2). In
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 case of complications to the RFA after enrolment in the trial, the patients will be handled
9 individually (e.g., arrhythmia or inguinal haematoma).

10
11
12 The patients answer questionnaires independently of the researchers, and before randomisation. All
13 questionnaires are distributed electronically, thus data management is handled independently from
14 the researchers that interpret data. All data are stored electronically in a coded database, and in an
15 independent spread sheet, only accessible for the CopenHeart group.
16
17
18

19
20
21 Personal information about potential and enrolled patients will be collected electronically and
22 shared in a database only accessible to those within the project group responsible for patient
23 recruitment, in order to protect confidentiality before, during and after the trial.
24
25
26

27
28 Due to the nature of rehabilitation, the intervention group is not blinded for the patients or the
29 investigators, but the outcome assessment of the primary outcome, the statistical analyses, and
30 drawing of conclusions will be conducted blinded for the allocated intervention group.
31
32
33

34 **The experimental intervention group**

35
36 Patients in the experimental intervention group will follow the integrated cardiac rehabilitation
37 programme consisting of a psycho-educational component and an exercise training component
38 alongside standard treatment (described below). The patients will be contacted at 1, 4, 6 and 12
39 months for outcome assessment including clinical data collection.
40
41
42

43 ***The physical exercise training component***

44
45 The intervention has been developed and partly tested in a clinical rehabilitation trial, the COPE-
46 ICD trial⁴⁵, which included patients with an implantable cardioverter defibrillator. We here
47 observed a significant impact of the intervention on peak VO₂, physical capacity and self-assessed
48 mental health. The intervention has been modified for patients treated for atrial fibrillation with
49
50
51
52

1
2
3
4
5
6
7
8 ablation as described below. The CopenHeart physical exercise intervention meets European²⁴ and
9 Danish guidelines⁴⁶ for physical exercise in patients with heart disease, and complies with The
10 National Danish Board of Health recommendations for physical exercise in daily living for heart
11 patients.⁴⁷

12
13
14
15 The physical exercise starts one month after the ablation and after the first ergospirometry test and
16 comprises the following three elements:
17

18
19
20
21 Individually planned physical exercise by specially trained physiotherapists. Integrating detailed
22 information concerning AF symptoms and RFA, co-morbidity, hospitalisation, activities of daily
23 living, and level of physical activity prior to RFA, a specially trained physiotherapist conducts a
24 patient telephone consultation up to 30 minutes. The consultation is based on initial testing of the
25 patient including a cardiopulmonary exercise test, a 6 minutes walking test and a 'sit and stand' test,
26 described in the outcome section. For all patients, a rehabilitation plan is prepared as an individual
27 training diary, and all patients are instructed in the use of a heart rate monitor (Polar Watch
28 provided by Rigshospitalet). The heart rate monitor and diary is essential to ensure CopenHeart
29 training protocol compliance and they are returned for data collection at the end of the exercise
30 training intervention.
31
32
33
34
35
36
37
38
39

40
41 Intensive exercise training programme. Physical exercise is initiated at Rigshospitalet four weeks
42 after RFA to ensure optimal rest and healing. Using wireless electrodes integrated into t-shirts
43 (Corus-Fit, CardioCardio and Corus Exercise Assistant, CEA, version 2.0.16, Finland) potential
44 cardiac arrhythmias, electrocardiographic abnormalities such as ST-depression, ST-elevation, Q- or
45 T-wave altering, atrial fibrillation, and ventricular arrhythmias and training intensity level are
46 monitored.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 After 1-3 exercise training sessions at Rigshospitalet, the patient continues the programme at a local
9 CopenHeart certified training facility supervised by physiotherapists or as supervised home-based
10 training. Supervised home-based exercise training has shown similar results to hospital-based
11 exercise training³¹ and has been confirmed in a Danish setting.⁴⁸

12
13
14
15 The physical exercise training continues for 12 weeks, comprising three sessions weekly of 60
16 minutes, in total, 36 sessions. The training protocol consists of cardiovascular training and strength
17 exercises to improve endurance and muscular strength.
18
19
20

21
22
23
24 An exercise session consists of 10 minutes warm up, 20 minutes bicycling, 20 minutes strength, and
25 a 10 minutes stretching and cool-down period. . Using the results from the cardiopulmonary
26 exercise test performed prior to the initial training session, in combination with the Borg scale
27 measuring subjective exhaustion, the aerobic exercise is performed with gradually increasing
28 intensity throughout the exercise intervention period, corresponding to 13 to 17 on the Borg Scale
29 and 50% to 80% of the maximum heart rate. The anaerobic resistance training is initiated at 30% to
30 40 % of 1 repetition maximum (RM) for the upper body, and 40% to 50 % of 1 RM for the lower
31 body, with an increasing work load during the training sessions. To achieve cardiovascular
32 adjustment and reduce the risk of malignant cardiac arrhythmias and ischemia, the training session
33 is initiated and terminated with a warm up and a cool down period to gradually increase and
34 decrease training intensity and heart rate. This cardiovascular adjustment has been proven to reduce
35 the risk of ischemia and arrhythmia in relation to exercise training.^{49, 50} Training is predominantly
36 performed in the upright position to reduce left ventricle preload (diastolic volume) and the risk of
37 ischemia and arrhythmias due to heart failure.⁵⁰
38
39
40
41
42
43
44
45
46
47
48
49

50 Sustained moderate physical exercise daily. Participants are instructed to perform moderate physical
51 exercise at least 30 minutes a day during the intervention period, e.g., bicycling, walking,
52
53
54

1
2
3
4
5
6
7
8 gardening, jogging or recreational sports. Participants are encouraged to continue with moderate
9 physical exercise throughout life.

12 *The psycho-educational component*

14 The aim of the psycho-educational intervention is to provide emotional support and improve coping
15 skills and illness appraisal in order for the patient to respond appropriately to physical and
16 psychological symptoms. Education and information about the disease prepare the patient for
17 expected symptoms and sensations. Dialogue and shared reflection facilitate strategies for coping
18 with symptoms and experiences associated with the condition, e.g., anxiety and fear. Cardiac care
19 nurses with specific training will perform the psycho-educational intervention. Some of the most
20 commonly reported concerns of patients treated for AF with RFA, such as recurrent AF, and
21 concerns about being able to manage a working life are outlined in a guide which nurses use to
22 address when and if relevant (see Table 1). Information given will also be based on national
23 guidelines and standard treatment of patients treated for AF. The consultations focus on managing
24 life after AF treated with RFA by establishing a joint approach to disease management and coping
25 strategies, taking a holistic view. The psycho-educational intervention is inspired by R.R. Parse's
26 Human Becoming Practice Methodologies' three dimensions.⁵¹ These are interpreted as: 1) discuss
27 and give meaning to the past, present and future, 2) explore and discuss events and possibilities and
28 3) move along with envisioned possibilities. According to this theory, there are three ways of
29 changing health: creative imaging, that is to see, hear and feel what a situation might be like if lived
30 in a different way, affirming personal patterns and value priorities, and shedding light on paradoxes,
31 that is, looking at the incongruence in a situation and changing the view held of something. The
32 nurse is present in the process through discussions, silent immersion and reflection. The human
33 becoming practice methodology was chosen to apply a holistic patient approach, focusing on the
34 coping and transformation process of the individual person. Furthermore, the method is already

15

extensively used in the outpatient heart clinics at the heart centre at Rigshospitalet, such as for patients with inherited heart diseases and adults with congenital heart disease and is documented in the COPE-ICD trial.^{45, 52} The consultations take place in a quiet setting at the out-patient clinic and will last for approximately one hour. The nurse is able to facilitate contact with or seek advice from a physician if needed. The first consultation will be approximately one month after discharge, and then once every four to six weeks, with a total of four consultations. Consultations can be done by telephone, in accordance with the patient's wishes. The primary investigator will attend the consultations regularly to ensure protocol compliance.

Table 1. Guide to the psycho-educative consultation.

Number visit	1	2	3	4
Ask the patient how he/she has been since the ablation.				
What has happened since last time he/she was here?	X	X	X	X
Invite the patient to talk about his/her thoughts and questions.	X	X	X	X
Ask about the time leading up to RFA and his/her AF history. Experiences before, under and after the hospitalization and RFA.	X			
Talk about how it is to have had/ have AF and been through RFA, how that have affected the patient's life. Is there something he/she avoids or feel like he/she cannot do anymore? This in relation to family relations, friends and free time/ leisure activities.	X			
Make sure that the patient has started the physical	X	X	X	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

training and talk about how it is going. Are training appointments booked?

X

Talk about recognition of symptoms, how the patient is feeling about recurrence of AF and opinions about future AF treatment. Worries about recurrence of AF, strategies of prevention.

X X (X) (X)

Information/recommendations in relation to the subjects/problems discussed.

X X X X

Intervention deviations

Both components of the intervention will be supervised regularly by the primary investigator to ensure protocol compliance. Modification of the allocated intervention due to surgery complications, rehospitalisation or emerging co-morbidities (e.g. recurrent AF, musculoskeletal problems) will be individually assessed, and the time of the primary outcome assessment at four months (described in section below) will be corrected in accordance with changes in the intervention.

Control group: treatment as usual

Patients in the control group will follow standard treatment for patients treated for AF with RFA including 3-6 months follow-up with a physician and a 12 months follow-up with a nurse. Furthermore, patients will be contacted at 1, 4, 6 and 12 months for outcome assessment including clinical data collection.

Outcomes and data collection

Data will be collected to evaluate the effect and meaning of the intervention. The primary and secondary outcomes reflect the primary modifiable factors of the intervention. Since this is a complex intervention with two main components, an exercise component and a psycho-educational component, this is reflected in the primary and secondary outcome. The intervention has been tested in ICD patients (unpublished data in the COPE-ICD trial, available on request) and the intervention reflects well in the chosen measures that have found to be sensitive to changes based on the intervention. Since almost no evidence exists for rehabilitation programmes for patients treated for AF with RFA, data on a number of outcomes will be collected for exploratory analyses.

Primary outcome

Physical capacity measured by peak VO₂ according to a standardised protocol developed in accordance with guidelines^{53,54} 1, 4 and 12 months after randomisation (Table 1).

Physical capacity is measured by peak VO₂ using cardiopulmonary exercise testing (Ergo-Spiro CS-200, Schiller, Schweiz). This is chosen as a primary outcome since this is standard in exercise based rehabilitation trails. The test is performed according to current guidelines for ergospirometry testing, and by ergometer bicycle, simultaneously monitoring heart-rhythm, blood pressure, electrocardiogram (ECG), and measuring gas-exchange during workload and in the following recovery period. The average test duration is 10-15 minutes including pre- and post- test phase without work load. Before each session calibration is performed to address changes in room temperature, humidity and air oxygen content. A standardised ramp-protocol is used with initial work load of 25 or 50 watts, increasing gradually by 12.5 watts every minute until peak exhaustion. Peak exhaustion is evaluated by a respiratory exchange ratio (RER) \geq T 1.10 or subjective

1
2
3
4
5
6
7
8 exhaustion of the patient. In order to equally encourage the patients, independent of the tester, a
9
10 standardised guide has been developed. During the test period, clinical manifestations, ECG
11
12 abnormalities (ST depression, ST elevation, Q- and T-wave changes, supraventricular or ventricular
13
14 arrhythmias), blood pressure response, and several physiological variables are observed and
15
16 documented. The test will be performed by either a cardiac care nurse or a physician. For safety
17
18 reasons preset criteria for initiation and/or termination of the test have been defined.
19

20 21 *Secondary outcome*

22
23 Self-rated mental health is measured by the SF-36 questionnaire,⁵⁵⁻⁵⁷ mental component score, after
24
25 1 month, 4 months, 6 months and 12 months (Table 2).
26
27

28 29 *Exploratory outcomes*

30
31 Long-term follow-up: Register data regarding mortality, causes of death, hospitalisation/re-
32
33 hospitalisation, emergency room visits, outpatient visits, health care costs, visits to the general
34
35 practitioner, medication use, employment status and payment of welfare benefits (sick leave
36
37 payment and early retirement pension) will be collected at 24 months to assess long term effects of
38
39 the intervention (Table 2). Danish recording keeping for the data mentioned above functions well,
40
41 with only a small percentage of lost data.⁵⁸ Consequently the method is well suited as an outcome
42
43 measure in small patient populations. Data will be extracted from the Danish National Patient
44
45 Register, the Danish National Health Service Register, the Danish National Prescription Registry,
46
47 the Danish National Causes of Death Register and records of transfer payments and labour market
48
49 affiliation.⁵⁹⁻⁶²
50
51
52
53
54
55
56
57
58
59
60

6 minutes walking test: The maximum walking distance (in meters) within 6 minutes is measured, using standardized instructions,⁶³ while subjective exhaustion with regard to fatigue and dyspnoea using the Borg scale⁶⁴ is registered.

Sit and stand test: The maximum amount of times a patient can sit and rise from a normal chair within 30 seconds is recorded. Subjective exhaustion is measured using the Borg exhaustion scale.⁶⁴

Biochemical screening: Potassium, sodium, haemoglobin and creatinine. 1 EDTA plasma heparin tube will be frozen (80°) for further analyses (pro-BNP, BNP, copeptin).

Other exploratory outcomes: AF recurrence, self-rated health and sleep-quality, retirement from work, use of health care services, mortality and cost efficiency (Table 2).

Table 2. Exploratory quantities subjected to post-hoc analysis

Quantity	Time of measure (months)	Type of quantity
Demographic		
Sex	BL	Binary (M/F)
Age, height, weight,	BL, 1,4,12	Continuous
Marital, occupational, educational status	BL	Categorical
Clinical		
NYHA- classification	BL, 1, 4, 12	Continuous
Previous heart disease, diabetes mellitus, kidney disease, pulmonary disease (COPD), co-morbidities, hypertension, dyslipidaemia, smoking	BL	Binary (Y/N)
Medication	BL, 1, 4, 12	Binary (Y/N)
AF specific data:		
Type of atrial fibrillation	BL	Categorical
Number of ablations	BL, 1,4,12	Binary (Y/N)
Atrial fibrillation symptoms	BL, 1,4,12	Continuous
CHA ₂ DS ₂ VASc score	BL, 1,4, 12	Continuous
The European Heart Rhythm Association symptom score	BL, 1,4, 12	Continuous
Paraclinical and imaging		
Blood work (Haemoglobin, infection-, kidney- liver and selected nutritional parameters, electrolytes, cholesterol- and thyroid	BL, 1, 4, 12	Continuous

status, ProBNP)		
Electrocardiogram	BL, 4, 12	Continuous
Physical function		
6 minute walking test ⁶³	BL, 1, 4, 12	Continuous
Sit to stand test ⁶⁵	1, 4, 12	Continuous
EVO recording	1,4,12	Categorical
Questionnaires		
Physical activity level ⁶⁶	BL, 1, 4, 6, 12, 24	Binary (Y/N)
SF-36 ⁶⁷ HADS ⁶⁸ , QoL-CV ⁶⁹	BL, 1, 4, 6, 12, 24	Continuous
Emotions and Health ⁷⁰	BL	Continuous
Rehabilitation ⁷¹	12	Continuous
HeartQoL R ⁷² , EQ-5D ⁷³	BL, 6, 12, 24	Continuous
IPAQ ⁷⁴	1, 4, 12, 24	Continuous
MFI-20 ⁷⁵	BL, 1, 4, 12	Continuous
PSQI ⁷⁶	1, 6	Continuous
AFEQT ⁷⁷	BL, 1,4,12,24	Continuous

AFEQT, Atrial Fibrillation Effect on Quality-of-life; BL, baseline; CHA₂DS₂VASc, score for Atrial Fibrillation Stroke Risk; EQ-5D, EuroQoL; HADS, Hospital Anxiety and Depression Scale; HeartQoL R, Heart-Related Quality of Life; IPAQ, International Physical Activity Questionnaire; PSQI, Pittsburgh Sleep Quality Index; QoL-CV, Quality of Life - Cardiac Version; SF-36, Short Form 36.

Sample size calculation for the primary outcome

We are performing a randomised trial where the continuous variable VO₂ peak is the primary outcome. The control and the intervention group are independent and the ratio of patients in the intervention group to the patients in the control group is 1:1. A previous trial of patients with permanent AF found that VO₂ peak was normally distributed with a standard deviation of 3.8 ml/kg/min.⁴⁴ As the CopenHeart_{RFA} trial has a more varied patient population who have all been treated for AF with RFA, which means that the majority of the patients will have sinus rhythm and the rest will have AF, the patients are not directly comparable with the patients in the previous trial, and we assume a standard deviation of 6 ml/kg/min to be more relevant. We consider a 0.5 standard

21

1
2
3
4
5
6
7
8 deviation to be the minimal relevant difference, equivalent to 3 ml/kg/min. Therefore, if the true
9
10 difference between the intervention group and control group is 3 ml/kg/min and the standard
11
12 deviation is 6 ml/kg/min in the control group, 105 patients in the intervention group and 105 in the
13
14 control group (a total of 210 patients) are needed to reject the null hypothesis, stating that the mean
15
16 in the intervention group and the control group is the same, with a power of 95%. The type I error
17
18 probability associated with this test of this null hypothesis is 5%.

21 **Power calculation for the secondary outcome**

22
23 The secondary outcome measure is the continuous variable mental component, SF 36. If the true
24
25 difference between the intervention and control group is 7 points, and the standard deviation in the
26
27 control group is 18 points,²¹ ~~w~~We will be able to reject the null hypothesis that the population
28
29 means of the experimental and control groups are equal with a probability of (power) 0.80. The type
30
31 I error probability associated with this test of this null hypothesis is 5%.

34 **Statistical analyses**

35
36 Data will be pseudo-anonymised and analysed blinded by a trial-independent statistician using
37
38 intention-to-treat analyses and a mixed model with repeated measures (MMRM) for continuous
39
40 outcome measures.⁷⁸ Using MMRM ensures that missing data values (in case of the primary and
41
42 secondary outcome) will not create bias as long as the values are missing at random. Two-sided
43
44 tests are performed. The level of significance is set at 5%. With regard to multiplicity, gate keeping
45
46 will be used to adjust the observed P values for primary and secondary outcomes.⁷⁹ Both unadjusted
47
48 and adjusted P values will be reported.

49
50 For the primary and secondary outcomes, sensitivity analysis will be conducted to assess the
51
52 potential impact of values missing not at random. For each intervention group (A and B) some

1
2
3
4
5
6
7
8 quantities (imputing quantities) are computed to be used to impute missing values in a group (A or
9 B) as follows. A comparison between group A and group B where missing values in group A are
10 imputed using imputing quantities obtained from group A and missing values from group B are
11 imputed using imputing quantities obtained from group B is referred to as a best case analysis. If
12 missing values in group A are imputed using imputing quantities obtained from group B and vice
13 versa the comparison is called a worst case analysis. The imputing quantities for the primary
14 outcome are the group mean at T1 (X_1 -bar), the group mean at T4 (X_4 -bar), the group mean at T6
15 (X_6 -bar), the mean difference between the value measured at T4 and that measured at T1 (Δ_1),
16 and the mean difference between the value measured at T6 and that measured at T4 (Δ_2). Table
17 3 explains how the quantities are used to impute missing values in a group (either the same group or
18 the other intervention group). If the standard error (SE) of a parameter estimate calculated using
19 imputed data is smaller than that of the corresponding parameter calculated using complete case
20 data it is replaced by the latter SE when the P value is calculated (Table 3).
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Long-term register-based outcomes will be analysed by two different models: non-negative count
35 outcomes (e.g., number of contacts with hospital or number of visits to general practitioners) will be
36 analysed by a Poisson model or a zero-inflated Poisson model if the number of zeros are large, and
37 time-to-event data (e.g., cause-specific mortality and leaving the labor market) will be analysed
38 with survival methods (Kaplan-Meier estimator and Cox regression model). Especially for socio-
39 economic outcomes, competing risks due to mortality will be considered if a large proportion of
40 patients die during follow-up.
41
42
43
44
45
46
47
48

49 Exploratory data will be analysed using appropriate statistical methods according to the type of data
50 (see Table 2). SPSS version 17.0 and SAS version 9.3 will be used.
51
52
53
54
55
56
57
58
59
60

Table 3. Statistical analysis

Observed pattern in group B at 1, 4, and 6 months	Imputed value in group B at 1 month	Imputed value in group B at 4 month	Imputed value in group B at 6 months
mis ^A , mis, mis	X1-bar ^B	X4-bar ^C	X6-bar ^D
mis, mis, Y3 ^E	$Y3 - (\delta1^F + \delta2^G)^H$	Y3 - delta2	
mis, Y2, mis	Y2 - delta1		Y2 + delta2
Y1, mis, mis		Y1 + delta1	Y1 + delta1 + delta2
Y1, Y2, mis			Y2 + delta2
Y1, mis, Y3		$(Y1 + \delta1 + Y3 - \delta2)/2$	
mis, Y2, Y3	Y2 - delta1		

Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group B). mis=missing value, X1=value at month 1, X4=value at month 4, X6=value at month 6.

^AThe value at 4 months is missing in group B, ^BMean of values observed in group A at time 1 month. ^CMean of values observed in group A at time 4 months. ^DMean of values observed in group A at time 6 months. ^EObserved value in group B at time 6 months. ^FThe mean of difference between values observed at time 4 months and value observed at time 1 month in group A, ^GThe mean of difference between value observed at time 6 months and value observed at time 4 months in group A, ^HIf an imputed value is 0 it is set equal to 0.

Interim analysis and Data Monitoring Safety Committee (DMSC)

The DMSC works independently from the funder and has no competing interests, and consists of two clinicians and a statistician. The committee is responsible for safeguarding the interests of trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the clinical trial. In line with the terms of the Data Monitoring and Safety Committee charter, one formal interim analysis meeting will be held to review data relating to treatment efficacy, participant safety, and quality of trial conduct. The three members of

1
2
3
4
5
6
7
8 the Data Monitoring and Safety Committee will meet when the 12 week follow-up data of about
9
10 50% of the trial participants have been obtained. Any serious adverse events will be registered as
11
12 part of the data collection and the overall number of adverse events will be reported at the meeting.
13

14 **Complementary studies**

15
16 **The Surveysbased study.** The post-discharge status of the patients treated with RFA will be
17
18 explored through a national survey. The standardised questionnaires SF-36,⁶⁷ Hospital Anxiety and
19
20 Depression Scale (HADS),⁶⁸ EuroQoL-EQ-5D,^{69, 70} Heart Related Quality of Life (HeartQoL R),⁷¹
21
22 International Physical Activity Questionnaire (IPAQ),^{72, 73} and a questionnaire developed by the
23
24 Danish Heart Foundation on the extent and quality of rehabilitation offered will be sent to patients
25
26 having undergone treatment for RFA, 6-12 months post-discharge. The instruments are all validated
27
28 and have good reliability and responsiveness.^{68, 72, 74, 75, 80, 81} The data will provide knowledge on
29
30 patients' self-rated health, quality of life, anxiety and depression, economic situation and the extent
31
32 and quality of the rehabilitation currently received. Patients were identified through the National
33
34 Patient Register⁵⁹ and questionnaires were sent out to 608 patients. We anticipate 25% will decline
35
36 participation, leaving an estimated 456 questionnaire respondents. Data will be anonymised and
37
38 analysed by relevant descriptive statistical methods.
39

40 **Qualitative post intervention study**

41
42 After the intervention, 10% of the participants from the intervention group will be strategically
43
44 chosen for an interview in order to explore the experiences and processes behind the potential
45
46 effects of the intervention. The qualitative study will explore patient experiences of participating in
47
48 the CopenHeart_{RFA} programme and investigate which components were meaningful.
49
50
51
52
53
54

To achieve maximum variation, qualified interviewees are chosen on the basis of sex, AF type, and current heart rhythm.⁸² The analysis will be inspired by Ricoeur's theory of interpretation consisting

of three levels: naive reading, structured analysis and critical interpretation and discussion.⁸³

The results will be presented in themes based on patient experience and evaluation of the intervention. As an example we will look for explanations for the results in physical capacity and mental health as described by the patients. We are using mixed method to explore all aspects of the intervention, but the qualitative findings are seen as a complementary study to the primary randomised clinical trial.

Economic evaluation

An economic evaluation will be conducted alongside the trial to assess the cost-utility of cardiac rehabilitation compared with treatment as usual in the study population. The economic evaluation will compare the costs to quality adjusted life years (QALY) and take a societal perspective, as recommended nationally. QALYs and costs will be assessed at the end of the intervention, 6 months from randomisation, and later after 24 months from randomisation using register-based follow up.

QALYs will be estimated using the self-completed EQ-5D instrument, which is a standardised instrument assessing 5 dimensions of self-reported health status (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).^{84, 85} The estimated calculations will be valued using

Danish preference weights.⁸⁶ Information on costs will only include costs that are expected to differ between the intervention and usual care group.⁷³ Costs included in the evaluation are health costs associated with the rehabilitation programme, other health care costs (health care utilization besides rehabilitation), patient costs and costs of productivity losses. Information on costs will be collected by a mixture of activity-based costing, surveys, patient diary and by the use of public records.

Results from the analysis will be reported as an incremental cost-effectiveness analysis (ICER).

26

Formatted: Highlight

1
2
3
4
5
6
7
8 Sensitivity analysis will be conducted to express uncertainty in the estimates.⁸⁷ The reporting of the
9
10 ICER is presented using Bayesian methods, including bootstrapping and presented as cost-
11
12 effectiveness acceptability curves.⁸⁸
13

14 15 16 **Ethics**

17 The inclusion started December 2011 and is approved by the Regional Ethics Committee (number
18
19 H-1-2011-135) and the Danish Data Protection Agency (no. 2007-58-0015). All eligible patients
20
21 will be informed about the trial verbally and in writing, and the patients are included after informed
22
23 consent has been obtained. All data will be handled confidentially and patients ensured anonymity.
24
25 The trial complies with the latest Declaration of Helsinki and is registered at ClinicalTrials.gov
26
27 (NCT01523145). An independent international safety committee monitors the trial. All serious and
28
29 adverse events will be registered and reported in accordance with the safety charter.
30

31 Not providing rehabilitation to the control group can be ethically justified as current national and
32
33 international guidelines give no specific recommendations on cardiac rehabilitation for patients
34
35 treated for AF with RFA. The scope and quality of rehabilitation offered to this population is
36
37 unknown, but suspicions are that generally no rehabilitation is offered in Denmark. The only way
38
39 patients can get supervised exercise training is if they voluntarily enrol in a programme e.g. through
40
41 non-profit organisations. The survey based complementary study, described previously in this
42
43 paper, will hopefully provide more insight into this. In screening patients for participation, the
44
45 enrolling nurse or physician will exclude those with a compelling rehabilitation need. Furthermore,
46
47 patients are informed of the study design before giving their consent, and are free to decline
48
49 participation.
50
51
52
53
54
55
56
57
58
59
60

Discussion

Due to the difference in the three patient groups that are included in the overall CopenHeart trial, patients treated for infective endocarditis, heart valve surgery and patients treated for AF with RFA, the intervention and outcome measures differ slightly, most importantly in the case of the psycho-educational intervention, which is longer for patients treated for infective endocarditis and heart valve surgery, because of the complexity of the diseases and the longer hospitalisation. Biochemical markers are similarly chosen differently to address the various co-morbidities of the three diseases and some disease specific questionnaires are chosen to capture the specific disease relevant issues.

To our knowledge no previous randomised clinical trials or observational studies have been conducted focusing on integrated cardiac rehabilitation for AF patients treated with RFA, so therefore it is not known what effect, if any, rehabilitation has on these patients. However, in the light of evidence from other groups of patients with heart disease a positive effect can be expected.^{23, 89, 90}

This trial is different from previous trials because we apply a comprehensive rehabilitation intervention which consists of both a physical training component and a psycho-educational component. This combination is hypothesised to strengthen the patient both physically and mentally even if the patient has AF. Also we use mixed methods, which has its strengths in both using qualitative and quantitative research design.³⁴

The major strengths of this randomised clinical trial are that it includes consecutive patients with a reasonable number of inclusion and exclusion criteria securing external validity for the results. The trial employs central, stratified randomisation which secures against selection bias.⁹¹⁻⁹³ The primary outcome is assessed blinded to intervention and so are all statistical analyses, which should reduce

1
2
3
4
5
6
7
8 detection and interpretation bias.⁹¹⁻⁹³ The long-term outcomes are based on data taken from public
9 registry data, which are also likely not to include biased reporting of outcomes.
10
11

12
13 The secondary outcomes of self-rated mental health are by nature subjective and are likely to be
14 biased.⁹¹⁻⁹³ The patients answer questionnaires independently of the researchers. Data management
15 is handled independently from the researchers that interpret data. All questionnaires are distributed
16 electronically. All data entry is stored electronically in a coded database, and in an independent
17 spread sheet, only accessible for the CopenHeart Group.
18
19
20
21
22
23

24
25 Trial limitations include the fact that it is known from previous rehabilitation trials³³ that patients in
26 the control group have a tendency to do physical training due to the focus on the subject in the
27 recruitment process. We will be aware of that when we recruit and not focus on giving extensive
28 information about the exercise programme, or encourage patients to do physical training before
29 knowing what group they are randomised to. Any difference between patients completing the
30 intervention and those not completing (drop-outs) will be carefully discussed when evaluating the
31 intervention, results and the suitability for implementation. The trial is designed with multiple
32 statistical comparisons so results will be interpreted with caution. Further limitations of the trial and
33 methods used are similar to those of other trials including physical exercise and physical testing,
34 namely time-of-day, and day-to-day variation using exercise testing.⁹⁴ To ensure standard testing of
35 all physical exercise tests in the trial, standardised instructions for patients have been developed as
36 described in the methods section. Conversely, the trial population will be representative for the true
37 RFA population, meaning that some patients will have AF and some sinus rhythm while exercising
38 and testing, and this will facilitate implementation of The CopenHeart_{RFA} trial rehabilitation
39 programme in daily clinical practice. We are aware that patients treated with RFA are a highly
40
41
42
43
44
45
46
47
48
49
50
51
52
53

1
2
3
4
5
6
7
8 selected group of patients with paroxysmal or persistent AF, and they are properly more likely to
9 participate and complete a rehabilitation programme, compared to patients with e.g. permanent AF
10 since patients with permanent AF often are older and suffer from co-morbidity⁴. Therefore we do
11 not expect to generalize the results to all AF patients.
12
13
14
15
16

17 The challenge with the set-up is that patients come from considerable distances and therefore some
18 will decline participation. Also, due to the nature of rehabilitation trials, the patients have to meet at
19 the hospital frequently, especially when randomised to the experimental intervention group.
20
21
22

23 The trial will, to our knowledge, be the largest trial conducted dealing with rehabilitation AF
24 ablation recipients. If a positive effect of integrated rehabilitation is found, it may have an impact on
25 the rehabilitation offered to patients treated for AF with RFA at international level. The trial is
26 expected to identify an intervention which can improve health and quality of life for the patients,
27 and subsequently reduce healthcare utilization and costs, as well as mortality.
28
29
30
31
32
33

34 35 36 **Publication policy**

37 The results of the trial will be published in appropriate peer-reviewed journals regardless of the
38 outcome. Authorship will be determined according to the guidelines of the International Committee
39 of Medical Journal Editors.
40
41
42

43 The outcome data will be analysed and published in the short term of 4 and 6 months and the long
44 term of 24 months. Due to the comprehensiveness of the outcome measures further post hoc
45 analysis will be published in separate papers. Economic and long term follow up will be reported as
46 data becomes accessible.
47
48
49
50
51
52

Timetable

Recruitment started in December 2011 in one heart centre and in July 2012 in the other participating heart centre and is planned to finish in December 2013. To achieve adequate participant enrolment, patients in doubt are contacted after hospital discharge by phone. The inclusion rate is closely monitored every week.

Acknowledgements and Funding

The rehabilitation team responsible for the intervention programme and trial administration is:

Rikke Brandt Jakobsen, Lone Siersbæk-Hansen, Lars Tang, Helena Tjalk Sørensen, Signe Gills, Helle Tauby, Katrine Haase and Line Ellemann-Jensen.

The trial is partly funded by The Danish Council for Strategic Research, The Lundbeck Foundation, and The Heart Centre at Rigshospitalet. The funders have no influence on the trial design, the execution of the trial or the interpretation of data.

Authors' contributions

SKB and ADZ in collaboration with SSR, JLH, MP, LCT, PW and CG designed the trial. SSR in collaboration with SKB, ADZ, TBR, KLS, JHS, CG, LCT, SD, JLH and SD drafted the manuscript. All revised the manuscript critically. All authors have given their final approval of the version to be published.

Competing interests

None.

1
2
3
4
5
6
7
8 1. Stewart S, Hart CL, Hole DJ, McMurray JJV. Population prevalence, incidence, and
9
10 predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart* 2001; November
11
12 01;86(5):516-21.
13
14

15
16
17 2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of
18
19 diagnosed atrial fibrillation in adults: national implications for rhythm management and
20
21 stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA)
22
23 Study. *JAMA* 2001; May 9;285(18):2370-5.
24
25
26
27

28
29 3. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Predictors and
30
31 prognosis of paroxysmal atrial fibrillation in general practice in the UK. *BMC Cardiovasc*
32
33 *Disord* 2005; Jul 11;5:20.
34
35
36
37

38
39 4. European Heart Rhythm Association, European Association for Cardio-Thoracic
40
41 Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management
42
43 of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the
44
45 European Society of Cardiology (ESC). *Europace* 2010; Oct;12(10):1360-420.
46
47
48
49
50

1
2
3
4
5
6
7
8 5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergman. Antiarrhythmics for
9
10 maintaining sinus rhythm after cardioversion of atrial fibrillation (Review) 2009;The
11
12 Cochrane Library(1).
13

14
15
16
17
18 6. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome
19
20 parameters for trials in atrial fibrillation: recommendations from a consensus conference
21
22 organized by the German Atrial Fibrillation Competence NETwork and the European Heart
23
24 Rhythm Association. *Europace* 2007; Nov;9(11):1006-23.
25
26
27

28
29
30 7. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term
31
32 risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am*
33
34 *J Med* 2002; Oct 1;113(5):359-64.
35
36
37

38
39
40 8. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits.
41
42 *Int J Cardiol* 2011; Jun 25;.
43
44

45
46 9. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al.
47
48 Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart*
49
50 *J* 2006; Apr;27(8):949-53.
51
52
53

- 1
2
3
4
5
6
7
8 10. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation
9
10 and flutter in the United States. *Am J Cardiol* 2009; Dec 1;104(11):1534-9.
11
12
13
14 11. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk
15
16 for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004; Aug
17
18 31;110(9):1042-6.
19
20
21
22 12. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. *Eur J*
23
24 *Health Econ* 2011; Oct;12(5):479-87.
25
26
27
28 13. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost
29
30 of illness of atrial fibrillation: a systematic review of the recent literature. *Europace* 2011;
31
32 Oct;13(10):1375-85.
33
34
35
36 14. Brenyo AJ, Aktas MK. Non-pharmacologic management of atrial fibrillation. *Am J*
37
38 *Cardiol* 2011; Jul 15;108(2):317-25.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8 15. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of
9
10 atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic
11
12 literature reviews and meta-analyses. *Circ Arrhythm Electrophysiol* 2009; Aug;2(4):349-61.
13
14
15
16
17 16. Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN. Exercise capacity in
18
19 atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial
20
21 (SAFE-T). *Am Heart J* 2007; Apr;153(4):566-72.
22
23
24
25
26
27 17. Hansson A, Madsen-Hardig B, Olsson SB. Arrhythmia-provoking factors and
28
29 symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with
30
31 100 patients seeking hospital assistance. *BMC Cardiovasc Disord* 2004; Aug 3;4:13.
32
33
34
35
36
37 18. Hegbom F, Sire S, Heldal M, Orning OM, Stavem K, Gjesdal K. Short-term exercise
38
39 training in patients with chronic atrial fibrillation: effects on exercise capacity, AV
40
41 conduction, and quality of life. *J Cardiopulm Rehabil* 2006; Jan-Feb;26(1):24-9.
42
43
44
45
46 19. Hegbom F, Stavem K, Sire S, Heldal M, Orning OM, Gjesdal K. Effects of short-term
47
48 exercise training on symptoms and quality of life in patients with chronic atrial fibrillation.
49
50
51
52 *Int J Cardiol* 2007; Mar 2;116(1):86-92.
53
54

- 1
2
3
4
5
6
7
8 20. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized
9
10 study of the effects of exercise training on patients with atrial fibrillation. *Am Heart J* 2011;
11
12 Dec;162(6):1080-7.
13
14
15
16
17
18 21. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment
19
20 of health-related quality of life in patients with intermittent atrial fibrillation: implications for
21
22 the assessment of investigational therapy. *J Am Coll Cardiol* 2000; Oct;36(4):1303-9.
23
24
25
26
27 22. McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative
28
29 study. *J Cardiovasc Nurs* 2011; Jul-Aug;26(4):336-44.
30
31
32
33
34 23. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al.
35
36 Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A
37
38 position paper from the Cardiac Rehabilitation Section of the European Association of
39
40 Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2010;
41
42 Feb;17(1):1-17.
43
44
45
46
47
48
49 24. Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et
50
51 al. Secondary prevention in the clinical management of patients with cardiovascular
52
53

1
2
3
4
5
6
7
8 diseases. Core components, standards and outcome measures for referral and delivery.
9

10
11 *Eur J Prev Cardiol* 2012; Jun 20;.
12

13
14
15 25. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-
16

17
18 based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*
19

20
21 2011; Jul 6;(7)(7):CD001800.
22

23
24 26. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, et al. Exercise based
25

26
27 rehabilitation for heart failure. *Cochrane Database Syst Rev* 2010; Apr
28

29
30 14;(4)(4):CD003331.
31

32
33
34 27. Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review.
35

36
37 *Int J Nurs Stud* 2012; Jun;49(6):755-71.
38

39
40 28. Sire S. Physical training and occupational rehabilitation after aortic valve replacement.
41

42
43 *Eur Heart J* 1987; Nov;8(11):1215-20.
44
45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8 29. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in
9
10 older patients with heart failure and preserved ejection fraction: a randomized, controlled,
11
12 single-blind trial. *Circ Heart Fail* 2010; Nov 1;3(6):659-67.
13
14
15
16
17
18 30. Clark AM, Catto S, Bowman G, Macintyre PD. Design matters in secondary
19
20 prevention: individualization and supervised exercise improves the effectiveness of cardiac
21
22 rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2011; Oct;18(5):761-9.
23
24
25
26
27 31. Clark AM, Haykowsky M, Kryworuchko J, MacClure T, Scott J, DesMeules M, et al. A
28
29 meta-analysis of randomized control trials of home-based secondary prevention programs
30
31 for coronary artery disease. *Eur J Cardiovasc Prev Rehabil* 2010; Jun;17(3):261-70.
32
33
34
35
36
37 32. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. Psychological
38
39 interventions for coronary heart disease. *Cochrane Database Syst Rev* 2011; Aug
40
41 10;(8)(8):CD002902.
42
43
44
45
46 33. Berg SK. *Comprehensive rehabilitation for patients with ICD: PhD dissertation.*
47
48
49 [Aarhus]: Faculty of Health Sciences, Aarhus University; 2011.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 34. Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research*.
9

10
11 Thousand Oaks, Calif.: SAGE Publications; 2007.
12
13

14
15 35. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed
16

17
18 methods studies. *BMJ* 2010; Sep 17;341:c4587.
19

20
21
22 36. Carter RE, Lubinsky J, Domholdt E. *Rehabilitation research: principles and*

23
24 *applications*. 4. ed. ed. St. Louis, Mo.: Elsevier Saunders; 2011.
25
26

27
28 37. Law MC, MacDermid J. *Evidence-based rehabilitation: A guide to practice*. 2. edition
29

30
31 ed. Thorofare, NJ: Slack; 2008.
32
33

34
35 38. Clark N, Boyd NR, Goodman RM, Windsor RA. *Evaluation of health promotion, health*

36
37 *education, and disease prevention programs*. 3. ed. ed. Boston: McGraw-Hill; 2004.
38
39

40
41 39. Hammell KW, Carpenter C. *Qualitative research in evidence-based rehabilitation*.
42

43
44
45 Edinburgh: Churchill Livingstone; 2004.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8 40. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised
9
10 controlled trials of complex healthcare interventions: methodological study. *BMJ* 2009; Sep
11
12 10;339:b3496.
13
14
15
16
17 41. Neubeck L, Freedman SB, Clark AM, Briffa T, Bauman A, Redfern J. Participating in
18
19 cardiac rehabilitation: a systematic review and meta-synthesis of qualitative data. *Eur J*
20
21 *Prev Cardiol* 2012; Jun;19(3):494-503.
22
23
24
25
26 42. Chan A, Tetzlaff J, Altman D, Gotzsche P, Hrobjartsson A, et al. The SPIRIT initiative:
27
28 Defining Standard Protocol Items for Randomized Trials [conference abstract]. *German J*
29
30 *Evid Quality Health Care (Suppl)* 2008;(102:S27).
31
32
33
34
35 43. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group. Extending
36
37 the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation
38
39 and elaboration. *Ann Intern Med* 2008; Feb 19;148(4):295-309.
40
41
42
43
44 44. Mertens DJ, Kavanagh T. Exercise training for patients with chronic atrial fibrillation. *J*
45
46 *Cardiopulm Rehabil* 1996; May-Jun;16(3):193-6.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 45. Berg SK, Svendsen JH, Zwisler AD, Pedersen BD, Preisler P, Siersbaek-Hansen L, et

9
10
11 al. COPE-ICD: a randomised clinical trial studying the effects and meaning of a

12
13
14 comprehensive rehabilitation programme for ICD recipients -design, intervention and

15
16
17 population. *BMC Cardiovasc Disord* 2011; Jun 17;11:33.

18
19
20 46. Zwisler A, Madsen M, Konstantin Nissen N. *Hjerterehabilitering: en medicinsk*

21
22
23 *teknologivurdering: evidens fra litteraturen og DANREHAB-forsøget*. <http://www.si->

24
25
26 [folkesundhed.dk/upload/hjerterehabilitering_001.pdf](http://www.ssi-folkesundhed.dk/upload/hjerterehabilitering_001.pdf). Version: 1,0 ed. Kbh.:

27
28
29 Sundhedsstyrelsen; 2006.

30
31
32 47. Anbefalinger for fysisk aktivitet. Available at:

33
34
35 <http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til>

36
37
38 [%20voksne.aspx](http://www.sst.dk/Sundhed%20og%20forebyggelse/Fysisk%20aktivitet/Anbefalinger%20til%20voksne.aspx). Accessed 09/13, 2011.

39
40
41 48. Oerkild B, Frederiksen M, Hansen JF, Simonsen L, Skovgaard LT, Prescott E. Home-

42
43
44 based cardiac rehabilitation is as effective as centre-based cardiac rehabilitation among

45
46
47 elderly with coronary heart disease: results from a randomised clinical trial. *Age Ageing*

48
49
50 2011; Jan;40(1):78-85.

1
2
3
4
5
6
7
8 49. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ. Comprehensive
9
10 cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a
11
12 randomised controlled trial. *Heart* 2003; Feb;89(2):155-60.
13
14

15
16
17
18 50. Lampman RM, Knight BP. Prescribing exercise training for patients with defibrillators.
19
20
21 *Am J Phys Med Rehabil* 2000; May-Jun;79(3):292-7.
22

23
24 51. Parse RR. *The human becoming school of thought: a perspective for nurses and other*
25
26
27 *health professionals*. Thousand Oaks, Calif.: Sage; 1998.
28

29
30
31 52. Berg SK, Pedersen BD, Svendsen JH, Zwisler AD, Kristensen L, Pedersen PU.
32
33
34 COPE-ICD: Patient experience of participation in an ICD specific rehabilitation
35
36
37 programme. *Eur J Cardiovasc Nurs* 2011; Apr 22;.
38

39
40
41 53. Mezzani A, Agostoni P, Cohen-Solal A, Corra U, Jegier A, Kouidi E, et al. Standards
42
43
44 for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac
45
46
47 patients: a report from the Exercise Physiology Section of the European Association for
48
49
50 Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2009;
51
52 Jun;16(3):249-67.
53

1
2
3
4
5
6
7
8 54. Gibbons L, Blair SN, Kohl HW, Cooper K. The safety of maximal exercise testing.

9
10
11 *Circulation* 1989; Oct;80(4):846-52.
12
13

14
15 55. Børner JB, Trab Damsgaard M, Watt T, Bech P, Rasmussen NK, Søndergaard

16
17
18 Kristensen T, et al. *Dansk manual til SF-36: et spørgeskema om helbredsstatus*. [S.l.]: Lif;

19
20
21 1997.
22
23

24
25 56. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.

26
27
28 Conceptual framework and item selection. *Med Care* 1992; Jun;30(6):473-83.
29
30

31
32 57. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey

33
34 (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental

35
36
37 health constructs. *Med Care* 1993; Mar;31(3):247-63.
38
39

40
41 58. Andersen TF, Madsen M, Jorgensen J, Mellekjoer L, Olsen JH. The Danish National

42
43
44 Hospital Register. A valuable source of data for modern health sciences. *Dan Med Bull*

45
46
47 1999; Jun;46(3):263-8.
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8 59. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J*

9
10
11 *Public Health* 2011; Jul;39(7 Suppl):30-3.

12
13
14 60. Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service

15
16
17 Register. *Scand J Public Health* 2011; Jul;39(7 Suppl):34-7.

18
19
20 61. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry.

21
22
23 *Scand J Public Health* 2011; Jul;39(7 Suppl):38-41.

24
25
26 62. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health*

27
28
29 2011; Jul;39(7 Suppl):26-9.

30
31
32 63. ATS Committee on Proficiency Standards for Clinical Pulmonary Function

33
34
35 Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit*

36
37
38 *Care Med* 2002; Jul 1;166(1):111-7.

39
40
41 64. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*

42
43
44 1982;14(5):377-81.

45
46
47 65. Rikli RE, Jones CJ. *Senior fitness test manual*. Champaign, Ill.: Human Kinetics; 2001.

- 1
2
3
4
5
6
7
8 66. Ekholm O, Hesse U, Davidsen M, Kjoller M. The study design and characteristics of
9
10 the Danish national health interview surveys. *Scand J Public Health* 2009; Sep;37(7):758-
11
12
13
14 65.
15
16
17
18 67. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey.: Manual and Interpretation
19
20 guide 2005;The Health Institute, New England Medical Center, Boston, Massachussets.
21
22
23
24 68. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
25
26
27 *Scand* 1983; Jun;67(6):361-70.
28
29
30
31 69. Ferrans CE, Powers MJ. Quality of life index: development and psychometric
32
33
34 properties. *ANS Adv Nurs Sci* 1985; Oct;8(1):15-24.
35
36
37
38 70. Bowman G, Watson R, Trotman-Beasty A. Primary emotions in patients after
39
40 myocardial infarction. *J Adv Nurs* 2006; Mar;53(6):636-45.
41
42
43
44 71. Bøgelund M, Mønsted C. *Hjertepatienters brug og oplevelse af rehabilitering 2010*.
45
46
47 Kbh.: Hjerteforeningen; 2010.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8 72. Oldridge N, Saner H, McGee HM, HeartQoL Study Investigators. The Euro Cardio-QoL
9
10 Project. An international study to develop a core heart disease health-related quality of life
11
12 questionnaire, the HeartQoL. *Eur J Cardiovasc Prev Rehabil* 2005; Apr;12(2):87-94.
13
14
15
16
17 73. Drummond MF. *Methods for the economic evaluation of health care programmes*. 3rd
18
19 edition ed. Oxford: Oxford University Press; 2005.
20
21
22
23
24 74. Hallal PC, Victora CG. Reliability and validity of the International Physical Activity
25
26 Questionnaire (IPAQ). *Med Sci Sports Exerc* 2004; Mar;36(3):556.
27
28
29
30
31 75. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. *J*
32
33 *Psychosom Res* 1993; Oct;37(7):753-62.
34
35
36
37 76. Buisse DJ, Reynolds CF,3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
38
39 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*
40
41 1989; May;28(2):193-213.
42
43
44
45
46
47 77. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, et al.
48
49
50 Development and validation of the Atrial Fibrillation Effect on QualiTY-of-Life (AFEQT)
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 Questionnaire in patients with atrial fibrillation. *Circ Arrhythm Electrophysiol* 2011;

9
10
11 Feb;4(1):15-25.

12
13
14 78. DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for

15
16
17 handling missing data in clinical trials. *J Biopharm Stat* 2009; Nov;19(6):1055-73.

18
19
20 79. Dmitrienko A, Wiens BL, Tamhane AC, Wang X. Tree-structured gatekeeping tests in

21
22
23 clinical trials with hierarchically ordered multiple objectives. *Stat Med* 2007; May

24
25
26 30;26(12):2465-78.

27
28
29 80. McHorney CA, Ware JE, Rogers W, Raczek A, Lu JFR. The validity and relative

30
31
32 precision of MOS short- and long-form health status scales and Dartmouth COOP charts:

33
34
35 results from the Medical Outcomes Study.

36
37
38 81. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac

39
40
41 rehabilitation. *Heart* 2006; Jan;92(1):62-7.

42
43
44 82. Polit DF, Beck CT. *Essentials of nursing research: methods, appraisal, and utilization.*

45
46
47 6. edition ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.

- 1
2
3
4
5
6
7
8 83. Ricoeur P. *Interpretation theory: discourse and the surplus of meaning*. 5. print. ed.
9
10 Fort Worth, Tex.: Texas Christian University Press; 1976.
11
12
13
14 84. EuroQol—a new facility for the measurement of health-related quality of life. The
15
16 EuroQol Group. *Health Policy* 1990; Dec;16(3):199-208.
17
18
19
20 85. Brooks R. EuroQol: the current state of play. *Health Policy* 1996; Jul;37(1):53-72.
21
22
23
24 86. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO
25
26 value set for EQ-5D health states. *Scand J Public Health* 2009; Jul;37(5):459-66.
27
28
29
30 87. Fox-Rushby JA, Cairns J. *Economic evaluation*. Maidenhead: Open University Press;
31
32 2005.
33
34
35
36 88. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-
37
38 effectiveness acceptability curves. *Health Econ* 2001; Dec;10(8):779-87.
39
40
41
42 89. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based
43
44 rehabilitation for patients with coronary heart disease: systematic review and meta-
45
46 analysis of randomized controlled trials. *Am J Med* 2004; May 15;116(10):682-92.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8 90. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation for
9
10 heart failure. *Cochrane Database Syst Rev* 2004;(3)(3):CD003331.
11
12
13
14 91. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence
15
16 of bias in treatment effect estimates in controlled trials with different interventions and
17
18 outcomes: meta-epidemiological study. *BMJ* 2008; Mar 15;336(7644):601-5.
19
20
21
22
23 92. Gluud L. Bias in clinical intervention research. *Am J Epidemiol* 2006;163(6):493-501.
24
25
26
27
28 93. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported
29
30 study design characteristics on intervention effect estimates from randomised controlled
31
32 trials: combined analysis of meta-epidemiological studies. *Health Technol Assess* 2012;
33
34 Sep;16(35):1-82.
35
36
37
38 94. Rowland T, Unnithan V, Barker P, Lindley M, Roche D, Garrard M. Time-of-day effect
39
40 on cardiac responses to progressive exercise. *Chronobiol Int* 2011; Aug;28(7):611-6.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. The CopenHeart_{RFA} trial. Mixed methods research design. Embedded Experimental Model. QUAN= quantitative data, QUAL= qualitative data

192x90mm (300 x 300 DPI)

er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



119x90mm (300 x 300 DPI)

View only



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5-8
	2b	Specific objectives or hypotheses	10
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	8-9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	10-11
	4b	Settings and locations where the data were collected	10-11
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	12-17
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	18-21
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	21-22
	7b	When applicable, explanation of any interim analyses and stopping guidelines	24-25
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	11-12
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	11-12
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	N/A
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	11
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	11 + 22

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	N/A
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	22-24
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	25-26
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and	N/A
10	diagram is strongly	were analysed for the primary outcome	
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	N/A
12	Recruitment	14a Dates defining the periods of recruitment and follow-up	N/A
13		14b Why the trial ended or was stopped	N/A
14			
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	N/A
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was	N/A
17		by original assigned groups	
18			
19	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	N/A
20	estimation	precision (such as 95% confidence interval)	
21		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
22	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	N/A
23		pre-specified from exploratory	
24			
25	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
26			
27	Discussion		
28	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	29-30
29	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	30
30	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	N/A
31			27
32	Other information		
33	Registration	23 Registration number and name of trial registry	
34	Protocol	24 Where the full trial protocol can be accessed, if available	N/A
35	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	31
36			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.